



JSC Georgia Capital Statement of Responsible Persons

Pursuant to Article 11.6(c) of the Georgian Law on the Securities Market, we confirm that on August 3, 2023, JSC Georgia Capital (identification number: 404549690, hereinafter "issuer") issued 150 (one hundred and fifty) million USD sustainability-related bonds (international registration number (ISIN): GE 2700604475; state registration number: GE 2700604475-2-01) in connection with the public issue of the "issuer" prepared within the framework of the existing obligations, the audited consolidated financial statements prepared in accordance with relevant International Financial Reporting Standards (IFRS) and with the requirements of the Law of Georgia on Accounting, Reporting and Auditing fully, correctly and fairly reflect the assets, liabilities, financial position and profit and loss of JSC Georgia Capital and the management report fairly and comprehensively reviews the development, results and condition of the activities as well as a description of the main existing risks for the year ended 31 December 2023.

Irakli Gilauri

David Morrison

JSC Georgia Capital Chief Executive Officer

JSC Georgia Capital Chairperson of Supervisory Board



JSC Georgia Capital and Subsidiaries Consolidated Financial Statements

31 December 2023

CONTENTS

INDEPENDENT AUDITOR'S REPORT

CONSOLIDATED FINANCIAL STATEMENTS

Con	solidated Statement of Financial Position	1
Con	solidated Income Statement	2
Con	solidated Statement of Comprehensive Income	3
Con	solidated Statement of Changes in Equity	4
Con	solidated Statement of Cash Flows	5
NO	I'ES TO CONSOLIDATED FINANCIAL STATEMENTS	
1.	Principal Activities	6
2.	Basis of Preparation	6
3.	Material Accounting Policies	13
4.	Critical Accounting Judgements and Estimates	19
5.	Segment Information	20
6.	Cash and Cash Equivalents	26
7.	Amounts Due from Credit Institutions	26
8.	Marketable Securities and Investment in Redeemable Shares	26
9.	Loans Issued	26
10.	Equity Investments at Fair Value	27
11.	Debt Securities Issued	28
12.	Equity	29
13.	Salaries and Other Employee Benefits, and General and Administrative Expenses	29
14.	Impairment of Accounts Receivable, Other Assets and Provisions	30
15.	Share-based Payments	30
16.	Risk Management	31
17.	Fair Value Measurements	36
18.	Maturity Analysis	43
19.	Related Party Disclosures	44
20.	Events after Reporting Period	45



Independent Auditor's Report

To the Shareholder and Management of JSC Georgia Capital

Our opinion

In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of JSC Georgia Capital (the "Company") and its subsidiaries (together – the "Group") as at 31 December 2023, and the Group's consolidated financial performance and consolidated cash flows for the year then ended in accordance with International Financial Reporting Standards and with the requirements of the Law of Georgia on Accounting, Reporting and Auditing.

What we have audited

The Group's consolidated financial statements comprise:

- the consolidated statement of financial position as at 31 December 2023;
- the consolidated income statement for the year then ended;
- the consolidated statement of comprehensive income for the year then ended;
- the consolidated statement of changes in equity for the year then ended;
- the consolidated statement of cash flows for the year then ended; and
- the notes to the consolidated financial statements, comprising material accounting policy information and other explanatory information.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the consolidated financial statements section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Group in accordance with the International Code of Ethics for Professional Accountants (including International Independence Standards) issued by the International Ethics Standards Board for Accountants (IESBA Code). We have fulfilled our other ethical responsibilities in accordance with the IESBA Code.



Our audit approach

Overview



- Overall Group materiality: GEL 33,634 thousand, which represents 1% of Group's net assets.
- We conducted audit work at JSC Georgia Capital level.
 Consolidated subsidiaries were assessed as non-significant components.
- Matter which was of most significance in the audit of the consolidated financial statements is:

Valuation of equity investments using unobservable inputs.

As part of designing our audit, we determined materiality and assessed the risks of material misstatement in the consolidated financial statements. In particular, we considered where management made subjective judgements; for example, in respect of significant accounting estimates that involved making assumptions and considering future events that are inherently uncertain. As in all of our audits, we also addressed the risk of management override of internal controls, including among other matters, consideration of whether there was evidence of bias that represented a risk of material misstatement due to fraud.

Materiality

The scope of our audit was influenced by our application of materiality. An audit is designed to obtain reasonable assurance whether the consolidated financial statements are free from material misstatement. Misstatements may arise due to fraud or error. They are considered material if individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the consolidated financial statements.

Based on our professional judgement, we determined certain quantitative thresholds for materiality, including the overall Group materiality for the consolidated financial statements as a whole as set out in the table below. These, together with qualitative considerations, helped us to determine the scope of our audit and the nature, timing and extent of our audit procedures and to evaluate the effect of misstatements, if any, both individually and in aggregate on the consolidated financial statements as a whole.

Overall Group materiality	GEL 33,634 thousand
How we determined it	1% of net assets
Rationale for the materiality benchmark applied	We chose net assets as the benchmark because, given that JSC Georgia Capital meets the investment entity definition under IFRS 10 and therefore measures its investments at fair value, in our view, it is the benchmark against which the performance of the Group is most commonly measured by users of the consolidated financial statements. We chose 1% which is consistent with quantitative materiality thresholds used for companies where net assets is considered as a key metric.



Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matter

How our audit addressed the key audit matter

Valuation of equity investments using unobservable inputs

Refer to note 3 - Material Accounting Policies, note 4 - Critical Accounting Judgements and Estimates and note 10 - Equity Investments at Fair Value.

The equity investments at fair value balance presented in the Consolidated Statement of Financial Position includes equity investments valued using unobservable inputs.

In valuing the investment portfolio using unobservable inputs, key assumptions include discount rates, future growth projections, control premia and illiquidity discounts.

The inputs in the earnings multiples models include unobservable data, such as forecast earnings for the investments. In discounted cash flow models, unobservable inputs are the projected cash flows of the relevant investments and the discount rates applied.

The valuation of equity investments using unobservable inputs was identified as a key audit matter given the valuation is inherently subjective due to, among other factors, the individual nature of each investment and the expected future cash flows.

We obtained an understanding of management's processes and controls for determining the fair value of equity investments, including understanding management's interactions with management's external experts. We performed the following procedures over the valuation of equity investments using unobservable inputs as at 31 December 2023:

- We assessed the competence, capabilities and independence of management's expert and verified their qualifications
- Held discussions with management and third party valuers to challenge their assumptions and validate inputs used;
- Validated the appropriateness of the fair valuation policies to assess whether they are in accordance with applicable accounting requirements;
- Tested the classification of Level 3 investments to assess whether they were classified appropriately;
- Reviewed valuation methodologies to confirm they are in line with the Group's valuation policies and IFRS requirements;
- Recalculated the valuation models from their Excel formula to assess mathematical accuracy;
- Assessed the appropriateness of any unobservable inputs or significant estimates used in valuations, including benchmarking against publicly available information where available, and obtained corroborative evidence; and
- Validated ownership and other interests held through regulatory data, sale and purchase agreements or other third-party reports.



Key audit matter

How our audit addressed the key audit matter

The significance of the estimates and judgements involved, coupled with the fact that only a small percentage difference in individual investment valuations, when aggregated, could result in a material misstatement, warranted specific audit focus in this area.

In addition, given the inherent subjectivity involved in the valuation of the equity investments using unobservable inputs, and therefore the need for specialised market knowledge when determining the most appropriate assumptions and the technicalities of valuation methodology, we engaged our internal valuation experts to assist us in our audit of this area.

Our internal valuation experts performed the following procedures on a sample of investments:

- Obtained and read the valuation reports drafted by management's external experts for each asset in the sample;
- Discussed with management's external experts and management their rationale for the valuations:
- Reviewed and assessed the reasonableness of the valuation approaches and methodologies for compliance with the relevant industry best practice and IFRS;
- Reviewed certain key inputs and assumptions, including discount rates, future growth projections, control premia, illiquidity discounts and the applicable of weighted averages as at 31 December 2023; and
- Reported their findings to the audit team for overall considerations and conclusions.

We considered the appropriateness and adequacy of the disclosures around the estimation uncertainty and sensitivities on the accounting estimates.

How we tailored our Group audit scope

We tailored the scope of our audit in order to perform sufficient work to enable us to provide an opinion on the consolidated financial statements as a whole, taking into account the structure of the Group, the accounting processes and controls, and the industry in which the Group operates.

The Group's activities are primarily carried out in Georgia. The Group's business activities comprise of 5 segments for which it manages and reports its operating results and financial position, namely listed and observable portfolio companies, private large portfolio companies, private investment stage portfolio companies, private other portfolio companies, and corporate centre.

JSC Georgia Capital is the largest and the only significant component of the Group. Its main operations are buying, developing and selling businesses in Georgia and it identifies itself as an investment entity. It comprises over 99% of the Group's net assets. Other components of the Group do not represent investment entities and provide excess liquidity and share based payments scheme management services related to the Group's investment activities.

Our audit approach and team were also designed to reflect the structure of the Group. Based on the procedures we performed over the single material component our audit scoping/coverage accounted for over 99% of the net assets of the Group.



Other information

Management is responsible for the other information. The other information comprises the Management Report (but does not include the consolidated financial statements and our auditor's report thereon).

Our opinion on the consolidated financial statements does not cover the Management Report.

In connection with our audit of the consolidated financial statements, our responsibility is to read the Management Report and, in doing so, consider whether the Management Report is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement in the Management Report, we are required to report that fact. We have nothing to report in this regard.

In addition, we are required by the Law of Georgia on Accounting, Reporting and Auditing to express an opinion whether certain parts of the Management Report comply with respective regulatory normative acts and to consider whether the Management Report includes the information required by the Law of Georgia on Accounting, Reporting and Auditing.

Based on the work undertaken in the course of our audit, in our opinion:

- the information given in the Management Report for the financial year for which the consolidated financial statements are prepared is consistent with the consolidated financial statements;
- the information given in the Management Report complies with the requirements of paragraph 6 and paragraph 7 (c), (g) of article 7 of the Law of Georgia on Accounting, Reporting and Auditing;
- the information given in the Management Report includes the information required by paragraph 7
 (a), (b), (d) (f) of article 7 of the Law of Georgia on Accounting, Reporting and Auditing.

Responsibilities of management and those charged with governance for the consolidated financial statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with International Financial Reporting Standards and with the requirements of the Law of Georgia on Accounting, Reporting and Auditing, and for such internal control as management determines is necessary to enable the preparation of the consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Group's financial reporting process.



Auditor's responsibilities for the audit of the consolidated financial statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements,
 whether due to fraud or error, design and perform audit procedures responsive to those risks, and
 obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk
 of not detecting a material misstatement resulting from fraud is higher than for one resulting from
 error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the
 override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit
 procedures that are appropriate in the circumstances, but not for the purpose of expressing an
 opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the Group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.



From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partner on the audit resulting in this independent auditor's report is Lasha Janelidze.

George WC

PricewaterhouseCoopers Georgia LLC (Reg.# SARAS-F-775813)

Lasha Janelidze (Reg.#SARAS-A-562091)

21 March 2024 Tbilisi, Georgia

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 31 December 2023

(Thousands of Georgian Lari)

	Note	31 December 2023	31 December 2022
Assets			
Cash and cash equivalents	6	51,138	199,771
Amounts due from credit institutions	7	8,678	16,278
Marketable securities	8	18,203	25,445
Investment in redeemable securities	8	14,068	12,631
Accounts receivable		3,274	109
Prepayments		923	610
Loans issued	9	9,212	26,830
Property and equipment		340	391
Intangible assets		67	109
Other assets		456	1,132
Equity investments at fair value	10	3,671,945	3,198,627
Total assets		3,778,304	3,481,933
Liabilities			
Accounts payable		888	917
Debt securities issued	11	413,930	681,067
Other liabilities		75	4,889
Total liabilities		414,893	686,873
Equity			
Share capital	12	12,877	12,877
Additional paid-in capital		516,806	523,760
Treasury shares	12	(980)	(960)
Other reserves		(311)	(439)
Retained earnings		2,835,019	2,259,822
Total equity		3,363,411	2,795,060
Total liabilities and equity		3,778,304	3,481,933

Signed and authorised for release on behalf of the Supervisory Board and Management by:

David Morrison

Chairperson of Supervisory Board

Irakli Gilauri

Chief Executive Officer

Giorgi Alpaidze

Chief Financial Officer

21 March 2024

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 31 December 2023

(Thousands of Georgian Lari)

	Note	31 December 2023	31 December 2022
Assets	<u></u>		
Cash and cash equivalents	6	51,138	199,771
Amounts due from credit institutions	7	8,678	16,278
Marketable securities	8	18,203	25,445
Investment in redeemable securities	8	14,068	12,631
Accounts receivable		3,274	109
Prepayments		923	610
Loans issued	9	9,212	26,830
Property and equipment		340	391
Intangible assets		67	109
Other assets		456	1,132
Equity investments at fair value	10	3,671,945	3,198,627
Total assets		3,778,304	3,481,933
Liabilities			
Accounts payable		888	917
Debt securities issued	11	413,930	681,067
Other liabilities		75	4,889
Total liabilities		414,893	686,873
Equity			
Share capital	12	12,877	12,877
Additional paid-in capital		516,806	523,760
Treasury shares	12	(980)	(960)
Other reserves		(311)	(439)
Retained earnings		2,835,019	2,259,822
Total equity		3,363,411	2,795,060
Total liabilities and equity		3,778,304	3,481,933

Signed and authorised for release on behalf of the Supervisory Board and Management by:

David Morrison

Chairperson of Supervisory Board

Irakli Gilauri

Chief Executive Officer

Giorgi Alpaidze

Chief Financial Officer

21 March 2024

CONSOLIDATED INCOME STATEMENT

For the year ended 31 December 2023

	Note	2023	2022
Gains/(losses) on investments at fair value	10	517,988	(69,252)
Listed and Observable Investments		472,740	155,435
Of which:			
Sale consideration from disposal of listed shares		73,356	-
Disposal of listed shares		(65,766)	-
Private Investments		45,248	(224,687)
Dividend income	10	162,527	93,875
Interest income at effective interest rate method		5,953	19,942
Other interest income		3,119	12,087
(Loss)/gain on derecognition of liability	11	(3,111)	9,907
Net gains/(losses) from investment securities measured at FVPL		1,446	(10,801)
Net realised losses from investment securities measured at FVOCI		(162)	(1,750)
Other income		8	42
Gross investment profit		687,768	54,050
Salaries and other employee benefits	13	(23,783)	(25,843)
Depreciation and amortisation		(545)	(635)
Other administrative expenses	13	(5,894)	(6,797)
Interest expense	11	(39,660)	(59,763)
Profit/(loss) before provisions, foreign exchange and non-recurri	ng items	617,886	(38,988)
Expected credit loss (charge)/reversal	14	(75)	380
Net foreign currency gain		6,954	58,116
Loss on derivative financial assets		(11)	(4,507)
Non-recurring expense		(1,898)	(387)
Profit before income taxes		622,856	14,614
T			
Income tax			
Profit for the year		622,856	14,614

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the year ended 31 December 2023

	Note	2023	2022
Profit for the period		622,856	14,614
Other comprehensive income/(loss)			
Other comprehensive income/ (loss) to be reclassified to profit or loss in			
subsequent periods:			
Changes in the fair value of debt instruments at FVOCI		(34)	(1,822)
Realised loss on financial assets measured at FVOCI reclassified to the consolidated income statement		162	1,750
Net other comprehensive income/(loss) to be reclassified to profit or loss in subsequent periods		128	(72)
Other comprehensive income/(loss) for the period, net of tax		128	(72)
Total comprehensive income for the year	·	622,984	14,542

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the year ended 31 December 2023

	Share capital	Additional paid-in capital	Treasury shares	Other reserves	Retained earnings	Total
1 January 2023	12,877	523,760	(960)	(439)	2,259,822	2,795,060
Profit for the year		-			622,856	622,856
Other comprehensive income for the year	-	-	-	128	-	128
Total comprehensive income for the year	-	-	-	128	622,856	622,984
Increase in equity arising from share-based payments (Note 15)	-	25,249	-	-	-	25,249
Capital reduction (Note 12)	-	-	-	-	-	-
Dividend paid to the shareholder*	-	-	-	-	(47,659)	(47,659)
Acquisition of treasury shares under share-based payment plan (Note 12)	-	(32,203)	(20)	-	-	(32,223)
31 December 2023	12,877	516,806	(980)	(311)	2,835,019	3,363,411

	Share capital	Additional paid-in capital	Treasury shares	Other reserves	Retained earnings	Total
1 January 2022	13,286	624,186	(940)	(367)	2,245,208	2,881,373
Profit for the year		-		_	14,614	14,614
Other comprehensive loss for the year	-	-	-	(72)	-	(72)
Total comprehensive income for the year	-	-	-	(72)	14,614	14,542
Increase in equity arising from share-based payments (Note 15)	-	20,794	-	-	-	20,794
Capital reduction (Note 12)**	(409)	(86,829)	-	-	-	(87,238)
Acquisition of treasury shares under share-based payment plan (Note 12)	-	(34,391)	(20)	-	-	(34,411)
31 December 2022	12,877	523,760	(960)	(439)	2,259,822	2,795,060

^{*} During 2023 JSC Georgia Capital paid dividend of GEL 47,659 (GEL 3.9581 per share) to its 100% shareholder, GCAP PLC (2022: nil).

^{**} During 2022 the parent company, GCAP PLC, received GEL 87,238 in the form of capital redemption from JSC GCAP, of which GEL 87,238 was paid in cash.

CONSOLIDATED STATEMENT OF CASH FLOWS

For the year ended 31 December 2023

	Note	2023	2022
Cash flows from operating activities			_
Dividends received	10	162,527	93,875
Salaries and other employee benefits paid		(9,481)	(10,555)
Other administrative expenses paid		(5,894)	(6,797)
Interest income received		8,293	24,331
Net change in operating assets and liabilities		(441)	(385)
Net cash flows from operating activities before income tax		155,004	100,469
Income tax paid		<u> </u>	=
Net Cash flow from operating activities		155,004	100,469
Cash flows from investing activities			
Net withdrawal of amounts due from credit institutions		7,253	16,210
Loans issued	9	(58,113)	(281,660)
Loans repaid		75,503	227,896
Proceeds from sale of shares in portfolio companies	10	75,058	548,118
Transaction costs incurred in relation to sale of share in existing equity investment		-	(19,325)
Increase of equity investments	10	(22,588)	(25,999)
Purchase of marketable securities	10	(15,889)	(102,660)
Proceeds from sale and redemption of marketable securities		22,114	131,723
Purchase of property and equipment		(94)	(236)
Other investing activities		(868)	(3,693)
Net cash flows from investing activities		82,376	490,374
C			·
Cash flows from financing activities			
Dividend paid to the shareholder		(47,659)	-
Proceeds from debt securities issued	11	389,024	-
Redemption and buyback of debt securities issued	11	(652,206)	(285,797)
Share capital redemption	12	-	(87,238)
Interest paid		(34,835)	(60,056)
Acquisition of treasury shares under share-based payment plan	12	(32,223)	(34,411)
Cash payments for principal portion of lease liability	11	(304)	(359)
Cash payments for interest portion of the lease liability	11	(15)	(40)
Net cash used in financing activities		(378,218)	(467,901)
Effect of exchange rates changes on cash and cash equivalents		(7,796)	(12,884)
Effect of change in expected credit losses for cash and cash equivalents		1	(1)
Net (decrease)/increase in cash and cash equivalents		(148,633)	110,057
Cash and cash equivalents, beginning of the year	6	199,771	89,714
Cash and cash equivalents, end of the year	6	51,138	199,771

1. Principal Activities

JSC Georgia Capital ("Georgia Capital", "JSC GCAP", "GCAP", "Company") makes up a group of companies (the "Group"), focused on buying, building and developing businesses in Georgia and monetising investments as they mature. The Group currently has the following portfolio businesses (i) a retail (pharmacy) business, (ii) a hospitals business (consisting of a large and specialty hospitals and b. regional and community hospitals), (iii) an insurance business (P&C and medical insurance); (iv) a clinics and diagnostics business, (v) a renewable energy business (hydro and wind assets) and (vi) an education business; Georgia Capital also holds other small private businesses across different industries in Georgia; a 20% equity stake in the water utility business and a 19.7% (2022: 20.6%) equity stake in LSE premium-listed Bank of Georgia Group PLC ("BoG"), a leading universal bank in Georgia.

JSC Georgia Capital's (Company ID: 404549690) registered legal address is Petre Melikishvili Avenue N8a / Erekle Tatishvili Street N1, Tbilisi Georgia.

JSC Georgia Capital was established on 6 August 2015 as a joint stock company (JSC) under the laws of Georgia. As of 31 December 2023 and 31 December 2022, the Group's ultimate 100% owner was Georgia Capital PLC, a company incorporated in England and listed on the London Stock Exchange.

2. Basis of Preparation

General

The consolidated financial statements of JSC Georgia Capital have been prepared in accordance with International Financial Reporting Standards ('IFRS') as issued by the International Accounting Standards Board (IASB) and with the requirements of the Law of Georgia on Accounting, Reporting and Auditing.

These financial statements are prepared under the historical cost convention except for financial assets measured at fair value and equity investments held at fair value through profit or loss (FVPL).

The financial statements are presented in thousands of Georgian Lari ("GEL"), except per share amounts or unless otherwise indicated.

Investment entity status

On 31 December 2019 Georgia Capital concluded that it met the definition of investment entity as defined in IFRS 10 *Consolidated Financial Statements*. As per IFRS 10 an investment entity is an entity that:

- a) obtains funds from one or more investors for the purpose of providing those investor(s) with investment management services;
- b) commits to its investor(s) that its business purpose is to invest funds solely for returns from capital appreciation, investment income, or both; and
- c) measures and evaluates the performance of substantially all of its investments on a fair value basis.

Further details on financial impact of change in investment entity status and underlying significant judgments are provided in notes 3, 4 and 17 respectively.

2. Basis of Preparation (continued)

Going concern

The Supervisory Board of Georgia Capital has made an assessment of the Company's ability to continue as a going concern and is satisfied that it has the resources to continue in business for a period of at least 12 months from the date of approval of the financial statements, i.e. the period ending 31 March 2025. Furthermore, management is not aware of any material uncertainties that may cast significant doubt upon the Company's ability to continue as a going concern for the foreseeable future. Therefore, the financial statements continue to be prepared on a going concern basis.

The Directors have made an assessment of the appropriateness of the going concern basis of preparation and reviewed Georgia Capital's liquidity outlook for the period ending 31 March 2025.

On 2 February 2022 Group received USD 180 million (GEL 548 million) cash consideration for disposal of controlling interest in Water Utility business.

The liquidity needs of the Group during the Going Concern review period mainly consist of the coupon payments on JSC GCAP sustainability-linked bonds and the operating costs of running the holding companies and capital allocations to its portfolio companies. The liquidity outlook also assumes dividend income from the private portfolio companies (healthcare, pharmacy, renewable business, and insurance) and Bank of Georgia Group PLC. Capital allocations are assumed in relation to investment stage companies (Renewable Energy and Education).

On August 3, 2023, JSC GCAP issued US150 million sustainability-linked local bonds in Georgia, with an 8.5% coupon rate, payable in August 2028. The proceeds from the transaction, together with GCAP's existing liquid funds, were fully used to redeem GCAP's USD 300 million Eurobonds. Following these transactions, GCAP's gross debt balance decreased from USD 300 million to USD 150 million. In February 2024, GCAP made its first coupon payment on the bond in the amount of USD 6.4 million. The Directors remain confident that, given the strong liquidity and the Group's track record of proven access to capital, GCAP will successfully continue to service its existing bonds.

The Company has been increasingly assessing climate related risk and opportunities that may be present to the Group. During the going concern period no significant risk has been associated to the Group and portfolio companies that would materially impact their ability to generate sufficient cash and continue as going concern.

Based on the considerations outlined above, management of Georgia Capital concluded that going concern basis of preparation remains appropriate for these financial statements.

The Group performed stress testing for the assessment period, which involved modelling the impact of a combination of severe and plausible risks. Based on the results of the stress tests, the directors concluded that the Group remains solvent with solid financial position and has sufficient cash and liquid investment securities to withstand the distressed scenario.

2. Basis of Preparation (continued)

Subsidiaries and associates

The direct and indirect subsidiaries and associates of JSC Georgia Capital as at 31 December 2023 and 31 December 2022 are as follows:

- -	Proportion of v and ordinary s. held	hare capital *						
Subsidiaries Consolidated	31 December 2023	31 December 2022	Country of incorporation	Address	Industry	Date of incorporation	Date of acquisition	
⇒ GCMF, LLC	100.00%	100.00%	Georgia	8a Petre Melikishvili Ave, Tbilisi, 0179	Excess liquidity management company	2/5/2019	-	
	rights and o	n of voting rdinary share I held* 31			company			
Subsidiaries at FV	December 2023	December 2022	Country of incorporation	Address	Industry	Date of incorporation	Date of acquisition	
⇒ JSC Georgia Real Estate	100.00%	100.00%	Georgia	10 G. Kartozia street, Tbilisi, Georgia	Real estate	27/9/2006	-	
⇒ m2 group, LLC	100.00%	100.00%	Georgia	10 G. Kartozia street, Tbilisi, Georgia	Real estate	17/8/2015	-	
\Rightarrow M Square Park, LLC	100.00%	100.00%	Georgia	1 Marshal Gelovani ave., Tbilisi	Real estate	15/9/2015	-	
⇒ M square Park 3, LLC	100.00%	100.00%	Georgia	1 Marshal Gelovani ave., Tbilisi	Real estate	25/5/2022	-	
⇒ M square Park 4, LLC	100.00%	100.00%	Georgia	1 Marshal Gelovani ave., Tbilisi	Real estate	25/5/2022	-	
⇒ M square Park X, LLC	100.00%	100.00%	Georgia	1 Marshal Gelovani ave., Tbilisi	Real estate	23/06/2022	-	
⇒ Optima Saburtalo, LLC	100.00%	100.00%	Georgia	10 G. Kartozia street, Tbilisi, Georgia	Real estate	15/9/2015	-	
⇒ Land, LLC	100.00%	100.00%	Georgia	10 G. Kartozia street, Tbilisi, Georgia	Real estate	3/10/2014	-	
⇒ m2 at Nutsubidze 2, LLC	100.00%	100.00%	Georgia	10 G. Kartozia street, Tbilisi, Georgia	Real estate	24/1/2020	-	
⇒ m2 at Hippodrome, LLC	100.00%	100.00%	Georgia	10 Givi Kartozia st., Tbilisi	Real estate	6/7/2015	-	
⇒ Optima, LLC	100.00%	100.00%	Georgia	10 Givi Kartozia st., Tbilisi	Real estate	3/8/2016	-	
⇒ m2 Maintenance, LLC	100.00%	100.00%	Georgia	10 Givi Kartozia st., Tbilisi	Real estate	20/7/2021	-	
⇒ m2 at Mtatsminda Park, LLC	100.00%	100.00%	Georgia	10 Givi Kartozia st., Tbilisi	Real estate	31/12/2021	-	
\Rightarrow m2 Care Fund N(N)LE	100.00%	0.00%	Georgia	10 Givi Kartozia st., Tbilisi	Real estate	16/01/2023	-	
⇒ M square Park 5, LLC	100.00%	0.00%	Georgia	10 Givi Kartozia st., Tbilisi	Real estate	11/10/2023	-	
⇒ Georgia Real Estate Management Group, LLC	100.00%	100.00%	Georgia	10 Givi Kartozia st., Tbilisi	Hospitality	17/8/2015	-	
⇒ Kakheti Wine and Spa, LLC ⁽⁵⁾	0.00%	100.00%	Georgia	80 Aghmashenebeli ave., Tbilisi, 0102	Hospitality	23/04/2018	-	
⇒ Gudauri Lodge, LLC	100.00%	100.00%	Georgia	80 Aghmashenebeli ave., Tbilisi, 0102	Hospitality	24/04/2018	_	
⇒ m2 Svaneti, LLC ⁽⁶⁾	0.00%	100.00%	Georgia	80 Aghmashenebeli ave., Tbilisi, 0102	Hospitality	14/11/2018	-	
⇒ m2 Hatsvali, LLC ⁽⁵⁾	0.00%	100.00%	Georgia	80 Aghmashenebeli ave., Tbilisi, 0102	Hospitality	17/4/2019	-	
⇒ m2 Resort, LLC ⁽⁵⁾	0.00%	100.00%	Georgia	80 Aghmashenebeli ave., Tbilisi, 0102	Hospitality	11/2/2019	-	
⇒ m2 Mtatsminda, LLC	0.00%	100.00%	Georgia	22 Zaal Dumbadze st., Tbilisi	Hospitality	16/10/2014	26/12/2017	
⇒ Georgia Property Management	100.00%	100.00%	Georgia	10 Givi Kartozia st., Tbilisi	Commercial assets	4/10/2018	_	
Group, LLC ⇒ Vere Real Estate, LLC (5)	0.00%	100.00%	Georgia	10 Givi Kartozia st., Tbilisi	Commercial assets	4/3/2010	6/8/2018	
⇒ Caucasus Autohouse, LLC ⁽⁵⁾	0.00%	100.00%	Georgia	29 Ilia chavchavadze Ave., Tbilisi, 0105	Commercial	29/3/2011	-	
⇒ m2, LLC	100.00%	100.00%	Georgia	29 Ilia chavchavadze Ave., Tbilisi, 0105	Hospitality / Real estate	12/2/2014	-	
⇒ m2 Hotel Property, LLC (5)	0.00%	100.00%	Georgia	10 Givi Kartozia st., Tbilisi	Hospitality	15/12/2022	_	
⇒ m2 Kutaisi, LLC	100.00%	100.00%	Georgia	10 Melikishvili ave., Tbilisi	Hospitality	17/5/2017	_	
⇒ m2 at Melikishvili, LLC ⁽⁵⁾	0.00%	100.00%	Georgia	10 Melikishvili ave., Tbilisi	Hospitality	17/5/2017	-	
⇒ Melikishvili Hotel Property,	0.00%	100.00%	Georgia	10 Melikishvili ave., Tbilisi	Hospitality	3/2/2021	_	
LLC ⁽⁵⁾ ⇒ m2 Zugdidi, LLC ⁽⁵⁾	0.00%	100.00%	Georgia	80 Aghmashenebeli ave., Tbilisi, 0102	Hospitality	7/11/2018	_	
⇒ Georgia Commercial Assets,	0.00%	100.00%	_		Commercial	23/12/2020		
LLC ⁽⁵⁾ ⇒ Georgia Hospitality Management Group, LLC	100.00%	100.00%	Georgia Georgia	Kazbegi street 15, Tbilisi Georgia Givi Kartozia street 10, Saburtalo, Tbilisi	assets Hospitality	22/8/2018	-	
⇒ Georgia Hospitality Management Group Gudauri, LLC	100.00%	100.00%	Georgia	Georgia, Dusheti region, village Seturebi	Hospitality	12/5/2019	-	
⇒ Melikishvili Hotel Management, LLC	100.00%	100.00%	Georgia	10 Melikishvili ave., Tbilisi	Hospitality	8/4/2022	-	

2. Basis of Preparation (continued)

Subsidiaries and associates (continued)

	rights and capi	ion of voting ordinary share tal held*	.				
Subsidiaries at FV	31 December 2023	31 December 2022	Country of incorporation	Address	Industry	Date of incorporation	Date of acquisition
⇒ JSC Georgian Renewable Po		100.00%	Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Renewable Energy	23/8/2022	-
⇒ JSC Georgian Renewal	ole Power Company 100.00%	100.00%	Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Renewable Energy	15/9/2015	_
⇒ JSC Zoti Hydro	100.00%	100.00%	Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Renewable	20/8/2015	_
⇒ JSC Caucasus Wind	Company 100.00%	100.00%	Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Energy Renewable	14/9/2016	_
⇒ LLC Caucasus Solar	Company 100.00%	100.00%	Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Energy Renewable	27/10/2016	_
⇒ Hydro S, LLC	100.00%	100.00%	Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Energy Renewable	18/1/2019	10/28/2019
⇒ Georgia Geotherma	1 Company, LLC 100.00%	100.00%	Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Energy Renewable	16/12/2019	_
⇒ Qartli Solar Farm, L		0.00%	Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Energy Renewable	10/3/2023	_
⇒ JSC Georgian Renewal	ole Power Operations 100.00%	100.00%	Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Energy Renewable	28/6/2022	_
⇒ Svaneti Hydro, LLC		100.00%	Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Energy Renewable	6/12/2013	_
⇒ Qartli Wind Farm, L		100.00%	Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Energy Renewable	10/9/2012	30/12/2019
⇒ Hydrolea, LLC	100.00%	100.00%	Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Energy Renewable	6/7/2012	28/10/2019
⇒ Geoenergy, LLO	C 100.00%	100.00%	Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Energy Renewable	26/1/2012	28/10/2019
⇒ Hydro Georgia,			Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Energy Renewable	8/5/2012	28/10/2019
⇒ Darchi, LLC	100.00%		Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Energy Renewable	18/11/2013	28/10/2019
⇒ Kasleti 2, LLC	100.00%		Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Energy Renewable	18/11/2013	28/10/2019
⇒ GRPC Trade, LLC	100.00%		Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Energy Renewable	13/5/2022	_
⇒ JSC A Group	100.00%		Georgia	1, Berbuki str., Saburatlo, Tbilisi	Energy Various	20/9/2018	_
⇒ JSC Insurance Compan			Georgia	66A, David Aghmashenebeli Alley,	Insurance	11/8/1998	_
⇒ JSC Insurance Co	,		Georgia	Tbilisi 66A, David Aghmashenebeli Alley,	Insurance	22/8/2007	1/5/2015
⇒ Aliance, LLC	100.00%		Georgia	Tbilisi 20, Chavchavadze ave., floor 2, Vake-	Various	1/8/1998	30/4/2012
⇒ Auto Way LLC	100.00%		Georgia	Saburtalo, Tbilisi 20, Chavchavadze ave., Vake, Tbilisi	Various	27/12/2010	30/4/2012
⇒ JSC Carfest	75.00%		Georgia	20, Chavchavadze ave., Vake, Tbilisi	Leasing	17/11/2017	_
⇒ JSC Greenway Georgia	100.00%	100.00%	Georgia	6, University str., Vake, Tbilisi	Vehicle	9/7/2010	1/5/2012
⇒ JSC GreenWash	75.00%	75.00%	Georgia	6, University str., Vake, Tbilisi	Inspection Car Wash	31/8/2018	_
⇒ Georgia Healthcare Group I	Limited 0.00%	100.00%	United Kingdom	84 Brook Street, London, W1K 5EH	Healthcare	27/8/2015	28/8/2015
⇒ JSC Georgia Healthcare Gro	up 100.00%	100.00%	Georgia	142, A. Beliashvili str, Tbilisi	Healthcare	29/4/2015	_
⇒ JSC Insurance Compan	y Imedi L 100.00%	100.00%	Georgia	9, Anna Politkovskaias Str. Vake- Saburtalo District, Tbilisi	Insurance	22/6/2007	-
⇒ L Assistance LLC	100.00%	100.00%	Georgia	44, Al. Kazbegi Avenue, Vake, Tbilisi	Insurance	27/10/2022	
⇒ JSC GEPHA	97.56%	76.98%	Georgia	142, A. Beliashvili str, Tbilisi	Pharmacy and Distribution	19/10/1995	4/5/2016
⇒ JSC ABC Pharam	cia (Armenia) 100.00%	100.00%	Armenia	Kievyan Str. 2/8, Erevan, Armenia	Pharmacy and Distribution	28/12/2013	6/1/2017
⇒ ABC Pharmalogis	stics, LLC 100.00%	100.00%	Georgia	Peikrebi str. 14a, Tbilisi, Georgia	Pharmacy and Distribution	24/2/2004	6/1/2017
⇒ JSC Iverta	100.00%	100.00%	Georgia	A. Beliashvili str. 142, Tbilisi, Georgia	Pharmacy and Distribution	17/2/2021	-
\Rightarrow AKG AVELIN (Armenia)	QAN DEGHATUN, LLC 100.00%	100.00%	Armenia	26/1 Vazgen Sargsyan Street, /Office 412/ Yerevan 0010, Armenia	Pharmacy and Distribution	28/6/2019	-
⇒ JSC Georgian Log	gistics 100.00%	100.00%	Georgia	A. Beliashvili str. 142, Tbilisi, Georgia	Other	8/10/2021	-
⇒ AZPHA LLC (Az	zerbaijan) 100.00%	100.00%	Azerbaijan	Azerbaijan, Baku, Sabunchu District, Bakikhanovi area, 131, A. Ahgaievi Street, Apartment 43	Pharmacy and Distribution	17/9/2021	-
⇒ Euroline LLC	100.00%	100.00%	Georgia	Stanislavski str. 5, Tbilisi, Georgia	Other	24/11/2021	14/12/2015

2. Basis of Preparation (continued)

Subsidiaries and associates (continued)

Proportion of voting rights
and ordinary share capital
held*

Substitute			he						
⇒ Vian-Logistics ILC ^(1)C) 100.00% 100.00% Georgia 142, A. Beliasbvili str, Tbilisi Healthcare 13/2/2015 ⇒ Caucasus Medical Center, ILC ⁽²⁾ 99.81% 99.80% Georgia 23, P. Kavtaradze Str., Tbilisi Healthcare 12/1/2012 ⇒ JSC Kutaisi Regional Mother and Infant 66.70% 67.00% Georgia Djavakhishvili str. 85, Kutaisi, Georgia Healthcare 5/5/2003 ⇒ West Georgia Medical Center, ILC ⁽²⁾ 66.70% 67.00% Georgia A Djavakhishvili str. 85A, Kutaisi, Georgia Healthcare 9/12/2011 ⇒ N(NL)E Blood Center ⁽²⁾ 100.00% 100.00% Georgia 142, A. Beliasbvili str. Nis Javakhishvili str. Healthcare 2/12/2021 ⇒ Van LLC 100.00% 100.00% Georgia 142, A. Beliasbvili str. Tbilisi Healthcare 15/66/2023 ⇒ JSC Georgian Clinics 100.00% 0.00% Georgia 142, A. Beliasbvili str, Tbilisi Healthcare 1/8/2014 ⇒ New Clinic, LLC ⁽³⁾ 100.00% 100.00% Georgia 142, A. Beliasbvili str, Tbilisi, Georgia Healthcare 2/9/2023 ⇒ New Ellary ⁽⁴⁾	Subsidiari	ies at FV	31 December	31 December		Address	Industry		Date of acquisition
⇒ Caucasus Medical Center, I.I.C ^{Cl} 99.81% 99.80% Georgia 23, P. Kavtaradze Str., Tbilisi Healthcare 12/1/2012 ⇒ JSC Kutaisi Regional Mother and Infant Treatment-Diagnostic Centre ^{Cl} 66.70% 67.00% Georgia Djavakhishvili str. 83A, Kutaisi, Georgia Healthcare 5/5/2003 ⇒ West Georgia Medical Center, I.I.C ^{Cl} 66.70% 67.00% Georgia A Djavakhishvili str. 83A, Kutaisi, Georgia Healthcare 9/12/2011 ⇒ N(N.I.)E Blood Center ^{Cl} 100.00% 100.00% Georgia Javakhishvili str. NB5/ Javakhishvili str. Healthcare 23/12/2021 ⇒ Van I.I.C 100.00% 100.00% Georgia 142, A. Beliashvili str. Tbilisi Healthcare 15/66/2023 ⇒ BONO Healthcare I.I.C 100.00% 0.00% Georgia 142, A. Beliashvili str, Tbilisi Healthcare 15/66/2023 ⇒ JSC Georgian Clinics 100.00% 100.00% Georgia 142, A. Beliashvili str, Tbilisi Healthcare 1/8/2014 ⇒ New Clinic, ILIC ^D 100.00% 100.00% Georgia 142, A. Beliashvili str, Tbilisi Healthcare 5/9/2003 ⇒ JSC Pe	\Rightarrow	Vian JSC	100.00%	0.00%	Georgia	142, A. Beliashvili str, Tbilisi	Healthcare	30/11/2023	-
⇒ JSC Kutaiss Regional Mother and Infant Teatment-Diagnostic Centre (¹) 66.70% 67.00% Georgia Djavakhishvii str. 85, Kutaisi, Georgia Healthcare 5/5/2003 ⇒ West Georgia Medical Center (¹) 100.00% 67.00% Georgia A Djavakhishvii str. 85, Kutaisi, Georgia Healthcare 9/12/2011 ⇒ N(NL)E Blood Center (¹) 100.00% 100.00% Georgia Javakhishviii str. N85 / Javakhishviii str. Healthcare 23/12/2021 ⇒ Vian LLC 100.00% 100.00% Georgia 142, A. Beliashviii str, Tbilisi Healthcare 05/09/2022 ⇒ BONO Healthcare LLC 100.00% 0.00% Georgia 142, A. Beliashviii str, Tbilisi Healthcare 15/06/2023 ⇒ JSC Georgian Clinics 100.00% 0.00% Georgia 142, A. Beliashviii str, Tbilisi Healthcare 1/8/2014 ⇒ New Clinic, LLC (¹) 100.00% 100.00% Georgia U. Chkeidze str. 10, Tbilisi, Georgia Healthcare 5/9/2003 ⇒ NCLE Evex Learning Centre (¹) 100.00% 100.00% Georgia #83.0, Javakhishviii str. Tbilisi Other 20/12/2013 ⇒ Georgian Clinics LLC		⇒ Vian-Logistics LLC ⁽¹⁾⁽²⁾	100.00%	100.00%	Georgia	142, A. Beliashvili str, Tbilisi	Healthcare	13/2/2015	-
Secondary Sec		⇒ Caucasus Medical Center, LLC ⁽²⁾	99.81%	99.80%	Georgia	23, P. Kavtaradze Str., Tbilisi	Healthcare	12/1/2012	11/6/2015
No.	Treatment		66.70%	67.00%	Georgia	Djavakhishvili str. 85, Kutaisi, Georgia	Healthcare	5/5/2003	29/11/2011
Nonly Brood Center Nonly Brood Center Nonly Reorgia Nonly Nonly Reorgia Nonly R		⇒ West Georgia Medical Center, LLC ⁽²⁾	66.70%	67.00%	Georgia		Healthcare	9/12/2011	29/11/2011
⇒ BONO Healthcare LLC 100.00% 0.00% Georgia 142, A. Beliashvili str, Tbilisi Healthcare 15/06/2023 ⇒ JSC Georgian Clinics 100.00% 0.00% Georgia 142, A. Beliashvili str, Tbilisi Healthcare 1/8/2014 ⇒ New Clinic, LLC (b) 100.00% 100.00% Georgia U. Chkeidze str. 10, Tbilisi, Georgia Healthcare 5/9/2003 ⇒ NCLE Evex Learning Centre (b) 100.00% 100.00% Georgia #83A, Javakhishvili street, Tbilisi Other 20/12/2013 ⇒ JSC Emergency Service (c) 85.00% 85.00% Georgia #6 Building, #13/6 Lubliana str. Tbilisi, Georgia Healthcare 18/6/2013 ⇒ Georgian Clinics LLC 100.00% 0.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 29/09/2023 ⇒ JSC Evex Clinics 100.00% 67.00% Georgia 16 Eristavi street, Tskhaltubo Healthcare 1/4/2019 ⇒ Tskaltubo Regional Hospital, LLC 66.70% 67.00% Georgia 16 Eristavi street, Tskhaltubo Healthcare 2/9/1999 ⇒ LLC Aliance Med 100.00% 75.00%		⇒ N(NL)E Blood Center (2)	100.00%	100.00%	Georgia		Healthcare	23/12/2021	-
⇒ JSC Georgian Clinics 100.00% 0.00% Georgia 142, A. Beliashvili str, Tbilisi Healthcare 1/8/2014 ⇒ New Clinic, LLC ⁽ⁱ⁾ 100.00% 100.00% Georgia 142, A. Beliashvili str, Tbilisi Healthcare 3/1/2017 ⇒ JSC Pediatry ⁽ⁱ⁾ 100.00% 100.00% Georgia U. Chkeidze str. 10, Tbilisi, Georgia Healthcare 5/9/2003 ⇒ NCLE Evex Learning Centre ⁽ⁱ⁾ 100.00% 100.00% Georgia #85A, Javakhishvili str, et. Tbilisi Other 20/12/2013 ⇒ JSC Emergency Service ⁽ⁱ⁾ 85.00% 6eorgia #6 Building, #13/6 Lubliana str. Tbilisi, Georgia Healthcare 18/6/2013 ⇒ JSC Emergency Service ⁽ⁱ⁾ 85.00% 6eorgia #6 Building, #13/6 Lubliana str. Tbilisi, Georgia Healthcare 18/6/2013 ⇒ JSC Emergency Service ⁽ⁱ⁾ 85.00% 6eorgia #6 Building, #13/6 Lubliana str. Tbilisi Healthcare 18/6/2013 ⇒ JSC Ewex Clinics 100.00% 0.00% Georgia 142, A. Beliashvili str, Tbilisi Healthcare 29/09/2023 ⇒ Tskaltuba Regional Clinics LLC 100.00% 6corgia 40,		⇒ Vian LLC	100.00%	100.00%	Georgia	142, A. Beliashvili str, Tbilisi	Healthcare	05/09/2022	-
⇒ New Clinic, LLC (b) 100.00% 100.00% Georgia 142, A. Beliashvili str., Tbilisi Healthcare 3/1/2017 ⇒ JSC Pediatry (b) 100.00% 100.00% Georgia U. Chkeidze str. 10, Tbilisi, Georgia Healthcare 5/9/2003 ⇒ NCLE Evex Learning Centre (b) 100.00% 100.00% Georgia #88A, Javakhishvili street, Tbilisi Other 20/12/2013 ⇒ JSC Emergency Service (b) 85.00% 85.00% Georgia #6 Building, #13/6 Lubliana str. Tbilisi Healthcare 18/6/2013 ⇒ Georgian Clinics LLC 100.00% 0.00% Georgia 142, A. Beliashvili str., Tbilisi Healthcare 29/09/2023 ⇒ JSC Evex Clinics 100.00% 100.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 1/4/2019 ⇒ Tskaltubo Regional Hospital, LLC 66.70% 67.00% Georgia 16 Eristavi street, Tskhaltubo Healthcare 29/9/1999 ⇒ LLC Aliance Med 100.00% 100.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 7/7/2015 ⇒ JSC Polyclinic Vere 98.35% 98.35% Geor		⇒ BONO Healthcare LLC	100.00%	0.00%	Georgia	142, A. Beliashvili str, Tbilisi	Healthcare	15/06/2023	-
⇒ JSC Pediatry (3) 100.00% 100.00% Georgia U. Chkeidze str. 10, Tbilisi, Georgia Healthcare 5/9/2003 ⇒ NCLE Evex Learning Centre (3) 100.00% 100.00% Georgia #83A, Javakhishvili street, Tbilisi Other 20/12/2013 ⇒ JSC Emergency Service (3) 85.00% 85.00% Georgia #6 Building, #13/6 Lubbiana str. Tbilisi, Georgia. Healthcare 18/6/2013 ⇒ Georgian Clinics LLC 100.00% 0.00% Georgia 142, A. Beliashvili str, Tbilisi Healthcare 29/09/2023 ⇒ JSC Evex Clinics 100.00% 100.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 1/4/2019 ⇒ Tskaltubo Regional Hospital, LLC 66.70% 67.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 29/9/1999 ⇒ LLC Aliance Med 100.00% 100.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 7/7/2015 ⇒ JSC Polyclinic Vere 98.35% 98.35% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 22/11/2015 ⇒ New Dent, LLC 75.00% 75.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 24/12/2018 ⇒ Mkurnali 2002, LLC 100.00% 0.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 24/12/2018 ⇒ JSC Mega-Lab 91.98% 92.00% Georgia 87, Ts. Dadiani Str., Tbilisi Healthcare 8/4/2004 ⇒ JLC Patgeo-Union of Pathologists 100.00% 100.00% Georgia Petre Kavtaradze str. 23, Tbilisi Healthcare 13/1/2010 ⇒ Scientific- Research Center - Mega-Lab 100.00% Georgia Petre Kavtaradze str. 23 Tbilisi Healthcare 25/5/2021	\Rightarrow	JSC Georgian Clinics	100.00%	0.00%	Georgia	142, A. Beliashvili str, Tbilisi	Healthcare	1/8/2014	1/8/2014
⇒ NCLE Evex Learning Centre (3) 100.00% 100.00% Georgia #83A, Javakhishvili street, Tbilisi Other 20/12/2013 ⇒ JSC Emergency Service (3) 85.00% 85.00% Georgia #6 Building, #13/6 Lubliana str. Tbilisi, Georgia 18/6/2013 ⇒ Georgian Clinics LLC 100.00% 0.00% Georgia 142, A. Beliashvili str, Tbilisi Healthcare 29/09/2023 ⇒ JSC Evex Clinics 100.00% 100.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 1/4/2019 ⇒ Tskaltubo Regional Hospital, LLC 66.70% 67.00% Georgia 16 Eristavi street, Tskhaltubo Healthcare 29/9/1999 ⇒ LLC Aliance Med 100.00% 100.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 7/7/2015 ⇒ JSC Polyclinic Vere 98.35% 98.35% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 22/11/2015 ⇒ New Dent, LLC 75.00% 75.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 24/12/2018 ⇒ Mkurnali 2002, LLC 100.00% 0.00% Georgia 87, Ts. Dadiani Str., Tbilisi Healthcare 8/4/2004 ⇒ JSC Mega-Lab 91.98% 92.00% Georgia Petre Kavtaradze str. 23, Tbilisi Healthcare 13/1/2010 ⇒ Scientific- Research Center - Mega-Lab 100.00% 100.00% Georgia Petre Kavtaradze str. 23 Tbilisi Healthcare 25/5/2021		⇒ New Clinic, LLC (3)	100.00%	100.00%	Georgia	142, A. Beliashvili str, Tbilisi	Healthcare	3/1/2017	20/7/2017
⇒ JSC Emergency Service (3) 85.00% 85.00% 85.00% Georgia #6 Building, #13/6 Lubliana str. Tbilisi, Georgia Healthcare 18/6/2013 ⇒ Georgia Clinies LLC 100.00% 100.00% Georgia 142, A. Beliashvili str, Tbilisi Healthcare 29/09/2023 ⇒ JSC Evex Clinies 100.00% 100.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 29/9/1999 ⇒ LLC Aliance Med 100.00% 100.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 29/9/1999 ⇒ LLC Aliance Med 100.00% 100.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 7/7/2015 ⇒ JSC Polyclinie Vere 98.35% 98.35% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 22/11/2015 ⇒ New Dent, LLC 75.00% 75.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 24/12/2018 ⇒ Mkurnali 2002, LLC 100.00% 0.00% Georgia 87, Ts. Dadiani Str., Tbilisi Healthcare 8/4/2004 ⇒ JSC Mega-Lab 91.98% 92.00% Georgia Petre Kavtaradze str. 23, Tbilisi Healthcare 13/1/2010 ⇒ Scientific- Research Center - Mega-Lab 100.00% 100.00% Georgia Petre Kavtaradze str. 23, Tbilisi Healthcare 25/5/2021		⇒ JSC Pediatry ⁽³⁾	100.00%	100.00%	Georgia	U. Chkeidze str. 10, Tbilisi, Georgia	Healthcare	5/9/2003	6/7/2016
St. Emergency Service of St. 100.00% St. 100.00% Georgia Georgia. Healthcare 18/6/2013 ⇒ Georgian Clinics LLC 100.00% 0.00% Georgia 142, A. Beliashvili str, Tbilisi Healthcare 29/09/2023 ⇒ JSC Evex Clinics 100.00% 100.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 29/9/1999 ⇒ Tskaltubo Regional Hospital, LLC 66.70% 67.00% Georgia 16 Eristavi street, Tskhaltubo Healthcare 29/9/1999 ⇒ LLC Aliance Med 100.00% 100.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 7/7/2015 ⇒ JSC Polyclinic Vere 98.35% 98.35% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 22/11/2015 ⇒ New Dent, LLC 75.00% 75.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 24/12/2018 ⇒ Mkurnali 2002, LLC 100.00% 0.00% Georgia 87, Ts. Dadiani Str., Tbilisi Healthcare 8/4/2004 ⇒ JSC Mega-Lab 91.98% 92.00% Georgia Petre Kavtaradze str. 23, Tbilisi Healthcare 13/1/2010 ⇒ Scientific- Research Center - Mega-Lab 100.00% 100.00% Georgia Petre Kavtaradze str. 23 Tbilisi Healthcare 25/5/2021		⇒ NCLE Evex Learning Centre ⁽³⁾	100.00%	100.00%	Georgia	#83A, Javakhishvili street, Tbilisi	Other	20/12/2013	20/12/2013
⇒ JSC Evex Clinics 100.00% 100.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 1/4/2019 ⇒ Tskaltubo Regional Hospital, LLC 66.70% 67.00% Georgia 16 Eristavi street, Tskhaltubo Healthcare 29/9/1999 ⇒ LLC Aliance Med 100.00% 100.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 7/7/2015 ⇒ JSC Polyclinic Vere 98.35% 98.35% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 22/11/2015 ⇒ New Dent, LLC 75.00% 75.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 24/12/2018 ⇒ Mkurnali 2002, LLC 100.00% 0.00% Georgia 87, Ts. Dadiani Str., Tbilisi Healthcare 8/4/2004 ⇒ JSC Mega-Lab 91.98% 92.00% Georgia Petre Kavtaradze str. 23, Tbilisi Healthcare 6/6/2017 ⇒ LLC Patgeo-Union of Pathologists 100.00% 100.00% Georgia Petre Kavtaradze str. 23, Tbilisi Healthcare 13/1/2010 ⇒ Scientific- Research Center - Mega-Lab		⇒ JSC Emergency Service (3)	85.00%	85.00%	Georgia		Healthcare	18/6/2013	8/5/2015
⇒ Tskaltubo Regional Hospital, LLC 66.70% 67.00% Georgia 16 Eristavi street, Tskhaltubo Healthcare 29/9/1999 ⇒ LLC Aliance Med 100.00% 100.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 22/11/2015 ⇒ JSC Polyclinic Vere 98.35% 98.35% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 22/11/2015 ⇒ New Dent, LLC 75.00% 75.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 24/12/2018 ⇒ Mkurnali 2002, LLC 100.00% 0.00% Georgia 87, Ts. Dadiani Str., Tbilisi Healthcare 8/4/2004 ⇒ JSC Mega-Lab 91.98% 92.00% Georgia Petre Kavtaradze str. 23, Tbilisi Healthcare 6/6/2017 ⇒ LLC Patgeo-Union of Pathologists 100.00% 100.00% Georgia Petre Kavtaradze str. 23, Tbilisi Healthcare 13/1/2010 Scientific- Research Center - Mega-Lab		⇒ Georgian Clinics LLC	100.00%	0.00%	Georgia	142, A. Beliashvili str, Tbilisi	Healthcare	29/09/2023	-
⇒ LLC Aliance Med 100.00% 100.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 7/7/2015 ⇒ JSC Polyclinic Vere 98.35% 98.35% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 22/11/2015 ⇒ New Dent, LLC 75.00% 75.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 24/12/2018 ⇒ Mkurnali 2002, LLC 100.00% 0.00% Georgia 87, Ts. Dadiani Str., Tbilisi Healthcare 8/4/2004 ⇒ JSC Mega-Lab 91.98% 92.00% Georgia Petre Kavtaradze str. 23, Tbilisi Healthcare 6/6/2017 ⇒ LLC Patgeo-Union of Pathologists 100.00% 100.00% Georgia Mukhiani, II mcr. District, Building 22, 1a, Tbilisi Healthcare 13/1/2010 ⇒ Scientific- Research Center - Mega-Lab 100.00% 100.00% Georgia Petre Kavtaradze str. 23 Tbilisi Healthcare 25/5/2021	\Rightarrow	JSC Evex Clinics	100.00%	100.00%	Georgia	40, Vazha-Pshavela Avenue, Tbilisi	Healthcare	1/4/2019	-
⇒ JSC Polyclinic Vere 98.35% 98.55% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 22/11/2015 ⇒ New Dent, LLC 75.00% 75.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 24/12/2018 ⇒ Mkurnali 2002, LLC 100.00% 0.00% Georgia 87, Ts. Dadiani Str., Tbilisi Healthcare 8/4/2004 ⇒ JSC Mega-Lab 91.98% 92.00% Georgia Petre Kavtaradze str. 23, Tbilisi Healthcare 6/6/2017 ⇒ LLC Patgeo-Union of Pathologists 100.00% 100.00% Georgia Mukhiani, II mer. District, Building 22, 1a, Tbilisi Healthcare 13/1/2010 ⇒ Scientific- Research Center - Mega-Lab 100.00% 100.00% Georgia Petre Kavtaradze str. 23 Tbilisi Healthcare 25/5/2021		⇒ Tskaltubo Regional Hospital, LLC	66.70%	67.00%	Georgia	16 Eristavi street, Tskhaltubo	Healthcare	29/9/1999	9/12/2011
⇒ New Dent, LLC 75.00% 75.00% 75.00% Georgia 40, Vazha-Pshavela Avenue, Tbilisi Healthcare 24/12/2018 ⇒ Mkurnali 2002, LLC 100.00% 0.00% Georgia 87, Ts. Dadiani Str., Tbilisi Healthcare 8/4/2004 ⇒ JSC Mega-Lab 91.98% 92.00% Georgia Petre Kavtaradze str. 23, Tbilisi Healthcare 6/6/2017 ⇒ LLC Patgeo-Union of Pathologists 100.00% 100.00% Georgia Mukhiani, II mer. District, Building 22, 1a, Tbilisi Healthcare 13/1/2010 ⇒ Scientific- Research Center - Mega-Lab 100.00% 100.00% 100.00% Georgia Petre Kavtaradze str. 23 Tbilisi Healthcare 25/5/2021		⇒ LLC Aliance Med	100.00%	100.00%	Georgia	40, Vazha-Pshavela Avenue, Tbilisi	Healthcare	7/7/2015	20/7/2017
⇒ Mkurnali 2002, LLC 100.00% 0.00% Georgia 87, Ts. Dadiani Str., Tbilisi Healthcare 8/4/2004 ⇒ JSC Mega-Lab 91.98% 92.00% Georgia Petre Kavtaradze str. 23, Tbilisi Healthcare 6/6/2017 ⇒ LLC Patgeo-Union of Pathologists 100.00% 100.00% Georgia Mukhiani, II mcr. District, Building 22, 1a, Tbilisi Healthcare 13/1/2010 ⇒ Scientific- Research Center - Mega-Lab 100.00% 100.00% Georgia Petre Kavtaradze str. 23 Tbilisi Healthcare 25/5/2021		⇒ JSC Polyclinic Vere	98.35%	98.35%	Georgia	40, Vazha-Pshavela Avenue, Tbilisi	Healthcare	22/11/2015	25/12/2017
⇒ JSC Mega-Lab 91.98% 92.00% Georgia Petre Kavtaradze str. 23, Tbilisi Healthcare 6/6/2017 ⇒ LLC Patgeo-Union of Pathologists 100.00% 100.00% Georgia Petre Kavtaradze str. 23, Tbilisi Healthcare 13/1/2010 ⇒ Scientific- Research Center - Mega-Lab 100.00% 100.00% 100.00% Georgia Petre Kavtaradze str. 23, Tbilisi Healthcare 25/5/2021		⇒ New Dent, LLC	75.00%	75.00%	Georgia	40, Vazha-Pshavela Avenue, Tbilisi	Healthcare	24/12/2018	-
⇒ LLC Patgeo-Union of Pathologists 100.00% 100.00% Georgia Mukhiani, II mer. District, Building 22, 1a, Tbilisi Healthcare 13/1/2010 ⇒ Scientific- Research Center - Mega-Lab 100.00% 100.00% Georgia Petre Kawtaradze str. 23 Tbilisi Healthcare 25/5/2021		⇒ Mkurnali 2002, LLC	100.00%	0.00%	Georgia	87, Ts. Dadiani Str., Tbilisi	Healthcare	8/4/2004	1/12/2023
⇒ LLC Patgeo-Union of Pathologists 100.00% 100.00% Georgia 1a, Tbilisi Healthcare 13/1/2010 ⇒ Scientific- Research Center - Mega-Lab 100.00% 100.00% Georgia Petre Kaytaradze str. 23 Tbilisi Healthcare 25/5/2021	⇒	JSC Mega-Lab	91.98%	92.00%	Georgia	Petre Kavtaradze str. 23, Tbilisi	Healthcare	6/6/2017	-
		⇒ LLC Patgeo-Union of Pathologists	100.00%	100.00%	Georgia		Healthcare	13/1/2010	27/9/2016
N(N)LE	N(N)LE	⇒ Scientific- Research Center - Mega-Lab	100.00%	100.00%	Georgia	Petre Kavtaradze str. 23, Tbilisi	Healthcare	25/5/2021	-

2. Basis of Preparation (continued)

Subsidiaries and associates (continued)

Proportion of voting rights and ordinary share capital held*

	capital held* 31 31							
Subsidiaries at FV	December 2023	31 December 2022	Country of incorporation	Address	Industry	Date of incorporation	Date of acquisition	
⇒ JSC Vabaco	67.00%	67.00%	Georgia	Bochorishvili str. 37, Tbilisi, Georgia	Software Development	9/9/2013	28/9/2018	
⇒ Vabaco International, LLC	100.00%	100.00%	Georgia	A. Tsereteli ave. 123, Tbilisi, Georgia	Software Development	30/3/2022	-	
⇒ JSC Ekimo	100.00%	67.00%	Georgia	A. Tsereteli ave. 123, Tbilisi, Georgia	Other	14/12/2021	-	
⇒ Ekimo App, LLC	100.00%	0.00%	Georgia	24, University str., Vake, Tbilisi	Other	5/12/2023	-	
⇒ Dart, LLC	0.00%	100.00%	Georgia	A. Beliashvili str. 142, Tbilisi, Georgia	Other	14/6/2021	-	
\Rightarrow ITFY LLC	100.00%	0.00%	Georgia	A. Beliashvili str. 142, Tbilisi, Georgia	Other	1/2/2023	-	
⇒ Georgian Beverages LLC	100.00%	100.00%	Georgia	8a Petre Melikishvili Ave, Tbilisi, 0179	Beer Production and Distribution	14/11/2016	7/2/2018	
⇒ JSC Georgian Beverages Holding	92.35%	92.35%	Georgia	8a Petre Melikishvili Ave, Tbilisi, 0179	Investment	17/12/2019	_	
⇒ JSC Teliani Valley	100.00%	100.00%	Georgia	43 Tbilisi highway, Telavi.	Winery	30/6/2000	28/2/2007	
⇒ Teliani Trading (Ukraine), LLC	100.00%	100.00%	Ukraine	18/14 Khvoiki St. Kiev	Distribution	3/10/2006	31/12/2007	
⇒ Teliani Europe GmbH	100.00%	100.00%	Germany	Kurfürstendamm 195 10707 Berlin	Distribution	15/6/2021	_	
⇒ Georgia Logistics and	100.00%	100.00%	Georgia	2 Marshal Gelovani St, Tbilisi	Distribution	10/1/2006	27/3/2007	
Distribution, LLC ⇒ Le Caucase, LLC	100.00%	100.00%	Georgia	2 Marshal Gelovani St, Tbilisi	Cognac Production	23/9/2006	20/3/2007	
⇒ Kupa, LLC	70.00%	70.00%	Georgia	3 Tbilisi highway, Telavi	Oak Barrel Production	12/10/2006	20/3/2007	
⇒ Global Beer Georgia, LLC	100.00%	100.00%	Georgia	Tsilkani, Mtskheta Region, Georgia	Production and distribution of alcohol and non-alcohol beverages	24/12/2014	-	
⇒ Kindzmarauli Marani, LLC	100.00%	100.00%	Georgia	Gavazi, Kvareli district, Georgia	Winery	18/12/2001	25/4/2018	
⇒ Alaverdi, LLC	100.00%	100.00%	Georgia	Chumlaki, Gurjaani Region, Georgia	Winery	8/4/2008	19/8/2019	
⇒ Global Coffee Georgia, LLC	100.00%	100.00%	Georgia	29a Gagarini street, Tbilisi	Coffee Distribution	26/12/2016	-	
⇒ New Coffee Company, LLC	100.00%	100.00%	Georgia	Isakiani cul-de-sac 2, Gldani-Nadzaladevi District, Tbilisi	Coffee Distribution	23/9/2009	15/2/2017	
⇒ Genuine Brewing Company, LLC	100.00%	100.00%	Georgia	Tsilkani, Mtskheta Region, Georgia	Beer Production and Distribution	7/6/2011	7/2/2018	
⇒ Craf and Draft, LLC	100.00%	100.00%	Georgia	Tsilkani, Mtskheta Region, Georgia	Beer Production	20/2/2019	-	
⇒ Artisan Wine and Drinks LLC	100.00%	100.00%	Georgia	8a Petre Melikishvili Ave, Tbilisi, 0179	Wine distribution	26/8/2019	_	
⇒ Amboli, LLC	90.00%	90.00%	Georgia	142 Beliashvili str., Didube-Chugureti District, Tbilisi	Car Services	13/8/2004	25/6/2019	
⇒ Redberry, LLC	0.00%	60.00%	Georgia	9, Tashkenti st, Tbilisi, Georgia	Digital Services	29/8/2014	1/5/2019	
⇒ Redberry International, LLC	0.00%	100.00%	Georgia	Mtskheta str, 13a, Tbilisi, Georgia	Digital Services	13/5/2021	_	
⇒ Lunchoba, LLC	0.00%	60.00%	Georgia	22 Nutsubidze IV Micro-district, Tbilisi	Catering Services	8/10/2018	_	
⇒ Shabatoba, LLC	0.00%	100.00%	Georgia	8 Zurab Sakandelidze st, Tbilisi, Georgia	Delivery Services	2/6/2020	_	
⇒ JSC Carfest	0.00%	25.00%	Georgia	3, Pushkini str., Krtsanisi, Tbilisi	Leasing	17/11/2017	_	
⇒ Georgia Education Group, LLC	100.00%	100.00%	Georgia	8a Petre Melikishvili Ave, Tbilisi, 0179	Education	16/7/2019	_	
⇒ Contemporary school LLC	90.00%	90.00%	Georgia	N, Khudadovi str. 1b, Tbilisi, Georgia	Education	18/8/2021	_	
⇒ Green School - Didi Dighomi,	100.00%	100.00%	Georgia	D. Tavdadebuli str. 6, Tbilisi, Georgia	Education	27/9/1995	20/8/2021	
LLC ⇒ Green School, LLC	100.00%	100.00%	Georgia	8a Petre Melikishvili Ave, Tbilisi, 0179	Education	21/10/2019	,,	
⇒ JSC Green School Real	100.00%			8a Petre Melikishvili Ave, Tbilisi, 0179	Education	5/1/2019		
Estate		100.00%	Georgia				_	
⇒ Green School - Saburtalo, LLC	100.00%	0.00%	Georgia	37 B. Zhgenti Str., Vake, Tbilisi Didube-Chughureti / Dighomi massive	Education	29/06/2023	-	
⇒ Green School Dighomi LLC ⇒ Rughgayand Integrational School	80.00%	80.00%	Georgia	IV, Building 5A, Apartment 35	Education	7/6/2011	22/8/2019	
⇒ Buckswood International School - Tbilisi, LLC	80.00%	80.00%	Georgia	152 Rustaveli Street, Tskneti, Tbilisi	Education	24/8/2005	29/7/2019	
⇒ Sakhli Tsknetshi, LLC	100.00%	100.00%	Georgia	152 Rustaveli Street, Tskneti, Tbilisi	Education	1/5/2005	-	
⇒ British Georgian Academy, LLC	70.00%	70.00%	Georgia	17, Leo Kvachadze str, Tbilisi	Education	3/2/2006	23/7/2019	
⇒ NNLE British International School of Tbilisi	100.00%	100.00%	Georgia	17, Leo Kvachadze str, Tbilisi	Education	3/2/2015	-	
⇒ British International School of Tbilisi LLC	100.00%	100.00%	Georgia	17, Leo Kvachadze str, Tbilisi	Education	5/9/2019	-	
⇒ British Georgian Academy - Okrokana, LLC	100.00%	100.00%	Georgia	17, Leo Kvachadze str, Tbilisi	Education	16/9/2021	_	
⇒ Oncloud LLC	100.00%	100.00%	Georgia	8a Petre Melikishvili Ave, Tbilisi, 0179	Digital Services	28/2/2020	_	

2. Basis of Preparation (continued)

Subsidiaries and associates (continued)

Proportion of voting
rights and ordinary share
capital held*

Associates	31 December 2023	31 December 2022	Country of incorporation	$\it Address$	Industry	Date of incorporation	Date of acquisition
Squadro, LLC	0.00%	12.00%	Georgia	Kostava street #74, Tbilisi, Georgia	Software Service	2/3/2021	27/8/2021
N(NL)E Georgian Medical Tourism Council (8)	28.57%	28.60%	Georgia	I-II floor, house N10, N 13, b. N1 almond Gardens Street, tskneti, Vake district, Tbilisi	Healthcare	16/5/2019	-
JSC Diflex	40.00%	40.00%	Georgia	Shalikashvili str. 8, Tbilisi, Geogia	Software Development	29/12/2016	12/11/2021
NPO Healthcare Association (2)	25.00%	25.00%	Georgia	Vazha-Pshavela Ave. 27b, Tbilisi, Georgia	Healthcare	25/3/2016	-
Complex-Med-Service, LLC (3)	20.00%	20.00%	Georgia	Tsinandali sts. 9, Tbilisi, Georgia	Healthcare	18/11/2008	30/7/2021
Insurance Informational Bureau, LLC	22.50%	22.50%	Georgia	Baratashvili bridge underground crossing, Mtkvari Left Bank, Old Tbilisi, Tbilisi	Insurance	23/7/2008	-
⇒ JSC Georgian Global Utilities	20.00%	20.00%	Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Utilities	22/01/2020	31/12/2014
⇒ Georgian Water and Power, LLC	100.00%	100.00%	Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Utilities	25/06/1997	31/12/2014
⇒ Rustavi Water, LLC (4)	0.00%	100.00%	Georgia	5, St. Nino St., Rustavi	Utilities	31/08/1999	31/12/2014
⇒ Gardabani Sewage Treatment, LLC	100.00%	100.00%	Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Utilities	20/12/1999	31/12/2014
⇒ Georgian Engineering and Management Company (GEMC), LLC	100.00%	100.00%	Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Utilities	20/03/2011	31/12/2014
⇒ JSC Saguramo Energy	100.00%	100.00%	Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Utilities	11/12/2008	31/12/2014
\Rightarrow Georgian Energy Trading Company (GETC), LLC	100.00%	100.00%	Georgia	10 Medea (Mzia) Jugheli st, Tbilisi, 0179	Renewable Energy Sales	23/4/2019	-

^{*}The table displays effective percentages of holding in the companies

- 1) As of 31 December 2023 renamed: Vian-Logistics (As of 31 December 2022: EVEX-Logistics, LLC)
- 2) As of 31 December 2023 subsidiaries of JSC Vian (31 December 2022: subsidiaries of JSC Evex Hospitals)
- 3) As of 31 December 2023 subsidiaries of JSC Georgia Clinics (31 December 2022: subsidiaries of JSC Evex Hospitals)
- 4) As of 31 December 2023 Rustavi Water, LLC merged with Georgian Water and Power, LLC.
- 5) As of 31 December 2023 merged with Georgia Property Management Group, LLC.
- 6) As of 31 December 2023 merged with Georgia Real Estate Management Group, LLC.

3. Material Accounting Policies

The following are the material accounting policies applied by the Group in preparing its consolidated financial statements:

Fair value measurement

The Group measures investments in subsidiaries and other financial instruments, such as debt securities owned, equity investments and derivatives, if any, at fair value at each balance sheet date. Also, fair values of financial instruments measured at amortised cost are disclosed in note 17.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability; or
- In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible by the Group. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data is available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the consolidated financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 Quoted (unadjusted) market prices in active markets for identical assets or liabilities;
- Level 2 Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable;
- Level 3 Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

For assets and liabilities that are recognised in the consolidated financial statements on a recurring basis, the Group determines whether transfers have occurred between Levels in the hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

Cash and cash equivalents

Cash and cash equivalents consist of cash on hand and amounts due from credit institutions that mature within ninety days of the date of contract origination and are free from contractual encumbrances and readily convertible to known amount of cash.

Financial assets

Initial recognition

Financial assets in the scope of IFRS 9 are classified at initial recognition, as subsequently measured at amortised cost, fair value through other comprehensive income (OCI), and fair value through profit or loss.

The classification of financial assets at initial recognition depends on the financial asset's contractual cash flow characteristics and the Group's business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient, the Group initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient are measured at the transaction price determined under IFRS 15.

3. Material Accounting Policies (continued)

Financial assets (continued)

Initial recognition (continued)

In order for a financial asset to be classified and measured at amortised cost or fair value through OCI, it needs to give rise to cash flows that are 'solely payments of principal and interest (SPPI)' on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed at an instrument level.

The Group's business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both.

Date of recognition

All regular way purchases and sales of financial assets are recognised on the trade date i.e. the date that the Group commits to purchase or sell the asset. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the period generally established by regulation or convention in the marketplace.

Subsequent measurement

For purposes of subsequent measurement, financial assets are classified in three categories under IFRS 9:

- Financial assets at amortised cost (cash and cash equivalents, amounts due from credit institutions)
- Financial assets at fair value through OCI with recycling of cumulative gains and losses (debt instruments)
- Financial assets at fair value through profit or loss (equity investments at fair value, perpetual debt instruments)

Financial assets at amortised cost

The Group measures financial assets at amortised cost if both of the following conditions are met:

• The financial asset is held within a business model with the objective to hold financial assets in order to collect contractual cash flows

And

• The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding

Financial assets at amortised cost are subsequently measured using the effective interest (EIR) method and are subject to impairment. Gains and losses are recognised in profit or loss when the asset is derecognised, modified or impaired.

The Group's financial assets at amortised cost includes cash and cash equivalents and amounts due from credit institutions.

Financial assets at fair value through OCI (debt instruments)

The Group measures debt instruments at fair value through OCI if both of the following conditions are met:

• The financial asset is held within a business model with the objective of both holding to collect contractual cash flows and selling

And

• The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding

For debt instruments at fair value through OCI, interest income, foreign exchange revaluation and impairment losses or reversals are recognised in the statement of profit or loss and computed in the same manner as for financial assets measured at amortised cost. The remaining fair value changes are recognised in OCI. Upon derecognition, the cumulative fair value change recognised in OCI is recycled to profit or loss.

The Group's debt instruments at fair value through OCI includes investments in quoted debt instruments included under marketable securities.

3. Material Accounting Policies (continued)

Financial assets (continued)

Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss include financial assets designated upon initial recognition at fair value through profit or loss, or financial assets mandatorily required to be measured at fair value. Equity investments are classified at fair value through profit or loss. Derivatives and financial assets with cash flows that are not solely payments of principal and interest are classified and measured at fair value through profit or loss, irrespective of the business model. Notwithstanding the criteria for debt instruments to be classified at amortised cost or at fair value through OCI, as described above, debt instruments may be designated at fair value through profit or loss on initial recognition if doing so eliminates, or significantly reduces, an accounting mismatch.

Financial assets at fair value through profit or loss are carried in the statement of financial position at fair value with net changes in fair value recognised in the statement of profit or loss. This category includes equity investments.

Loans to subsidiaries are measured at FVPL in accordance with IFRS 9 as the loans are held within a business model with the objective other than held to collect contractual cash flows or held both to collect contractual cash flows and to sell financial assets.

Impairment of financial assets

The Group recognises an allowance for expected credit losses (ECLs) for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

ECLs are recognised in three stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition (stage 2) or for which there is objective evidence of impairment as at the reporting date (stage 3), a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).

The Group considers a financial asset in default when contractual payments are 90 days past due. However, in certain cases, the Group may also consider a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows. Subsequent recoveries of amounts previously written off decrease the charge for impairment of financial assets in the consolidated profit or loss.

Derecognition of financial assets and liabilities

Financial assets

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognised (i.e., removed from the Group's consolidated statement of financial position) when:

• The rights to receive cash flows from the asset have expired

Or

• The Group has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Group has transferred substantially all the risks and rewards of the asset, or (b) the Group has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

3. Material Accounting Policies (continued)

Derecognition of financial assets and liabilities (continued)

Financial assets (continued)

When the Group has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if, and to what extent, it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Group continues to recognise the transferred asset to the extent of its continuing involvement. In that case, the Group also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Group has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Group could be required to repay.

Financial liabilities

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires.

Where an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and the recognition of a new liability, and the difference in the respective carrying amounts is recognised in the consolidated income statement. Modification is substantial if present value of cash flows under new terms discounted at original effective interest rate is at least 10% different from the liability's carrying amount right before the modification, or there is a substantial modification to the terms identified through a qualitative assessment.

Financial liabilities

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate.

All financial liabilities, including financial guarantees, are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

Debt securities issued

Debt securities issued are initially recognised at fair value of the consideration received less directly attributable transaction costs. After initial recognition, debt securities issued are subsequently measured at amortised cost using the effective interest method. Gains and losses are recognised in the consolidated income statement when borrowings are derecognised as well as through the amortisation process.

Offsetting

Financial assets and liabilities are offset and the net amount is reported in the consolidated statement of financial position when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Provisions

Provisions are recognised when the Group has a present legal or constructive obligation as a result of past events, and it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate of the amount of obligation can be made.

Contingencies

Contingent liabilities are not recognised in the consolidated statement of financial position but are disclosed unless the possibility of any outflow in settlement is remote. A contingent asset is not recognized in the consolidated statement of financial position but disclosed when an inflow of economic benefits is probable.

3. Material Accounting Policies (continued)

Share-based payment transactions

Employees (including senior executives) of the Group receive share-based remuneration, whereby they render services and receive equity instruments of Georgia Capital PLC ('equity settled transactions') as consideration for the services provided.

Equity-settled transactions

The cost of equity settled transactions with employees is measured by reference to the fair value of shares at the grant date.

The cost of equity settled transactions is recognised together with the corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled, ending on the date when the relevant employee is fully entitled to the award ('the vesting date'). The cumulative expense recognised for equity settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Group's best estimate of the number of equity instruments that will ultimately vest. The consolidated income statement charge and credit entry to equity for the period represents the movement in cumulative expense recognised as at the beginning and end of that period. No expense is recognised for the awards that do not ultimately vest.

Where the terms of an equity settled award are modified, the minimum expense is recognised as if the terms had not been modified. An additional expense is recognised for any modification which increases the total fair value of the share-based payment arrangement, or is otherwise beneficial to the employee as measured at the date of the modification.

Where an equity-settled award is cancelled, it is treated as if it has vested on the date of cancellation, and any expense not yet recognised for the award is recognised immediately. However, if a new award is substituted for the cancelled award, and designated as the replacement award on the date that it is granted, the cancelled and the new awards are treated as if they were a modification of the original award, as described in the previous paragraph.

Share capital

Share capital

Ordinary shares are classified as equity. External costs directly attributable to the issue of new shares, other than on a business combination, are shown as a deduction from the proceeds in equity. Any excess of the fair value of consideration received over the par value of shares issued is recognised as additional paid-in capital.

Treasury shares

Where the Group purchases the shares of Georgia Capital PLC, the consideration paid, including any attributable transaction costs, net of income taxes, is deducted from total equity as treasury shares until they are cancelled or reissued. Where such shares are subsequently sold or reissued, any consideration received is included in equity. Treasury shares are stated at par value, with adjustment of premiums against additional paid in capital.

Dividends

Dividends are recognised as a liability and deducted from equity at the reporting date only if they are declared before or on the reporting date. Dividends are disclosed when they are proposed before the reporting date or proposed or declared after the reporting date but before the consolidated financial statements are authorised for issue. All expenses associated with dividend distribution are added to dividend amount and recorded directly through equity.

Dividend income

Dividend revenue is recognised when the Group's right to receive the payment is established. Dividend revenue is presented gross of any non-recoverable withholding taxes, which are disclosed separately in the statement of comprehensive income.

Net gain or loss on financial assets and liabilities at fair value through profit or loss

Net gains or losses on financial assets and liabilities at FVPL are changes in the fair value of equity investment at fair value, financial assets and liabilities held for trading or designated upon initial recognition as at FVPL and exclude interest and dividend income and expenses. Interest and dividend income and expense FVPL instruments are recognised in profit or loss at effective interest.

3. Material Accounting Policies (continued)

Non-recurring items

The Group separately classifies and discloses those income and expenses that are non-recurring by nature. The Group defines non-recurring income or expense as an income or expense triggered by or originated from an economic, business or financial event that is not inherent to the regular and ordinary business course of the Group and is caused by uncertain or unpredictable external factors that cannot be reasonably expected to occur in the future and thus they should not be taken into account when making projections of the future results.

Taxation

The current income tax expense is calculated in accordance with the regulations in force in the respective territories in which the Group and its subsidiaries operate.

The annual profit earned by entities is not taxed in Georgia, except for insurance companies and banks. Corporate income tax is paid on dividends, donations, abnormal losses, non-business related disbursements, etc. The corporate income tax arising from the payment of dividends is accounted for as a liability and expensed in the period in which dividends are declared, regardless of the actual payment date or the period for which the dividends are paid. The corporate income tax rate is 15% in Georgia.

Georgia also has various operating taxes that are assessed on the Group's activities. These taxes are included as a component of general and administrative expenses.

Functional, presentation currencies and foreign currency translation

The consolidated financial statements are presented in Georgian Lari, which is GCAP's functional and presentation currency. Each entity in the Group determines its own functional currency and items included in the consolidated financial statements of each entity are measured using that functional currency. Transactions in foreign currencies are initially recorded in the functional currency, converted at the rate of exchange ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into functional currency at functional currency rate of exchange ruling at the reporting date. Gains and losses resulting from the translation of foreign currency transactions are recognised in the consolidated income statement as net foreign currency gain (loss). Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates as at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. When a gain or loss on a non-monetary item is recognised in other comprehensive income, any exchange component of that gain or loss is recognised in other comprehensive income. Conversely, when a gain or loss on a non-monetary item is recognised in profit or loss, any exchange component of that gain or loss is recognised in profit or loss.

Differences between the contractual exchange rate of a certain transaction and the National Bank of Georgia ("NBG") exchange rate on the date of the transaction are included in Net foreign currency gain (loss). The official NBG exchange rates at 31 December 2023 and 31 December 2022 were as follows:

	Lari to GBP	Lari to USD	Lari to EUR
31 December 2023	3.4228	2.6894	2.9753
31 December 2022	3.2581	2.7020	2.8844

Adoption of new or revised standards and interpretations

The following amendments became effective from 1 January 2023 and had no impact on the Group's financial statements:

IFRS 17 Insurance contracts

Amendments to IAS 8 Accounting Policies Changes in Accounting Estimates and Errors – Definition of Accounting Estimates

Amendments to IAS 1 and IFRS Practice Statement 2 – Disclosure of accounting policies

Amendments to IAS 12 Income Taxes – Deferred Tax related to Assets and Liabilities arising from a Single Transaction

Amendments to IAS 12 Income Taxes — Deferred Tax Assets and Liabilities related to Pillar Two Income Taxes

3. Material Accounting Policies (continued)

Adoption of new or revised standards and interpretations (continued)

The following standards that are issued but not yet effective are also expected to have no material impact on the Group's financial statements:

Amendments to IFRS 16 Leases – Lease Liability in a Sale and Leaseback

Amendments to LAS 1 Presentation of Financial Statements — Classification of Liabilities as Current or Non-current

IFRS 14 - Regulatory Deferral Accounts

Amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments — Disclosures: Supplier Finance Arrangements

Amendments to IFRS 10 and IAS 28 – Sale or Contribution of Assets between an Investor and its Associate or Joint Venture

4. Critical Accounting Judgements and Estimates

In the process of applying the Group's accounting policies, the management board use their judgment and make estimates in determining the amounts recognised in the consolidated financial statements. The most significant judgments and estimates are as follows:

Assessment of investment entity status

Entities that meet the definition of an investment entity within IFRS 10 are required to measure their subsidiaries at FVPL rather than consolidate them. The criteria which define an investment entity are, as follows:

- An entity that obtains funds from one or more investors for the purpose of providing those investors with investment management services
- An entity that commits to its investors that its business purpose is to invest funds solely for returns from capital
 appreciation, investment income, or both; and
- An entity that measures and evaluates the performance of substantially all of its investments on a fair value basis

The Group invests funds, originally obtained from GCAP PLC's investors, in its private portfolio companies, obtains dividend inflows from its mature investments and once the businesses are developed, exits the investment ideally at a higher multiple (vs entry multiple) to monetise on capital appreciation gains. The Group reports to its investors on a fair value basis. All investments are reported at fair value in the Group's annual reports.

Georgia Capital PLC (an investment entity on its own) holds a single investment in JSC Georgia Capital, which holds a portfolio of investments; although JSC Georgia Capital is wholly capitalised by Georgia Capital PLC, Georgia Capital PLC is funded by many investors who are unrelated to the entity; and ownership in Georgia Capital PLC is represented by units of equity interests acquired through a capital contribution. Thus the judgement above refers to both entities in aggregation. The Board has concluded that Georgia Capital meets the definition of an investment entity. These conclusions will be reassessed on a continuous basis, if any of these criteria or characteristics change.

Georgia Capital met the investment entity definition on 31 December 2019. As of 31 December 2023, Georgia Capital continues to meet the definition of investment entity. In making this assessment, the Group considered each criteria and characteristic described above as well as developments during the year.

Fair valuation of the investment portfolio

The investment portfolio, a material asset of the Group, is held at fair value. Details of valuation methodologies used and the associated sensitivities are disclosed in note 17. Given the importance of this area, the Board has formed a separate Audit and Valuations Committee to review the valuations to be placed on portfolio companies, compliance with the valuation standards and usage of appropriate judgement. The detailed valuation process is disclosed in note 17.

Shares of the parent company

Under the Group's Executives' Equity Compensation Plan ("EECP") senior executives of JSC Georgia Capital are awarded ordinary shares of Georgia Capital PLC, its parent company. Georgia Capital PLC holds a single investment in JSC Georgia Capital, which in turn owns a portfolio of investments, each measured at fair value. Georgia Capital PLC has no operations of its own and has no material assets and liabilities other than its 100% investment in JSC Georgia Capital. Management concluded that effectively PLC and JSC Georgia Capital represent the same company, therefore PLC Georgia Capital's shares are treated as treasury shares in JSC Georgia Capital's financial statements. Shares awarded to senior executives under EECP are classified as equity-settled share-based payment in the financial statements of JSC Georgia Capital.

5. Segment Information

For management purposes, the Group is organised into the following operating segments as follows: listed and observable portfolio companies, private large portfolio companies, private investment stage portfolio companies, private other portfolio companies, and corporate centre.

Listed and observable portfolio companies segment

BOG - the Group has a significant investment in London Stock Exchange premium listed Bank of Georgia Group PLC. GCAP does not hold voting rights in BOG.

Water Utility - the Group has 20% equity stake in the Water Utility business, following the disposal of 80% of its shares during 2021. Water Utility is a regulated monopoly in Tbilisi and the surrounding area, where it provides water and wastewater services.

Private portfolio companies

Large portfolio companies segment:

The large portfolio companies are companies that are close to reaching more than a GEL 300 million equity value. This segment includes investments in hospitals (large and specialty hospitals, regional and community hospitals), retail (pharmacy) and insurance businesses.

Hospitals business comprises two segments: Large and Specialty Hospitals, the leading participant in Georgia's healthcare market, offering secondary and tertiary healthcare services; and Regional and Community Hospitals, encompassing regional hospitals and community clinics that deliver outpatient and essential inpatient services.

Retail (Pharmacy) business consists of a retail pharmacy chain and a wholesale business that sells pharmaceuticals and medical supplies to hospitals and other pharmacies.

Insurance business comprises a property and casualty insurance and medical insurance businesses, principally providing widescale property and casualty and medical insurance services to corporate and retail clients.

Investment stage portfolio companies segment:

The investment stage portfolio companies have the potential to reach more than a GEL 300 million equity value. This segment includes investments into clinics, diagnostics, renewable energy and education businesses.

Clinics & Diagnostics business consists of polyclinics providing outpatient diagnostic and treatment services, and diagnostics business, operating the largest laboratory in the entire Caucasus region.

Renewable energy business principally operates three wholly owned commissioned renewable assets. In addition, a pipeline of renewable energy projects is under advanced stage of development.

Education business combines majority stakes in four leading private schools in Tbilisi. It provides education for preschool to 12th grade (K-12);

Other portfolio companies segment:

The other portfolio companies are companies which GCAP believes to have limited potential to reach a GEL 300 million equity value. This segment includes Housing Development, Hospitality, Beverages and Auto Service businesses.

Corporate Centre comprising of JSC Georgia Capital.

Management monitors the fair values of its segments separately for the purposes of making decisions about resource allocation and performance assessment. Transactions between segments are accounted for at actual transaction prices.

In 2023, Georgia Capital revised presentation of its segment note. The hospitals business is split into two distinct sub-segments: "Large and Specialty Hospitals" and "Regional and Community Hospitals". The Regional and Community Hospitals also incorporates the community clinics that were previously managed and presented as part of the clinics and diagnostics business. The clinics & diagnostics business, alongside the renewable energy and education businesses, is presented under the investment stage portfolio.

5. Segment Information (continued)

The following table presents the net asset value (NAV) statement of the Group's operating segments at 31 December 2023 and the roll-forward from 31 December 2022:

	31 December 2022	1.Value Creation	2a. Investments and Divestments	2b. Buybacks	2c. Dividends	3.Operatin g Expenses	4. Liquidity Management / FX / Other	31 Decembe r 2023
Listed and Observable Portfolio Companies	985,463	553,255	-	-	(153,871)	-	-	1,384,847
BoG	830,463	549,255	-	_	(153,871)*	-	-	1,225,847
Water Utility	155,000	4,000	-	-	-	-	-	159,000
Private Portfolio Companies	2,213,164	127,260	18,420	_	(82,012)	_	10,266	2,287,098
Large Portfolio Companies	1,437,610	74,786	<u>-</u>	_	(76,825)	-	660	1,436,231
Retail (Pharmacy)	724,517	39,397	-	_	(50,904)	-	991	714,001
Hospitals	433,193	(81,526)	-	_	(6,018)	-	(1,293)**	344,356
Insurance (P&C and Medical)	279,900	116,915	-	-	(19,903)	-	962	377,874
Of which, P&C Insurance	228,045	71,447	-	-	(14,888)	-	962	285,566
Of which, Medical Insurance	51,855	45,468	-	_	(5,015)	-	-	92,308
Investment Stage Portfolio Companies	<i>501,407</i>	47,044	<i>18,388</i>	_	(5,187)	-	4,962	566,614
Clinics and diagnostics	112,178	(3,922)	-	-	-	-	2,505**	110,761
Renewable energy	224,987	38,684	6,218	-	(5,187)	-	1,925	266,627
Education	164,242	12,282	12,17 0	-	-	-	532	189,226
Other Portfolio Companies	274,147	5,430	32	-	-	-	4,644	284,253
Total Portfolio Value	3,198,627	680,515	18,420	-	(235,883)	-	10,266	3,671,945
Net Debt	(403,567)	-	(18,420)	(28,440)	235,883	(30,222)	(63,768)	(308,534)
Net Asset Value	2,795,060	680,515	-	(28,440)	-	(30,222)	(53,502)	3,363,411

^{*} In segment information, dividend income includes consideration received as a result of participation in BoG buyback programme in the amount of GEL 73,356. The amount is disclosed under Investment and Divestments in Note 10.

In 2021 Bank of Georgia PLC incorporated capital distribution policy which combines ordinary cash dividend and share repurchases. It is the Bank of Georgia PLC's overall capital distribution policy to target a dividend/share buyback payout ratio in the range of 30-50% of annual profits. Starting from 2022 Bank of Georgia announced Share Buybacks and cancellation program in line with its Capital Distribution Policy mentioned above. As a result, GCAP has sold GEL 73,356 worth shares through participating in the share buyback program announced by BOG. Participating in BOG share buyback program enable shareholders maintain effective ownership interest in the business while increasing shareholders' return. The sales consideration received through the program along with ordinary dividend distribution, is regarded as dividend income by the GCAP's management, as it reflects capital distribution by listed portfolio company, and does not result in a change in effective ownership interest.

^{**} Includes the transfer of community clinics from the Clinics and diagnostics sub-segment to Hospitals in 2023. As of 31 December 2022, Hospitals and Clinics and diagnostics balances would have been GEL 429,272 and GEL 116,099 respectively, applying this transfer retrospectively.

5. Segment Information (continued)

The following table presents the NAV statement of the Group's operating segments at 31 December 2022 and the roll forward from 31 December 2021:

	31 December 2021	1.Value Creation	2a. Investments and Divestments	2b. Buybacks	2c. Dividends	3.Operating Expenses	4. Liquidity Management/FX/ Other	31 December 2022
Listed and Observable Portfolio Companies	681,186	205,783	139,392	-	(40,898)	-	-	985,463
$B_{\theta}G$	681,186	190,175	-	-	(40,898)	-	-	830,463
Water Utility	-	15,608	139,392	-	-	-	-	155,000
Private Portfolio Companies	2,935,045	(171,710)	(501,011)	-	(52,977)	-	3,817	2,213,164
Large Portfolio Companies	2,249,260	(70,728)	(696,960)	-	(44,783)	-	821	1,437,610
Retail (Pharmacy)	710,385	30,150	-	-	(16,018)	-	-	724,517
Hospitals	573,815	(127,607)	-	-	(13,015)	-	-	433,193
Water Utility	696,960	-	(696,960)	-	-	-	-	-
Insurance (P&C and Medical)	268,100	26,729	-	-	(15,750)	-	821	279,900
Of which, P&C Insurance	211,505	30,468	-	-	(14,749)	-	821	228,045
Of which, Medical Insurance	56,595	(3,739)	-	-	(1,001)	-	-	51,855
Investment Stage Portfolio Companies	461,140	13,266	<i>34,196</i>	-	(8,194)	-	<i>999</i>	<i>501,407</i>
Clinics and diagnostics	158,004	(45,826)	-	-	-	-	-	112,178
Renewable energy	173,288	31,040	27,854	-	(8,194)	-	999	224,987
Education	129,848	28,052	6,342	-	-	-	-	164,242
Other Portfolio Companies	224,645	(114,248)	161,753	-	-	-	1,997	274,147
Total Portfolio Value	3,616,231	34,073	(361,619)	-	(93,875)	-	3,817	3,198,627
Net Debt	(734,858)	-	394,987	(28,535)	93,875	(33,275)	(95,761)	(403,567)
Net Asset Value	2,881,373	34,073	33,368	(28,535)	-	(33,275)	(91,944)	2,795,060

^{1.} Value Creation – measures annual shareholder return on each portfolio company for Georgia Capital. It is the aggregation of a) change in beginning and ending fair values, b) dividend income during the period. The net result is then adjusted to remove capital injections (if any) to arrive at the total value creation/investment return.; 2a. Investments and Divestments – represents capital injections and divestments in portfolio companies made by Georgia Capital, as well as reclassification of Water Utility business into Listed and Observable Portfolio Companies in 2022; 2b. Buybacks – represent buybacks made by Georgia Capital in order to satisfy share compensation of executives; 2c. Dividends – represent dividends received from portfolio companies by JSC GCAP; 3. Operating Expenses – holding company operating expenses of Georgia Capital; 4. Liquidity Management/FX/Other – holding company movements of Georgia Capital related to liquidity management, foreign exchange movement, non-recurring and other.

5. Segment Information (continued)

Reconciliation of IFRS financial statements to NAV:

31 December 2023 JSC Georgia NAV Statement Reclassifications* Capital Cash and cash equivalents 51,138 (51,138)Amounts due from credit institutions 8,678 (8,678) Marketable securities 18,203 (18,203) Investment in redeemable securities 14,068 (14,068)3,274 Accounts receivable (3,274)Prepayments 923 (923)9,212 (9,212)Loans issued Property and equipment 340 (340)Intangible assets 67 (67)Other assets, net 456 (456)3,671,945 Equity investments at fair value 3,671,945 (106,359)Total assets 3,778,304 3,671,945 Accounts payable 888 (888)Debt securities issued (413,930) 413,930 Other liabilities 75 Total liabilities 414,893 (414,893) Net Debt (308,534)(308,534)Total equity/NAV 3,363,411 3,363,411

	31 December 2022					
	JSC Georgia Capital	Reclassifications*	NAV Statement			
Cash and cash equivalents	199,771	(199,771)	_			
Amounts due from credit institutions	16,278	(16,278)	-			
Marketable securities	25,445	(25,445)	-			
Investment in redeemable securities	12,631	(12,631)	-			
Accounts receivable	109	(109)	-			
Prepayments	610	(610)	-			
Loans issued	26,830	(26,830)	-			
Property and equipment	391	(391)	-			
Intangible assets	109	(109)	-			
Other assets, net	1,132	(1,132)	-			
Equity investments at fair value	3,198,627	- · ·	3,198,627			
Total assets	3,481,933	(283,306)	3,198,627			
Accounts payable	917	(917)	-			
Debt securities issued	681,067	(681,067)	-			
Other liabilities	4,889	(4,889)	-			
Total liabilities	686,873	(686,873)	-			
Net Debt	-	(403,567)	(403,567)			
Total equity/NAV	2,795,060	-	2,795,060			

^{*} Reclassifications to aggregated balances to arrive at NAV specific presentation, such as aggregating GCAP net debt

5. Segment Information (continued)

The following table presents income statement information of the Group's operating segments for the year ended 31 December 2023:

		Private 1	Portfolio Companies	5		
	Listed and Observable Portfolio Companies	Large	Investment Stage	Other	Corporate Center	Total
Gains/(losses) on investments at fair value	399,384	(2,039)	41,857	5,430	-	444,632
Listed and Observable Investments	399,384	-	-	, , , , , , , , , , , , , , , , , , ,	-	399,384
Private Investments	-	(2,039)	41,857	5,430	-	45,248
Dividend income	153,871	76,825	5,187	· -	-	235,883
Interest income	-	-	· -	-	9,072	9,072
Loss on derecognition of liability	-	-	-	-	(3,111)	(3,111)
Net gains from investment securities measured at FVPL	-	-	-	-	1,446	1,446
Net realised losses from investment securities measured at FVOCI	-	-	-	-	(162)	(162)
Other income	-	-	-	-	8	8
Gross investment profit/(loss)	553,255	74,786	47,044	5,430	7,253	687,768
Administrative expenses	-	-	-	-	(5,894)	(5,894)
Salaries and other employee benefits	-	-	-	-	(23,783)	(23,783)
Depreciation and amortisation	-	-	-	-	(545)	(545)
Interest expense	-	-	-	-	(39,660)	(39,660)
Profit/(loss) before provisions, foreign exchange and non-recurring items	553,255	74,786	47,044	5,430	(62,629)	617,886
Expected credit loss charge	_	_	_	_	(75)	(75)
Net foreign currency gain	-	_	-	_	6,954	6,954
Loss on derivative financial assets	-	-	-	-	(11)	(11)
Non-recurring expense	-	-	-	-	(1,898)	(1,898)
Profit /(loss) before income taxes	553,255	74,786	47,044	5,430	(57,659)	622,856
Income tax	-	-	_	-	_	_
Profit/(loss) for the period	553,255	74,786	47,044	5,430	(57,659)	622,856

5. Segment Information (continued)

The following table presents income statement information of the Group's operating segments for the year ended 31 December 2022:

Private Portfolio	Companies
-------------------	-----------

		riivale.	Portiono Companies			
	Listed and Observable Portfolio Companies	Large	Investment Stage	Other	Corporate Center	Total
Gains/(losses) on investments at fair value	164,885	(115,511)	5,072	(114,248)		(59,802)
Listed and Observable Investments	164,885	(113,311)	3,072	(114,240)		164,885
Private Investments	104,887	- (115,511)	5,072	(414.240)	-	
	40.000	(/ /		(114,248)	-	(224,687)
Dividend income	40,898	44,783	8,194	-	-	93,875
Interest income	-	-	-	-	32,029	32,029
Gain on derecognition of liability	-	-	-	-	9,907	9,907
Net losses from investment securities measured at FVPL	-	-	-	-	(10,801)	(10,801)
Net realised losses from investment securities measured at FVOCI	-	-	-	-	(1,750)	(1,750)
Other income	-	-	-	-	42	42
Gross investment profit/(loss)	205,783	(70,728)	13,266	(114,248)	29,427	63,500
Administrative expenses Salaries and other employee benefits Depreciation and amortisation Interest expense	- - -	- - -	- - -	- - - -	(6,797) (25,843) (635) (59,763)	(6,797) (25,843) (635) (59,763)
Profit/(loss) before provisions, foreign exchange and non-recurring items	205,783	(70,728)	13,266	(114,248)	(63,611)	(29,538)
Expected credit loss reversal Net foreign currency gain Loss on derivative financial assets Non-recurring expense Profit / (loss) before income taxes Income tax	205,783	(70,728)	13,266	(114,248)	380 48,666 (4,507) (387) (19,459)	380 48,666 (4,507) (387) 14,614
	205 702	/EO EOO\	12.000	(11.4.0.40)	(10, 450)	14 (14
Profit/(loss) for the period	205,783	(70,728)	13,266	(114,248)	(19,459)	14,614

6. Cash and Cash Equivalents

	<i>31 December 2023</i>	31 December 2022
Current accounts with financial institutions*	51,139	33,541
Time deposits with financial institutions with original maturities of up to 90 days*	-	166,232
Cash and cash equivalents	51,139	199,773
Allowance (Note 14)	(1)	(2)
Cash and cash equivalents, Net	51,138	199,771

The carrying value of cash and cash equivalents approximates fair value of the asset.

7. Amounts Due from Credit Institutions

	31 December 2023	31 December 2022
Time deposits with maturities of more than 90 days	8,721	16,299
Amounts due from credit institutions, Gross	8,721	16,299
Allowance (Note 14)	(43)	(21)
Amounts due from credit institutions, Net	8,678	16,278

8. Marketable Securities and Investment in Redeemable Shares

	31 December 2023	31 December 2022
Internationally listed marketable securities (FVPL)		21,068
Internationally listed marketable securities (FVOCI)*	669	1,183
Locally listed marketable securities (FVOCI)*	17,534	3,194
Marketable securities	18,203	25,445

^{*} During 2023 GCAP recorded foreign exchange gain of GEL 14 (2022 loss: GEL 12,583) on marketable securities presented through FVOCI.

Locally listed marketable securities in the amount of GEL 9 million were pledged as a collateral under loan arrangement of one of JSC GCAP's portfolio companies. The loan was repaid by the borrower on 1 February 2024, pledged marketable securities were released on the same date.

Investment in redeemable shares

In August 2021 a 100% owned portfolio company of Georgia Capital, JSC Insurance Company Aldagi (P&C Insurance), issued 6 million preference shares. 100% of preference shares were subscribed by Georgia Capital at the price of USD 6 million (GEL 18.6 million). The proceeds from preference shares are invested by JSC Insurance Company Aldagi in a fund that invest in fixed income securities. Preference shares are mandatorily redeemable by JSC Insurance Company Aldagi upon redemption of the underlying fund shares. Redemption amount for preferred shares is equal to proceeds from underlying fund shares subject to certain adjustments. As at 31 December 2023 the fair value of the investment was GEL 14,068 (2022: GEL 12,631) presented as investment in redeemable shares in the consolidated statement of financial position. Investment in redeemable shares are accounted at fair value through profit or loss at net asset value of underlying fund shares.

9. Loans Issued

	31 December	31 December
	2023	2022
Loans to equity investments (FVPL)	9,212	26,830
Loans issued, Net	9,212	26,830

As at 31 December 2023 and Loans to equity investments are denominated in GEL (2022: GEL, USD and EUR), carry interest rates from 15.0% to 16.5% (2022: 5.5% to 16.5%), with average remaining terms of maturity of 0.7 year (2022: 1 years).

^{*}As of 31 December 2023, cash and cash equivalents amounting to GEL 8 million (time deposits amounting to GEL 108 million as of 31 December 2022) was signed under a currency swap agreement.

10. Equity Investments at Fair Value

	31 December 2022	Value Change	Dividends	Total gains / (Losses) on investments at fair value	Investments and Divestments**	Other***	31 December 2023
Listed and Observable Portfolio	005 462	552.055	(00 515)	450 540	(52.250)		1 204 045
Companies	985,463	553,255	(80,515)	472,740	(73,356)	-	1,384,847
$B_{\theta}G$	830,463	549,255	(80,515)	468,740	(73,356)	-	1,225,847
Water utility	155,000	4,000	-	4,000	-	-	159,000
Private Portfolio Companies	2,213,164	127,260	(82,012)	45,248	18,420	10,266	2,287,098
Large Portfolio Companies	1,437,610	74,786	(76,825)	(2,039)	-	660	1,436,231
Retail (Pharmacy)	724,517	39,397	(50,904)	(11,507)	=	991	714,001
Hospitals	433,193	(81,526)	(6,018)	(87,544)	=	(1,293)	344,356
Insurance (P&C and Medical)	279,900	116,915	(19,903)	97,012	=	962	377,874
Of which, P&C Insurance	228,045	71,447	(14,888)	56,559	=	962	285,566
Of which, Medical Insurance	51,855	45,468	(5,015)	40,453	=	=	92,308
Investment Stage Portfolio Companies	501,407	47,044	(5,187)	41,857	18,388	4,962	566,614
Clinics and diagnostics	112,178	(3,922)	=	(3,922)	=	2,505	110,761
Renewable Energy	224,987	38,684	(5,187)	33,497	6,218	1,925	266,627
Education	164,242	12,282	=	12,282	12,170	532	189,226
Other Portfolio Companies	274,147	5,430		5,430	32	4,644	284,253
Equity investments at fair value	3,198,627	680,515	(162,527)	517,988	(54,936)	10,266	3,671,945

	31 December 2021	Portfolio decomposition and Transfer between stages*	Value Change	Dividends	Total gains / (Losses) on investments at fair value	Investments and Divestments**	Other***	31 December 2022
Listed and Observable Portfolio	681,186	_	205,783	(40,898)	164,885	139,392	_	985,463
Companies	001,100		200,700	(10,070)	10 1,000	137,372		705,105
$B_{\theta}G$	681,186	-	190,175	(40,898)	149,277	-	-	830,463
Water utility	=	≡	15,608	=	15,608	139,392	=	155,000
Private Portfolio Companies	2,935,045	-	(181,160)	(52,977)	(234,137)	(491,561)	3,817	2,213,164
Large Portfolio Companies	2,407,264	(158,004)	(80,178)	(44,783)	(282,965)	(687,510)	821	1,437,610
Retail (Pharmacy)	710,385	-	30,150	(16,018)	14,132	-	-	724,517
Hospitals	731,819	(158,004)	(127,607)	(13,015)	(298,626)	=	-	433,193
Water utility	696,960		(9,450)	=	(9,450)	(687,510)	=	=
Insurance (P&C and Medical)	268,100	=	26,729	(15,750)	10,979	=	821	279,900
Of which, P&C Insurance	211,505	≡	30,468	(14,749)	15,719	≡	821	228,045
Of which, Medical Insurance	56,595	≡	(3,739)	(1,001)	(4,740)	≡	=	51,855
Investment Stage Portfolio	303,136	158,004	13,266	(8,194)	163,076	34,196	999	501,407
Companies	303,130	130,004	13,200	(0,194)	103,070	34,170	999	301,407
Clinics and diagnostics	=	158,004	(45,826)	=	112,178	=	=	112,178
Renewable Energy	173,288	≡	31,040	(8,194)	22,846	27,854	999	224,987
Education	129,848	≡	28,052	- -	28,052	6,342	=	164,242
Other Portfolio Companies	224,645	-	(114,248)	-	(114,248)	161,753	1,997	274,147
Equity investments at fair value	3,616,231	-	24,623	(93,875)	(69,252)	(352,169)	3,817	3,198,627

^{*} Stages refer to Large, Investment and Other portfolio companies (note 5).

During 2023, divestments represent sale of shares in BOG and the sale of other portfolio company. Refer to Note 5 for a presentation of BoG share sales in the segment information. During 2022, divestments represent the sale of an 80% interest in water utility business. On 2 February 2022 the JSC GCAP completed the first stage in the proposed two-stage transaction, disposal of a controlling interest in Georgia Global Utilities JSC ("GGU") to FCC Aqualia for USD 180 million. Sale proceeds (GEL 548,118) have been received on 2 February 2022.

^{**} Capital injections in portfolio companies made by JSC GCAP (cash contribution of GEL 22,588 for the year ended 2023, GEL 26,005 in 2022).

^{***} Other investments in portfolio companies and the transfer of community clinics from the Clinics and diagnostics subsegment to Hospitals.

11. Debt Securities Issued

Debt securities issued comprise:

	31 December	31 December
	2023	2022
USD denominated local sustainability-linked bonds	413,930	-
USD denominated Eurobonds	-	681,067
Debt securities issued	413,930	681,067

On 3 August 2023 JSC Georgia Capital has successfully issued a USD 150 million sustainability-linked bond on the Georgian market. The Notes are USD-denominated with 5-year bullet maturity (callable after two years), carry an 8.50% fixed coupon and were issued at par. The proceeds from the Notes, together with the existing liquid funds of GCAP were used to fully redeem USD 300 million Eurobond. As a result, GCAP's gross debt balance decreased from the current USD 300 million to USD 150 million.

In March 2018 JSC Georgia Capital issued a USD 300 million (GEL 734 million) 6.125% notes due in March 2024 denominated in US Dollars which were admitted to the official list of the Irish Stock Exchange and to trading on the Global Exchange Market (the "Notes"). Notes were sold at the price of 98.770% of par value at the initial offering. On 16 March 2021, Georgia Capital placed USD 65,000 (GEL 215,826) tap issue, which was consolidated and forms a single series with the Notes. From the tap issue, notes with par value of USD 4,154 (GEL 13,809) were repurchased by Georgia Capital at the issue date. Cash proceeds from the tap issue, net of fees paid, was GEL 212,725. In 2022 GCAP cancelled USD 65,000 notes (GEL 180,427).

On 12 July 2023 JSC Georgia Capital launched an invitation to holders of its outstanding USD 300 million, to tender their notes for purchase by the Issuer for cash. On 10 August 2023 JSC Georgia Capital cancelled USD 176.5 million principal amount of the Notes purchased as a result of Tender offer and USD 106.9 million principal amount of Notes owned by the GCAP in treasury. On 4 September 2023 JSC Georgia capital repaid remaining outstanding principal amount of USD 16.6 million notes.

Changes in liabilities arising from financing activities

	Debt securities	Lease liabilities
Carrying amount at 31 December 2021	1,095,433	823
Redemption and buyback/Cash repayments	(285,797)	(399)
Foreign currency translation	(117,866)	(79)
Gain on Eurobonds repurchases	(9,907)	-
Other*	(796)	40
Carrying amount at 31 December 2022	681,067	385
Proceeds from debt securities issued	389,024	-
Redemption and buyback/Cash repayments	(652,206)	(319)
Foreign currency translation	(11,875)	(9)
Loss on Eurobonds repurchases	3,111	-
Other*	4,809	15
Carrying amount at 31 December 2023	413,930	72

^{*} Other movement for debt securities represents difference between interest accrued of GEL 39,644 in 2023 (GEL 59,724 in 2022) and interest paid of GEL 34,835 in 2023 (GEL 60,520 in 2022).

12. Equity

Share capital

As at 31 December 2023 issued share capital comprised 12,876,582 authorised common shares (2022: 12,876,582), of which 12,876,582 were fully paid (2022: 12,876,582). Each share has a nominal value of one Georgian Lari. Shares issued and outstanding as at 31 December 2023 and 2022 are described below:

	Number	
	of ordinary	
	shares	Amount
1 January 2022	13,285,616	13,286
Capital Reduction	(409,034)	(409)
31 December 2022	12,876,582	12,877
31 December 2023	12,876,582	12,877

Capital Reduction

During 2022 JSC GCAP bought back from its Parent 409,034 own shares for total consideration of GEL 87,238 (of which cash consideration amounted to GEL 87,238). All of the repurchased ordinary shares were cancelled. GEL 86,829 difference between GEL 409 par value of the acquired shares and the consideration transferred was recognized as deduction from additional paid-in capital.

Treasury Shares

Treasury shares consist of GEL 837 (2022: 837) JSC Georgia Capital shares and GEL 143 (2022: 123) shares of Georgia Capital PLC (shareholder) repurchased as a result of management compensation scheme, which are considered as treasury shares for the Group.

In 2023, the Group acquired treasury shares in connection to its share-based compensation plans for total consideration of GEL 32,223 (2022: GEL 34,411).

13. Salaries and Other Employee Benefits, and General and Administrative Expenses

	2023	2022
Equity compensation plan costs	(14,386)	(17,900)
Salaries and bonuses	(9,397)	(7,943)
Salaries and other employee benefits	(23,783)	(25,843)

General and administrative expenses

	2023	2022
Legal and other professional services	(1,966)	(2,474)
Insurance	(1,066)	(1,277)
Travel expenses	(831)	(765)
Corporate hospitality and entertainment	(503)	(640)
Operating taxes	(354)	(381)
Personnel training and recruitment	(224)	(118)
Repair and maintenance	(184)	(239)
Office supplies	(104)	(83)
Communication	(81)	(79)
Security	(33)	(36)
Occupancy and rent	(38)	(25)
Banking services	(38)	(15)
Other	(472)	(665)
General and administrative expenses	(5,894)	(6,797)

13. Salaries and Other Employee Benefits, and General and Administrative Expenses (continued)

Auditors' remuneration

Auditors' remuneration is included within legal and other professional services expenses above and comprises:

	2023	2022
Fees for the audit of the Company's annual financial statements for the year ended 31		
December	308	382
Fees for the review of the Company's interim accounts	103	67
Expenditures for other professional services	_	34
	411	483

14. Impairment of Accounts Receivable, Other Assets and Provisions

The movements in the allowance for financial assets according to IFRS 9 are as follows:

	Cash and cash equivalents 2023	Amounts due from credit institutions 2023	Marketable Securities 2023	Total 2023
At 1 January	2	21	37	60
(Reversal) Charge	(1)	22	54	75
At 31 December	1	43	91	135
	Cash and cash equivalents 2022	Amounts due from credit institutions 2022	Marketable Securities 2022	Total 2022
At 1 January	1	151	288	440
(Reversal) Charge	1_	(130)	(251)	(380)
At 31 December	2	21	37	60

For debt financial assets, the ECL is based on the 12-month ECL since there has not been a significant increase in credit risk since origination.

15. Share-based Payments

Executives' Equity Compensation Plan

In 2018, Georgia Capital introduced Group's Executives' Equity Compensation Plan ("EECP"). Under the EECP, shares of the parent are granted to senior executives of the parent. In July 2018, the executives signed new five-year fixed contingent share-based compensation agreements with a total of 1,650,000 ordinary shares of Georgia Capital PLC. The total amount of shares fixed to each executive will be awarded in five equal instalments during the five consecutive years starting January 2019, of which each award will be subject to a six-year vesting period subject to continued employment within the Group during such vesting period. In 2022, newly appointed executives signed five-year fixed contingent share-based compensation agreements with a total of 215,000 ordinary shares of Georgia Capital PLC. In October 2022 CEO contract maturity was extended until 31 December 2025 from May 2023, extending fixed contingent share-based compensation with additional 518,357 ordinary shares of Georgia capital. The fair value of the shares is determined at the grant date using available market quotations.

At the sole discretion of the Board, executives are also awarded additional ordinary shares of Georgia Capital PLC (discretionary securities). Each award is subject to a four-year or five-year vesting period subject to continued employment within the Group during such vesting period.

In 2018 the Group set up Executive Equity Compensation Trustee – Sanne Fiduciary Services Limited (the "Trustee") which acts as the trustee of the Group's Executives' Equity Compensation Plan ("EECP"). In 2023 the Trustee has repurchased 1,151,848 (2022: 1,190,522) shares. Trustee is considered as an extension of the Company rather than as a separate entity.

15. Share-based Payments (continued)

Executives' Equity Compensation Plan (continued)

The following table illustrates the number and weighted average prices of, and movements in, shares awards granted to the senior executives of the Group during the year:

	2023	2022
Shares outstanding at 1 January	2,624,988	1,940,788
Granted during the year	615,881	1,042,624
Vested during the year	(982,743)	(358,424)
Shares outstanding at 31 December	2,258,126	2,624,988

In addition to Executives' Equity Compensation Plan, the Group grants shares of the parent to the employees of the Group. Number of shares granted and vested during 2023 amounted to 141,603 (2022: 212,641) and 160,596 (2022: 112,083) respectively.

The weighted average remaining contractual life for the share awards outstanding as at 31 December 2023 was 2.3 years (2022: 2.4 years).

The weighted average fair value of shares granted during the year was GEL 24.24 (2022: GEL 22.8). The weighted average fair value of shares vested was GEL 23.78 (2022: 29.74).

Expense recognition:

The expense recognised for employee services received during the year and the respective increase in equity arising from equity-settled share-based payments is shown in the following table:

	2023	2022
Increase in equity arising from equity-settled share-based payments	25,249	20,794
Expense arising from equity-settled transactions	16,284	17,900

16. Risk Management

Introduction

Risk is inherent in the Group's activities but it is managed through a process of on-going identification, measurement and monitoring, subject to risk limits and other controls. This process of risk management is critical to the Group's continuing profitability and each individual within the Group is accountable for the risk exposures relating to his or her responsibilities. The Group is exposed to investment risk, credit risk, liquidity risk and market risk. It is also subject to operational risks and insurance risk.

The independent risk control process does not include business risks such as changes in the environment, technology and industry. They are monitored through the Group's strategic planning process.

All non-executive Board members of Georgia Capital PLC are also members of Supervisory Board of JSC Georgia Capital. JSC Georgia Capital established Audit and Valuation, Investment and Remuneration Committees with the same terms of reference and the same members as those of Georgia Capital PLC. As such, all relevant decisions of Audit and Valuation, Investment and Remuneration Committees of Georgia Capital PLC apply to the Group.

Risk management structure

Audit and Valuation Committee

The Audit and Valuation Committee of Georgia Capital assists the Management Board of the Group in relation to the oversight of the Group's financial and reporting processes. It monitors the integrity of the financial statements and is responsible for governance around both the internal audit function and external auditor, reporting back to the Board. It reviews the effectiveness of the policies, procedures and systems in place related to, among other operational risks, compliance, IT and IS (including cyber-security) and assessed the effectiveness of the risk management and internal control framework.

16. Risk Management (continued)

Introduction (continued)

Risk management structure (continued)

Audit and Valuation Committee (continued)

It is responsible for reviewing and approving half-yearly and annual valuations of the Company's portfolio investments prepared and presented to it by the Management Board. The Committee will ensure that the Valuation Policy complies with the obligations within any agreements in place, legislation, regulations, guidance and other policies of the Company.

Management Board

The Management Board of Georgia Capital has overall responsibility for the Group's asset, liability and risk management activities, policies and procedures. The Management Board comprises of senior manager of GCAP PLC and JSC GCAP. In order to effectively implement the risk management system, the Board of Directors delegate individual risk management functions to the Management Board, which in turn assigns specific functions to the various decision-making and execution bodies within the portfolio entities of JSC Georgia Capital.

Internal Audit

The Internal Audit Department of Georgia Capital is responsible for the annual audit of the Group's risk management, internal control and corporate governance processes, with the aim of reducing the levels of operational and other risks, auditing the Group's internal control systems and detecting any infringements or errors on the part of the Group's departments and divisions. It examines both the adequacy of and the Group's compliance with those procedures. The Group's Internal Audit Department discusses the results of all assessments with management, and reports its findings and recommendations to the Audit and Valuation Committee.

Risk measurement and reporting systems

The Group's risks are measured using a method which reflects both the expected loss likely to arise in normal circumstances and unexpected losses, which are an estimate of the ultimate actual loss based on different forecasting models. The models make use of probabilities derived from historical experience, adjusted to reflect the economic environment.

Monitoring and controlling risks is primarily performed based on limits established by the Group. These limits reflect the business strategy and market environment of the Group as well as the level of risk that the Group is willing to accept, with additional emphasis on selected industries and countries. In addition, the Group monitors and measures the overall risk bearing capacity in relation to the aggregate risk exposure across all risks types and activities.

Information compiled from all the businesses is examined and processed in order to analyse, control and identify early risks. This information is presented and explained to the Management Board.

Risk mitigation

As part of its overall risk management, the Group may use derivatives and other instruments to manage exposures resulting from changes in interest rates, foreign currencies, equity risks, credit risks, and exposures arising from forecast transactions. Risks at portfolio company level are mitigated by instruments applicable to specific industries they operate in.

Credit risk

Credit risk is the risk that the Group will incur a loss because its customers, clients or counterparties fail to discharge their contractual obligations. The Group manages and controls credit risk by setting limits on the amount of risk it is willing to accept for individual counterparties and by monitoring exposures in relation to such limits. Credit terms by debtors, for various portfolio companies are managed and monitored separately, given industry specifics in which respective entities operate.

16. Risk Management (continued)

Credit risk (continued)

Liquid financial instruments

Credit risk from balances with banks and financial institutions is managed by the Group's treasury department in accordance with the Group's policy. Investments of surplus funds are made only with approved counterparties and within credit limits assigned to each counterparty. The limits are set to minimise the concentration of risks and therefore mitigate financial loss through a counterparty's potential failure to make payments.

The table below demonstrates the Group's financial assets credit risk profile by external rating grades:

	31 December 2023			
	BB+ to BB-	B+ to B-	CC+ to CC-	Not graded
Cash and cash equivalents	32,635	18,503	-	-
Amounts due from credit institutions	-	8,678	-	-
Marketable securities	17,534	-	669	-
Investment in redeemable securities (note 8)	-	-	-	14,068
Loans issued (note 9)**	-	-	-	9,212
Total	50,169	27,181	669	23,280

	31 December 2022						
	A + to	BB + to	B + to	CC + to	C + to	D + to	Mad and ded
	A-	BB-	<i>B</i> -	CC-	C-	D-	Not graded
Cash and cash equivalents	71,066	105,541	23,164	-	-	-	-
Amounts due from credit institutions	-	16,278	-	-	-	-	-
Marketable securities	_	1,183	23,540	262	190	270	-
Investment in redeemable securities (note 8)	-	-	-	-	-	-	12,631
Loans issued (note 9)**	-	-	-	-	-	-	26,830
Other assets*,**		<u> </u>					369
Total	71,066	123,002	46,704	262	190	270	39,830

^{*} Not graded Other assets represents fee receivable from guarantee issued to a portfolio company, with nominal amount of GEL 18,460 as at 31 December 2022.

Credit quality per class of financial assets

The credit quality of financial assets is also managed by the Group based on the number of overdue days. None of the Group's financial assets are past due as at 31 December 2023 and 2022.

No significant increase in credit risk since initial recognition occurred in respect of the Group's financial assets as at 31 December 2023 and 2022.

The Group's maximum exposure to credit risk is limited to carrying value of respective financial assets and to notional amount of guarantees issued.

Liquidity risk

Liquidity risk is the risk that the Group will be unable to meet its payment obligations when they fall due under normal and stress circumstances. To limit this risk, management has arranged diversified funding sources in addition to its capital, manages assets with liquidity in mind, and monitors future cash flows and liquidity on a regular basis. This incorporates daily monitoring of expected cash flows and liquidity needs.

^{**} Assessed internally. For fair value measurement and sensitivity analysis refer to Notes 9 and 17, respectively.

16. Risk Management (continued)

Liquidity risk (continued)

The Group manages the maturities of its assets and liabilities for better matching, which helps the Group additionally mitigate the liquidity risk. Maturities of assets and liabilities of JSC Georgia Capital and each portfolio entities are managed separately. The major liquidity risks confronting the Group are the daily calls on its available cash resources in respect of supplier contracts and the maturity of borrowings.

Georgia Capital does not have any formal capital or debt commitments to its portfolio companies (31 December 2022: financial guarantee issued to a portfolio company EUR 6 million).

The table below summarises the maturity profile of the Group's financial liabilities based on contractual undiscounted repayment obligations. Repayments, which are subject to notice, are treated as if notice were to be given immediately.

Financial liabilities	Less than	3 to 12	1 to 5	Total
31 December 2023	3 months	months	years	10tai
Debt securities issued	17,145	17,145	540,569	574,859
Accounts payable	888	-	-	888
Other financial liabilities	76	-		76
Total undiscounted financial liabilities	18,109	17,145	540,569	575,823
Financial liabilities 31 December 2022	Less than 3 months	3 to 12 months	1 to 5 years	Total
Debt securities issued	20,633	20,633	694,349	735,615
Accounts payable	917	-	-	917
Financial guarantees	18,460	-	-	18,460
Other financial liabilities	58_	4,742	97	4,897
Total undiscounted financial liabilities	40,068	25,375	694,446	759,889

Market risk

Market risk is the risk that the value of financial instruments will fluctuate due to changes in market variables such as interest rates and foreign exchange rates. The Group has exposure to market risks. The Group structures the levels of market risk it accepts through a Group market risk policy that determines what constitutes market risk for the Group.

Interest rate risk affects fair values of assets measured at fair value through profit or loss. For sensitivities of fair value please, refer to note 17.

Price risk

Equity securities price risk arises from investment for which price in the future is uncertain. Where non-monetary financial instruments – for example, equity securities – are denominated in currencies other than the Georgian Lari, the price initially expressed in foreign currency and then converted into Georgian Lari will also fluctuate because of changes in foreign exchange rates. For details on currency risk management, refer to respective paragraph below.

If the price of our listed investment increased by 10% (2022: 10%) GCAP's profit for the year and NAV would have increased by GEL 122,584 (2022: GEL 83,046). If the price of our listed investment decreased by 10% (2022: 10%) GCAP's profit for the year and NAV would have decreased by GEL 122,585 (2022: GEL 83,046). As a result, GCAP's NAV would have increased by 4% (2022: 3%) or decreased by 4% (2022: 3%).

Sensitivity analysis of private portfolio companies are presented in note 17.

16. Risk Management (continued)

Market risk (continued)

Currency risk

The Group is exposed to the effects of fluctuations in the prevailing foreign currency exchange rates on its financial position and cash flows. The Group's principal transactions are carried out in Georgian Lari and its exposure to foreign exchange risk arises primarily with respect to US Dollar.

The currency risk management process is an integral part of the Group's activities; currency risk is managed through regular and frequent monitoring of the Group's currency positions and through timely and efficient elaboration of responsive actions and measures.

The tables below indicate the currencies to which the Group had significant exposure at 31 December 2023 and 31 December 2022 on its monetary assets and liabilities. The analysis calculates the effect of a reasonably possible movement of the currency rate against the Georgian Lari, with all other variables held constant on the income statement (due to the fair value of currency sensitive non-trading monetary assets and liabilities). The reasonably possible movement of the currency rate against the Georgian Lari is calculated as a standard deviation of daily changes in exchange rates over the twelve months. A negative amount in the table reflects a potential net reduction in income statement or equity, while a positive amount reflects a net potential increase.

Currency	Change in currency rate in %	Effect on profit before tax	Change in currency rate in %	Effect on profit before tax
		023	20	022
EUR	+8.8%	5	+13.4%	2,348
GBP	+10.1%	57	+15.1%	1,812
USD	+4.9%	(17,676)	+10.9%	(60,477)

Operating environment

Most of the Group's portfolio investments is concentrated in Georgia. As an emerging market, Georgia does not possess a well-developed business and regulatory infrastructure that would generally exist in a more mature market economy. Operations in Georgia may involve risks that are not typically associated with those in developed markets (including the risk that the Georgian Lari is not freely convertible outside the country, and undeveloped debt and equity markets). However, over the last few years the Georgian government has made a number of developments that positively affect the overall investment climate of the country, specifically implementing the reforms necessary to create banking, judicial, taxation and regulatory systems. This includes the adoption of a new body of legislation (including new Tax Code and procedural laws). In the view of the Board, these steps contribute to mitigate the risks of doing business in Georgia.

The existing tendency aimed at the overall improvement of the business environment is expected to persist. The future stability of the Georgian economy is largely dependent upon these reforms and developments and the effectiveness of economic, financial and monetary measures undertaken by the Government. However, the Georgian economy is vulnerable to market downturns and economic slowdowns elsewhere in the world.

Georgia has elaborated climate change strategy. Georgia's 2030 Climate Change Strategy and Action Plan (Climate Change Strategy and Action Plan – CSAP, Climate Action Plan – CAP) are a planning and implementation mechanism for coordinated effort and planning towards meeting the nationally determined targets for climate change mitigation.

Capital Management

Management monitors the Group's capital on a regular basis based on statement of Net Asset Value (NAV) prepared on fair value bases, same as equity attributable to the shareholder of JSC Georgia Capital as at 31 December 2023 in the amount of GEL 3,363,411 (2022: GEL 2,795,060). Net Asset Value (NAV) statement, which breaks down NAV into its components, including fair values for the private businesses and follows changes therein, providing management with a snapshot of the Group's financial position at any given time. NAV statement provides a value of Georgia Capital that management uses as a tool for measuring its investment performance. Management closely monitors NAV in connection with capital allocation decisions.

16. Risk Management (continued)

Capital Management (continued)

The capital management objectives are as follows:

- to maintain the required level of stability of the Group thereby providing a degree of security to the shareholders;
- to manage capital needs such that Group does not depend on potentially premature liquidation of it's listed investments;
- to allocate capital efficiently and support the development of business by ensuring that returns on capital employed meet the requirements of its capital providers and of its shareholders; and
- to maintain financial strength to support new business growth and to satisfy the shareholder's requirements.

The Group manages its capital structure and makes adjustments in light of changes in economic conditions and the requirements of the financial covenants if any. To maintain or adjust the capital structure, the Group may adjust the amount of outstanding equity.

17. Fair Value Measurements

Fair value hierarchy

For the purpose of fair value disclosures, the Group has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability. The following tables show analysis of assets and liabilities measured at fair value or for which fair values are disclosed by level of the fair value hierarchy:

31 December 2023	Level 1	Level 2	Level 3	Total
Assets measured at fair value			<u> </u>	
Marketable securities	250	17,953	-	18,203
Investment in redeemable securities	-	-	14,068	14,068
Equity investments at fair value	1,225,847	159,000	2,287,098	3,671,945
Listed portfolio companies	1,225,847	-	-	1,225,847
Observable portfolio companies	-	159,000	-	159,000
Private portfolio companies	-	-	2,287,098	2,287,098
Loans issued	-	-	9,212	9,212
Assets for which fair values are disclosed				
Amounts due from credit institutions	-	8,678	-	8,678
Accounts receivable	-	-	3,274	3,274
Liabilities for which fair values are disclosed				
Debt securities issued	-	331,358	-	331,358

31 December 2022	Level 1	Level 2	Level 3	Total
Assets measured at fair value				
Marketable securities	1,183	24,262	-	25,445
Investment in redeemable securities	-	-	12,631	12,631
Equity investments at fair value	830,463	155,000	2,213,164	3,198,627
Listed portfolio companies	830,463	-	-	830,463
Observable portfolio companies	-	155,000	-	155,000
Private portfolio companies	-	-	2,213,164	2,213,164
Loans issued	-	-	26,830	26,830
Assets for which fair values are disclosed				
Amounts due from credit institutions	-	16,278	-	16,278
Accounts receivable	-	-	109	109
Liabilities for which fair values are disclosed				
Debt securities issued	-	650,308	-	650,308

^{*}There were no transfers between levels of the fair value hierarchy during the year.

17. Fair Value Measurement (continued)

Valuation techniques

The following is a description of the determination of fair value for financial instruments which are recorded at fair value using valuation techniques. These incorporate the Group's estimate of assumptions that a market participant would make when valuing the instruments.

Assets for which fair value approximates carrying value

For financial assets and financial liabilities that are liquid or have a short term maturity (less than three months), it is assumed that the carrying amounts approximate to their fair value. This assumption is also applied to demand deposits, savings accounts without a specific maturity and variable rate financial instruments.

Fixed rate financial instruments

The fair value of fixed rate financial assets and liabilities carried at amortised cost are estimated by comparing market interest rates when they were first recognised with current market rates offered for similar financial instruments. The estimated fair value of fixed interest bearing deposits is based on discounted cash flows using prevailing money-market interest rates for debts with similar credit risk and maturity.

Equity Investments in Listed and Observable Portfolio Companies

Equity instruments listed on an active market are valued at the price within the bid/ask spread, that is most representative of fair value at the reporting date, which usually represents the closing bid price. The instruments are included within Level 1 of the hierarchy. Listed and observable portfolio also includes instruments for which there is a clear exit path from the business, e.g. through a put and/or call options at pre-agreed multiples. In such cases, pre-agreed terms are used for valuing the company.

Equity Investments in Private Portfolio Companies

Large portfolio companies – An independent third-party valuation firm is engaged to assess fair value ranges of large private portfolio companies at the reporting date starting from 31 December 2020. The independent valuation company has extensive relevant industry and emerging markets experience. Valuation is performed by applying several valuation methods including an income approach based mainly on discounted cash flow and a market approach based mainly on listed peer multiples (the DCF and listed peer multiples approaches applied are described below for the other portfolio companies). The different valuation approaches are weighted to derive a fair value range, with the income approach being more heavily weighted than the market approach. Management selects what is considered to be the most appropriate point in the provided fair value range at the reporting date.

Investment stage portfolio companies – An independent third-party valuation firm is engaged to assess fair value ranges of investment stage private portfolio companies at the reporting date starting from 30 June 2022. The independent valuation company has extensive relevant industry and emerging markets experience. Valuation is performed by applying several valuation methods including an income approach based mainly on discounted cash flow and a market approach based mainly on listed peer multiples (the DCF and listed peer multiples approaches applied are substantially identical to those described below for the other portfolio companies). The different valuation approaches are weighted to derive a fair value range, with the income approach being more heavily weighted than the market approach. Management selects what is considered to be the most appropriate point in the provided fair value range at the reporting date.

Other portfolio companies - fair value assessment is performed internally as described below.

Equity investments in private portfolio companies are valued by applying an appropriate valuation method, which makes maximum use of market-based public information, is consistent with valuation methods generally used by market participants and is applied consistently from period to period, unless a change in valuation technique would result in a more reliable estimation of fair value.

The value of an unquoted equity investment is generally crystallised through the sale or flotation of the entire business. Therefore, the estimation of fair value is based on the assumed realisation of the entire enterprise at the reporting date. Recognition is given to the uncertainties inherent in estimating the fair value of unquoted companies and appropriate caution is applied in exercising judgments and in making the necessary estimates.

17. Fair Value Measurement (continued)

Valuation techniques (continued)

The fair value of equity investments is determined using one of the valuation methods described below:

Listed Peer Group Multiples

This methodology involves the application of a listed peer group earnings multiple to the earnings of the business and is appropriate for investments in established businesses and for which the Company can determine a group of listed companies with similar characteristics.

The earnings multiple used in valuation is determined by reference to listed peer group multiples appropriate for the period of earnings calculation for the investment being valued. The Company identifies a peer group for each equity investment taking into consideration points of similarity with the investment such as industry, business model, size of the company, economic and regulatory factors, growth prospects (higher growth rate) and risk profiles. Some peer-group companies' multiples may be more heavily weighted during valuation if their characteristics are closer to those of the company being valued than others.

As a rule of thumb, last 12-month earnings will be used for the purposes of valuation as a generally accepted method. Earnings are adjusted where appropriate for exceptional, one-off or non-recurring items.

a. Valuation based on enterprise value

Fair value of equity investments in private companies can be determined as their enterprise value less net financial debt (gross face value of debt less cash) appearing in the most recent Financial Statements.

Enterprise value is obtained by multiplying measures of a company's earnings by listed peer group multiple (EV/EBITDA) for the appropriate period. The measures of earnings generally used in the calculation is recurring EBITDA for the last 12 months (LTM EBITDA). In exceptional cases, where EBITDA is negative, peer EV/Sales (enterprise value to sales) multiple can be applied to last 12-month recurring/adjusted sales revenue of the business (LTM sales) to estimate enterprise value.

Once the enterprise value is estimated, the following steps are taken:

Net financial debt appearing in the most recent financial statements is subtracted from the enterprise value. If net debt exceeds enterprise value, the value of shareholders' equity remains at zero (assuming the debt is without recourse to Georgia Capital).

The resulting fair value of equity is apportioned between Georgia Capital and other shareholders of the company being valued, if applicable. Valuation based on enterprise value using peer multiples is used for businesses within non-financial industries.

b. Equity fair value valuation

Fair value of equity investment in companies can also be determined as using price to earnings (P/E) multiple of similar listed companies.

The measure of earnings used in the calculation is recurring adjusted net income (net income adjusted for non-recurring items and forex gains/ losses) for the last 12 months (LTM net income). The resulting fair value of equity is allocated between Georgia Capital and other shareholders of the portfolio company, if any. Fair valuation of equity using peer multiples can be used for businesses within financial sector (e.g. insurance companies).

Discounted cash flow

Under the discounted cash flow (DCF) valuation method, fair value is estimated by deriving the present value of the business using reasonable assumptions of expected future cash flows and the terminal value, and the appropriate risk-adjusted discount rate that quantifies the risk inherent to the business. The discount rate is estimated with reference to the market risk-free rate, a risk adjusted premium and information specific to the business or market sector. Under the discounted cash flow analysis unobservable inputs are used, such as estimates of probable future cash flows and an internally-developed discounting rate of return.

Net Asset Value

The net assets methodology involves estimating fair value of an equity investment in a private portfolio company based on its book value at reporting date. This method is appropriate for businesses (such as real estate) whose value derives mainly from the underlying value of its assets and where such assets are already carried at their fair values (fair values determined by professional third-party valuation companies) on the balance sheet.

17. Fair Value Measurement (continued)

Valuation techniques (continued)

Price of recent investment

The price of a recent investment resulting from an orderly transaction, generally represents fair value as of the transaction date. At subsequent measurement dates, the price of a recent investment may be an appropriate starting point for estimating fair value. However, adequate consideration is given to the current facts and circumstances to assess at each measurement date whether changes or events subsequent to the relevant transaction imply a change in the investment's fair value.

Exit price

Fair value of a private portfolio company in a sales process, where the price has been agreed but the transaction has not yet settled, is measured at the best estimate of expected proceeds from the transaction, adjusted pro-rata to the proportion of shareholding sold.

Validation

Fair value of investments estimated using one of the valuation methods described above is cross-checked using several other valuation methods as follows:

- Listed peer group multiples peer multiples such as P/E, P/B (price to book) and dividend yield are applied to the respective metrics of the investment being valued depending on the industry of the company. The Company develops fair value range based on these techniques and analyses whether fair value estimated above falls within this range.
- Discounted cash flow (DCF) The discounted cash flow valuation method is used to determine fair value of equity investment. Based on DCF, the Company might make upward or downward adjustment to the value of valuation target as derived from primary valuation method. If fair value estimated using discounted cash flow analysis significantly differs from the fair value estimate derived using primary valuation method, the difference is examined thoroughly, and judgement is applied in estimating fair value at the measurement date.
- In line with our strategy, from time to time, we may receive offers from interested buyers for our private portfolio companies, which would be considered in the overall valuation assessment, where appropriate.

Valuation process for Level 3 valuations

Georgia Capital hired third-party valuation professionals to assess fair value of the large private portfolio companies as at 31 December 2021. Starting from 2022 third-party valuation professionals are hired to assess fair value of the investment stage private portfolio companies as well. As of 31 December 2023, such businesses include Hospitals (consisting of a. large and specialty hospitals and b. regional and community hospitals), P&C insurance, Retail (Pharmacy), Medical Insurance, Clinics & Diagnostics, Renewable energy, Education. The valuation is performed by applying several valuation methods that are weighted to derive fair value range, with the income approach being more heavily weighted than market approach. Management selects most appropriate point in the provided fair value range at the reporting date. Fair values of investments in other private portfolio companies are assessed internally in accordance with Georgia Capital's valuation methodology by the Valuation Workgroup.

Georgia Capital's Management Board proposes fair value to be placed at each reporting date to the Audit and Valuation Committee. Audit and Valuation Committee is responsible for the review and approval of fair values of investments at the end of each reporting period.

Description of significant unobservable inputs to level 3 valuations

The approach to valuations as of 31 December 2023 was consistent with the Group's valuation process and policy.

Management analyses the impact of climate change on the valuations, such as by incorporation of known effects of climate risks to the future cash flow forecasts or through adjusting peer multiples the known differences in the climate risk exposure as compared to the investment being fair valued. As at 31 December 2023, the management concluded that the effects of the climate risks are reflected in the peer multiples and discount rates used in the valuations and that no specific adjustments are required in relation of the Group's investment portfolio measurement and respective fair value sensitivity disclosures.

17. Fair Value Measurement (continued)

Description of significant unobservable inputs to level 3 valuations (continued)

The following tables show descriptions of significant unobservable inputs to level 3 valuations of equity investments:

31 December 2023

Description	Valuation technique	Unobservable input	Range* [implied multiple**]	Fair value
Loans Issued	DCF	Discount rate	15.0%-16.5%	9,212
Equity investments at fair value Large portfolio				1,436,231
Retail (Pharmacy)	DCF, EV/EBITDA	EV/EBITDA multiple	6.3x-28.2x [9.7x]	714,001
Hospitals	DCF, EV/EBITDA	EV/EBITDA multiple	7.2x-12.8x [13.8x]	344,356
P&C insurance	DCF, P/E	P/E multiple	4.6x-12.6x [13.0x]	285,566
Medical insurance	DCF, P/E	P/E multiple	5.7x-11.6x [11.0x]	92,308
Investment stage				566,614
Clinics and diagnostics	DCF, EV/EBITDA	EV/EBITDA multiple	9.4x-12.8x [11.7x]	110,761
Renewable energy	DCF, EV/EBITDA	EV/EBITDA multiple	2.8x-17.0x [12.6x]	266,627
Education	DCF, EV/EBITDA	EV/EBITDA multiple	6.1x-42.7x [16.7x]	189,226
Od	C 5.1	EV/EBITDA multiples	2.1x-19.0x [6.7x-14.6x]	284 252
Other	Sum of the parts	Cashflow probability NAV multiple	[90%-100%] [1.0x]	284,253

31 December 2022

Description Valuation technique Unobservable input		Range* [implied multiple**]	Fair value
DCF	Discount rate	5.5%-16.5%	26,830
			1,437,610
DCF, EV/EBITDA	EV/EBITDA multiple	6.1x-20.9x [9.1x]	724,517
DCF, EV/EBITDA	EV/EBITDA multiple	7.5x-14.2x [12.2x]	433,193
DCF, P/E	P/E multiple	7.0x-37.0x [10.7x]	228,045
DCF, P/E	P/E multiple	10.3x-11.8x [10.6x]	51,855
			501,407
DCF, EV/EBITDA	EV/EBITDA multiple	7.9x-14.2x [16.5x]	112,178
DCF, EV/EBITDA	EV/EBITDA multiple	8.1x-20.9x [11.4x]	224,987
DCF, EV/EBITDA	EV/EBITDA multiple	7.6x-39.3x [16.9x]	164,242
0 6.1	EV/EBITDA multiples	2.0x-16.8x [6.3x-10.0x]	271.117
Sum of the parts	Cashflow probability	[90%-100%]	274,147
	DCF DCF, EV/EBITDA DCF, EV/EBITDA DCF, P/E DCF, P/E DCF, EV/EBITDA DCF, EV/EBITDA	DCF Discount rate DCF, EV/EBITDA EV/EBITDA multiple DCF, EV/EBITDA EV/EBITDA multiple DCF, P/E P/E multiple DCF, P/E P/E multiple DCF, EV/EBITDA EV/EBITDA multiple DCF, EV/EBITDA EV/EBITDA multiple DCF, EV/EBITDA EV/EBITDA multiple EV/EBITDA multiple Sum of the parts	Valuation technique Unobservable input multiple**/ [implied multiple**] DCF Discount rate 5.5%-16.5% DCF, EV/EBITDA EV/EBITDA multiple 6.1x-20.9x [9.1x] DCF, EV/EBITDA EV/EBITDA multiple 7.5x-14.2x [12.2x] DCF, P/E P/E multiple 7.0x-37.0x [10.7x] DCF, P/E P/E multiple 10.3x-11.8x [10.6x] DCF, EV/EBITDA EV/EBITDA multiple 7.9x-14.2x [16.5x] DCF, EV/EBITDA EV/EBITDA multiple 8.1x-20.9x [11.4x] DCF, EV/EBITDA EV/EBITDA multiple 7.6x-39.3x [16.9x] EV/EBITDA multiples 2.0x-16.8x [6.3x-10.0x] Gashflow probability [90%-100%]

^{*}For equity investments at fair value the range refers to LTM multiples of listed peer group companies, prior to any adjustments.

^{**}Implied multiples are derived by dividing selected value of the company by respective LTM earnings measure.

17. Fair Value Measurement (continued)

Description of significant unobservable inputs to level 3 valuations (continued)

Georgia Capital hired third-party valuation professionals to assess fair value of the large and investment stage private portfolio companies as at 31 December 2023 and 31 December 2022 including P&C insurance, Hospitals (consisting of a large and specialty hospitals and b. regional and community hospitals), Retail (Pharmacy), Medical Insurance and Clinics and Diagnostics. Starting from 30 June 2022, fair value assessment for Renewable Energy and Education businesses are performed by third-party valuation professionals as well. The valuation is performed by applying several valuation methods that are weighted to derive fair value range, with the income approach being more heavily weighted than market approach. Management selects most appropriate point in the provided fair value range at the reporting date.

On 31 December 2021, Georgia Capital signed SPA to dispose 80% interest in Water Utility business, which was previously included within the large private portfolio companies. As at 31 December 2023, the remaining 20% interest in Water Utility business was valued using the pre-agreed put option multiple in reference to the signed contract with the buyer as GCAP has a clear exit path from the business through a put and call structure at pre-agreed EBITDA multiples.

As at 31 December 2023, several portfolio companies (Hospitals, Clinics, P&C Insurance, together "Defendants") were engaged in litigation with the former shareholders of Insurance Company Imedi L who allege that the they sold their 66% shares in Imedi L to Defendants under duress at a price below market value in 2012. Since the outset, Defendants have vigorously defended their position that the claims are wholly without merit. Initial judgment of the First Instance Court which was in favour of the Defendants was later overruled and upon reconsideration the First Instance Court partially satisfied the claim and ruled that USD 12.7 million principal amount plus an annual 5% interest charge as lost income (c. USD 21 million in total) should be paid to Defendants. The Defendants appealed the decision of the First Instance Court and as of 31 December 2023 the case is at the stage of consideration at the Appellate Court. No hearing date has been set. Defendants are confident that they will prevail and there have not been made a provision for a potential liability in their financial statements. Management shares Defendants' assessment of the merits of the case and considers that the probability of incurring losses on this claim is low, accordingly, fair values of portfolio companies do not take into account a potential liability in relation to this litigation.

In December 2023, the Georgian National Competition Agency (the "Agency") imposed fines on four companies in the Georgian pharmaceutical retailers' sector, including GCAP's retail (pharmacy) business, for alleged anti-competitive actions related to price quotations on certain prescription medicines funded under the state programme. The penalty amount assessed by the Agency on our retail (pharmacy) business is GEL 20.0 million derived by utilising the single rate across all the alleged participants. The company has appealed the Agency's decision in court and plans to vigorously defend its position.

Sensitivity analysis to significant changes in unobservable inputs within Level 3 hierarchy

In order to determine reasonably possible alternative assumptions the Group adjusted key unobservable model inputs. The Group adjusted the inputs used in valuation by increasing and decreasing them within a range, which is considered by the Group to be reasonable. All sensitivities disclosed below (except for loans issued) refer to sensitivity of private portfolio company valuations as neither listed, nor observe portfolio valuations are within level 3.

If the interest rate for each individual loan issued to equity investments as at 31 December 2023 decreased by 3.0-3.3 percentage points (2022: 1.1-3.3 percentage points), the amount of loans issued would have decreased by GEL 257 or 2.8% (2022: GEL 150 or 0.6%). If the interest rates increased by 3.0-3.3 percentage points (2022: 1.1-3.3 percentage points) then loans issued would have increased by GEL 255 or 2.8% (2022: GEL 148 or 0.6%).

17. Fair Value Measurement (continued)

Sensitivity analysis to significant changes in unobservable inputs within Level 3 hierarchy (continued)

If the listed peer multiples used in the market approach to value unquoted investments as at 31 December 2023 decreased by 10% (2022: 10%), value of equity investments at fair value would decrease by GEL 59 million or 2% (2022: GEL 71 million or 2%). If the multiple increased by 10% (2022: 10%) then the equity investments at fair value would increase by GEL 59 million or 2% (2022: GEL 71 million or 2%).

If the discount rates used in the income approach to value unquoted investments decreased by 50 basis points (2022: 50 basis points), the value of equity investments at fair value would increase by GEL 82 million or 2% (2022: GEL 75 million or 2%). If the discount rates increased by 50 basis points (2022: 50 basis points) then the equity investments at fair value would decrease by GEL 87 million or 2% (2022: GEL 71 million or 2%). If the discount rate decreased by 100 basis points, the value of equity investments at fair value would increase by GEL 177 million or 5% (31 December 2022: GEL 155 million or 5%). If the discount rate increased by 100 basis points then the equity investments at fair value would decrease by GEL 164 million or 4% (31 December 2022: GEL 138 million or 4%).

If the multiple used to value unquoted investments valued on NAV and recent transaction price basis as at 31 December 2023 decreased by 10% (2022: 10%), value of equity investments at fair value would decrease by GEL 10 million or 0.3% (2022: GEL 11 million or 0.3%). If the multiple increased by 10% then the equity investments at fair value would increase by GEL 10 million or 0.3% (2022: GEL 11 million or 0.3%).

As set out in the description of significant unobservable inputs to level 3 valuations the valuations have been prepared on the basis that climate change risks are reflected in the peer multiples and discount rates. Therefore, the sensitivities noted above in respect of peer multiples and discount rates include the risk arising from climate change.

Set out below is a comparison by class of the carrying amounts and fair values of the Group's financial instruments that are carried in the consolidated statement of financial position at amortised cost. The table does not include the fair values of non-financial assets and non-financial liabilities, or fair values of other smaller financials assets and financial liabilities, fair values of which are materially close to their carrying values.

	Carrying value 31 December 2023	Fair value 31 December 2023	Unrecognised gain (loss) 31 December 2023	Carrying value 31 December 2022	Fair value 31 December 2022	Unrecognised gain (loss) 31 December 2022
Financial assets						
Cash and cash equivalents	51,138	51,138	-	199,771	199,771	-
Amounts due from credit institutions	8,678	8,678	-	16,278	16,278	-
Financial liabilities						
Debt securities issued	413,930	331,358	82,572	681,067	650,308	30,759
Total unrecognised change in unrealised fair value		· · · · · · · · · · · · · · · · · · ·	82,572		_	30,759

Movements in level 3 financial instruments measured at fair value

The following tables show a reconciliation of the opening and closing amounts of level 3 financial assets which are recorded at fair value:

	At 31 December	PL mo	PL movement*		Other changes**	Loans issued	Loans repaid	At 31 December	
	2022	realized	unrealized	Divestments	Changes			2023	
Level 3 financial assets									
Loans issued	26,830	976	(851)	-	(353)	58,113	(75,503)	9,212	
Equity investments at fair value - Private Portfolio	2,213,164	82,012	45,248	18,420	(71,746)	-	-	2,287,098	

17. Fair Value Measurement (continued)

Sensitivity analysis to significant changes in unobservable inputs within Level 3 hierarchy (continued)

Movements in level 3 financial instruments measured at fair value (continued)

	At 31 December	PL mo	vement*	Investments and	Other		Loans repaid	At 31 December
	2021	realized	unrealized	Divestments	Changes			2022
Level 3 financial assets								
Loans issued	154,214	3,422	(18,654)	-	(167,358)	281,652	(226,446)	26,830
Equity investments at fair value - Private Portfolio	2,238,085	52,977	(224,687)	195,949	(49,160)	-	-	2,213,164

^{*} PL movement represents gain on revaluation of call option, interest income and foreign exchange gain on loans issued and fair value loss and dividend income on investments at fair value.

18. Maturity Analysis

The table below shows an analysis of assets and liabilities analysed according to when they are expected to be recovered or settled:

	31 December 2023			<i>31 December 2022</i>			
	Less	More		Less	More		
	than	than	Total	than	than	Total	
	1 Year	1 Year		1 Year	1 Year		
Cash and cash equivalents	51,138	-	51,138	199,771	-	199,771	
Amounts due from credit institutions	8,678	-	8,678	16,278	-	16,278	
Marketable securities*	18,203	-	18,203	25,445	-	25,445	
Investment in redeemable securities	14,068	-	14,068	12,631	-	12,631	
Accounts receivable	842	2,432	3,274	109	-	109	
Prepayments	923	-	923	610	-	610	
Loans issued	9,212	-	9,212	5,730	21,100	26,830	
Property and equipment	-	340	340	-	391	391	
Intangible assets	-	67	67	-	109	109	
Other assets	456	-	456	348	784	1,132	
Equity investments at fair value	-	3,671,945	3,671,945	-	3,198,627	3,198,627	
Total assets	103,520	3,674,784	3,778,304	260,922	3,221,011	3,481,933	
Accounts payable	888	-	888	917	-	917	
Debt securities issued	14,271	399,659	413,930	10,911	670,156	681,067	
Other liabilities	75		75	4,539	350	4,889	
Total liabilities	15,234	399,659	414,893	16,367	670,506	686,873	
Net	88,286	3,275,125	3,363,411	244,555	2,550,505	2,795,060	

^{**} Other changes for loans issued represent interest repayment and loans conversion into the equity of private portfolio companies and for equity investments at fair value — dividends and other investments (note 10).

^{*}Internationally and locally listed debt and equity investments and investment in redeemable shares are allocated to "less than 1 year" rather than based on contractual maturity.

19. Related Party Disclosures

In accordance with IAS 24 "Related Party Disclosures", parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial or operational decisions. In considering each possible related party relationship, attention is directed to the substance of the relationship, not merely the legal form.

Related parties may enter into transactions which unrelated parties might not, and transactions between related parties may not be effected on the same terms, conditions and amounts as transactions between unrelated parties. All transactions with related parties disclosed below have been conducted on an arm's length basis.

The volumes of related party transactions, outstanding balances year end, and related expenses and income for the period are as follows:

	31 December 2023		31 Decen	nber 2022
	Management*	Equity Investments**	Management*	Equity Investments**
Assets				
Marketable securities	-	16,958	-	3,194
Investment in redeemable securities	-	14,068	-	12,631
Prepayments	-	387	-	484
Loans issued (note 9)	-	9,212	-	26,830
Other assets	-	-	-	369
	-	40,625	-	43,508
Liabilities				
Debt securities issued	7,802	-	4,053	-
Financial guarantees provided (notional value)	-	-	-	18,460
Other liabilities	-	-	-	350
	7,802		4,053	18,810

	20	123	2022			
	Management*	Equity Investments**	Management*	Equity Investments**		
Income and expenses				' <u> </u>		
Dividend income	-	82,012	-	52,977		
Administrative expenses	-	(1,066)	-	(1,240)		
Interest income at EIR method	-	3,041	-	11,342		
Other interest income	-	127	-	899		
Interest expense	(263)		(287)	(35)		
	(263)	84,114	(287)	63,943		

^{*} Management of JSC Georgia Capital consist of 5 executives and 4 members of supervisory board (2022: 5 executives and 6 members of supervisory board).

Compensation of key management personnel comprised the following:

	2023	2022
Salaries and other benefits	(3,431)	(2,579)
Share-based payments compensation	(21,159)	(16,734)
Total key management compensation	(24,590)	(19,313)

Key management personnel do not receive cash settled compensation, except for fixed salaries. The major part of the total compensation is share-based. The number of key management personnel at 31 December 2023 was 9 (2022: 11).

^{**} Equity investments comprise of investees of JSC Georgia Capital. Private portfolio companies as at 31 December 2023 and 31 December 2022 also represent balances with related parties (note 10).

20. Events after Reporting Period

Acquisiton of medical insurance contracts and brand name from "Ardi"

In January 2024, the medical insurance business signed a Memorandum of Understanding ("MOU") to acquire a GEL 73 million portfolio of medical insurance contracts and brand name from "Ardi". Upon the successful completion of this transaction, the combined market share of GCAP's medical insurance business will make it the largest health insurer in the country. The total cash outflow for this transaction is GEL 27 million, which will be fully financed by funds already available in the medical insurance business, with no cash investment required from GCAP. Following this acquisition, the insurance business will operate under three brand names: Aldagi, Imedi L, and Ardi, all of which will be managed under GCAP.

Proposed acquisition of Ameriabank CJSC by Bank of Georgia Group PLC

On 19 February 2024, Bank of Georgia Group PLC announced that it has reached an agreement for the proposed acquisition of 100% of Ameriabank CJSC a leading universal bank in Armenia with an attractive franchise (the "Transaction"). The Transaction price is approximately USD 303.6 million, which will be fully financed by the Bank's surplus capital. The Transaction - expected to be EPS and RoAE accretive - represents a significant catalyst for the Bank and its shareholders. The Bank intends to keep the targeted pay-out ratio unchanged in the range of 30-50% of annual profits, potentially enabling increased capital distributions for the Bank's shareholders.

As of 15 March 2024, the share price of Bank of Georgia Group PLC has seen a significant increase, rising from GBP 39.75 to GBP 48.45 compared to the end of 2023. This translates to a total value increase by 22% in GEL.



JSC Georgia Capital and Subsidiaries

The Group's Management Report

The Group's Management Report

Introduction

This document incorporates the essential components related to JSC Georgia Capital ("Georgia Capital", "GCAP") such as the review of the activities, achievements based on factual indicators, development outlooks, vision and future plans. It also describes the established standards of corporate ethics and the business risks that might impact the Group's performance.

Business Overview

About Us

JSC Georgia Capital ("Georgia Capital", "GCAP") makes up a group of companies (the "Group") whose primary business is to develop or buy businesses, help them develop their management and institutionalise their businesses that can further develop mainly on their own, either with continued oversight or independently. The Group's focus is typically on larger-scale investment opportunities in Georgia, which have the potential to reach at least GEL 300 million equity value over 3-5 years from the initial investment and to monetise them through exits, as investments mature. Georgia Capital manages its portfolio companies individually and does not focus on achieving intergroup synergies. Georgia Capital does not have capital commitments or a primary mandate to deploy funds or divest assets within a specific time frame. As such, it focuses on shareholder returns and on opportunities which meet its investment return and growth criteria.

JSC Georgia Capital was established on 6 August 2015 as a joint stock company ("JSC") under the laws of Georgia. Company ID – 404549690, registration authority – LEPL National Agency of Public Registry. Georgia Capital's registered legal address is Petre Melikishvili Avenue N8a / Erekle Tatishvili Street N1, Tbilisi Georgia. The Group does not have any branches.

All amounts in the management report are presented in thousands of Georgian Lari (GEL), except for per share amounts or unless otherwise indicated.

Portfolio and segments

The Group currently has the following portfolio businesses (i) a retail (pharmacy) business; (ii) a hospitals business (consisting of a large and specialty hospitals and b. regional and community hospitals); (iii) an insurance business (P&C and medical insurance); (iv) a clinics and diagnostics business; (v) a renewable energy business (hydro and wind assets) and (vi) an education business; Georgia Capital also holds other small private businesses across different industries in Georgia; a 20% equity stake in the water utility business and a 19.7% (31 December 2022: 20.6%) equity stake in LSE premium-listed Bank of Georgia Group PLC ("BoG"), a leading universal bank in Georgia.

Listed and Observable Portfolio

Bank of Georgia

Georgia Capital owns 19.7% (31 December 2022: 20.6%) of Bank of Georgia Group PLC, a UK incorporated holding company, comprising: a) retail banking and payment services (Retail Banking), b) banking services for small and medium-sized businesses (SME Banking) and c) corporate and investment banking operations (Corporate and Investment Banking) in Georgia. The Group expects to benefit from superior growth of the Georgian economy through both its retail banking and corporate and investment banking services and aims to deliver on its strategy and key medium-term objectives – at least 20% return on average equity (ROAE) and c.10% growth of its loan book. BoG targets to maintain a 30%-50% dividend/share buyback payout ratio through regular and progressive semi-annual capital distributions.

Water Utility

The Group's Water Utility business, 20% (31 December 2022: 20%) owned through Georgia Global Utilities (GGU), is a regulated natural monopoly in Tbilisi and the surrounding area, where it provides water and wastewater services to c.1.4 million residents representing more than one-third of Georgia's population and c.42,000 legal entities. The water utility business also operates hydro power plants (HPPs) with total installed capacity of 149MW. In 2022, Georgia Capital completed the sale of an 80% equity interest in the business to FCC Aqualia ("Aqualia") for a cash consideration of USD 180 million (GEL 548 million).

Portfolio and segments (continued)

Private Large Portfolio Companies

Retail (Pharmacy)

The Group's Retail (Pharmacy) business, owned by 97.6% (31 December 2022: 77.0%), is the largest pharmaceuticals retailer and wholesaler in Georgia, with a 32% market share by revenue. The business consists of a retail pharmacy chain and a wholesale business that sells pharmaceuticals and medical supplies to hospitals and other pharmacies. The business operates a total of 412 pharmacies (of which 397 are in Georgia and 15 are in Armenia) and 23 franchise stores (of which, two are in Armenia and four in Azerbaijan).

Hospitals

The Group's Hospitals business, owned by 100%, is the largest healthcare market participant in Georgia. In 2023, the hospitals business is split into two distinct sub-segments: "Large and Specialty Hospitals" and "Regional and Community Hospitals". The Regional and Community Hospitals also incorporates the community clinics that were previously managed and presented as part of the clinics and diagnostics business. The hospitals business comprises seven Large and Specialty Hospitals, providing secondary and tertiary level healthcare services across Georgia and 27 Regional and Community Hospitals, providing outpatient and basic inpatient services.

Insurance

The insurance business comprises a) Property and Casualty (P&C) insurance business and b) medical insurance business. The Group owns 100% of the insurance business.

The P&C insurance business is a leading player in the local insurance market with a 30.0% market share in property and casualty insurance based on gross premiums as of 30 September 2023. The P&C insurance business also offers a variety of non-property and casualty products such as life insurance.

GCAP's medical insurance business is one of the country's largest private medical insurers, with a 19.0% market share based on 9M23 net insurance premiums. The business offers a variety of medical insurance products primarily to Georgian corporate and retail clients and (selectively) to state entities.

Private Investment Stage Portfolio Companies

Renewable Energy

The Group's Renewable Energy business is owned by 100%. The business operates three wholly-owned commissioned renewable assets: 30MW Mestiachala HPP, 20MW Hydrolea HPPs and 21MW Qartli wind farm. In addition, the business has a pipeline of renewable energy projects in varying stages of development.

Education

The education business currently combines majority stakes in four private school brands operating across seven campuses, acquired in 2019-2023: British-Georgian Academy and British International School of Tbilisi (70% stake), the leading schools in the premium and international segments, Buckswood International School (80% stake), well positioned in the midscale segment and Green School (80%-90% ownership) well-positioned in the affordable segment.

Clinics and Diagnostics

The Group's Clinics and Diagnostics business is 100% owned. The business is the second largest healthcare market participant in Georgia after The Group's hospitals business. The clinics and diagnostics business comprises two segments: 1) 19 polyclinics (providing outpatient diagnostic and treatment services) and 14 lab retail points at GPC pharmacies; and 2) Diagnostics, operating the largest laboratory in the entire Caucasus region – "Mega Lab".

Portfolio and segments (continued)

Private Other Portfolio Companies

Other portfolio companies include the following businesses: Housing Development (100% owned through Georgia Real Estate), Hospitality (100% owned through Georgia Real Estate), Beverages (owned by 92%) and Auto Service (owned by 90-100%).

Short Financial Overview

The Group is 100% owned by Georgia Capital PLC, which is listed on the London Stock Exchange. Consequently, according to the founder's demand, the accounting policy of the Group has been compliant with the IFRS since its establishment.

On 31 December 2019 Georgia Capital concluded that it met the definition of investment entity as defined in IFRS 10 *Consolidated Financial Statements*. As per IFRS 10 an investment entity is an entity that:

- a) obtains funds from one or more investors for the purpose of providing those investor(s) with investment management services;
- b) commits to its investor(s) that its business purpose is to invest funds solely for returns from capital appreciation, investment income, or both; and
- c) measures and evaluates the performance of substantially all of its investments on a fair value basis.

The Group's audit services was provided by PricewaterhouseCoopers LLP. The published report includes the financial standing for the last two years. The condensed consolidated financial information of the Group is given below.

Consolidated Statement of Financial Position

	31 December	31 December
	2023	2022
Total Assets	3,778,304	3,481,933
Total Liabilities	414,893	686,873
Total Equity	3,363,411	2,795,060

Short Financial Overview (continued)

Statement of Comprehensive Income, for the year ended 31 December 2023

_	2023	2022
Gains/(losses) on investments at fair value	517,988	(69,252)
Listed and Observable Investments	472,740	155,435
Of which:	•	•
Sale consideration from disposal of listed shares	73,356	-
Disposal of listed shares	(65,766)	-
Private Investments	45,248	(224,687)
Dividend income	162,527	93,875
Interest income at effective interest rate method	5,953	19,942
Other interest income	3,119	12,087
(Loss)/gain on derecognition of liability	(3,111)	9,907
Net gains/(losses) from investment securities measured at FVPL	1,446	(10,801)
Net realised losses from investment securities measured at FVOCI	(162)	(1,750)
Other income	8	42
Gross investment profit	687,768	54,050
Salaries and other employee benefits	(23,783)	(25,843)
Depreciation and amortisation	(545)	(635)
Other administrative expenses	(5,894)	(6,797)
Interest expense	(39,660)	(59,763)
Profit/(loss) before provisions, foreign exchange and non-recurring items	617,886	(38,988)
Expected credit loss (charge)/reversal	(75)	380
Net foreign currency gain	6,954	58,116
Loss on derivative financial assets	(11)	(4,507)
Non-recurring expense	(1,898)	(387)
Profit before income taxes	622,856	14,614
Income tax	-	_
Profit for the year	622,856	14,614
Other comprehensive income/(loss) for the period, net of tax	128	(72)
Total comprehensive income for the year	622,984	14,542
- · · · · · · · · · · · · · · · · · · ·		

As mentioned above, following the change in investment entity status on 31 December 2019, the Group deconsolidated its subsidiaries and recognised them as investments in subsidiaries at their fair value as at 31 December 2019. In the year ended 31 December 2023 the Group recorded a gain on investments at fair of value of GEL 517,988 (31 December 2022: loss of GEL 69,252). The following table sets forth a breakdown of portfolio development during the year including gains (losses) on investments at fair value:

Short Financial Overview (continued)

	31 December 2022	Value Change	Dividends	Total gains / (Losses) on investments at fair value	Investments and Divestments	Other	31 December 2023
Listed and Observable Portfolio Companies	985,463	553,255	(80,515)	472,740	(73,356)	-	1,384,847
BoG	830,463	549,255	(80,515)	468,740	(73,356)	=	1,225,847
Water utility	155,000	4,000	-	4,000	-	-	159,000
Private Portfolio Companies	2,213,164	127,260	(82,012)	45,248	18,420	10,266	2,287,098
Large Portfolio Companies	1,437,610	74,786	(76,825)	(2,039)	-	660	1,436,231
Retail (Pharmacy)	724,517	39,397	(50,904)	(11,507)	-	991	714,001
Hospitals	433,193	(81,526)	(6,018)	(87,544)	-	(1,293)	344,356
Insurance (P&C and Medical)	279,900	116,915	(19,903)	97,012	-	962	377,874
Of which, P&C Insurance	228,045	71,447	(14,888)	56,559	-	962	285,566
Of which, Medical Insurance	51,855	45,468	(5,015)	40,453	-	-	92,308
Investment Stage Portfolio Companies	501,407	47,044	(5,187)	41,857	18,388	4,962	566,614
Clinics and diagnostics	112,178	(3,922)	-	(3,922)	-	2,505	110,761
Renewable Energy	224,987	38,684	(5,187)	33,497	6,218	1,925	266,627
Education	164,242	12,282	-	12,282	12,170	532	189,226
Other Portfolio Companies	274,147	5,430	-	5,430	32	4,644	284,253
Equity investments at fair value	3,198,627	680,515	(162,527)	517,988	(54,936)	10,266	3,671,945

	31 December 2021	Portfolio decomposition and Transfer between stages	Value Change	Dividends	Total gains / (Losses) on investments at fair value	Investments and Divestments	Other	31 December 2022
Listed and Observable Portfolio Companies	681,186	-	205,783	(40,898)	164,885	139,392	-	985,463
BoG	681,186	=	190,175	(40,898)	149,277	=	-	830,463
Water utility	=	=	15,608	=	15,608	139,392	-	155,000
Private Portfolio Companies	2,935,045	-	(181,160)	(52,977)	(234,137)	(491,561)	3,817	2,213,164
Large Portfolio Companies	2,407,264	(158,004)	(80,178)	(44,783)	(282,965)	(687,510)	821	1,437,610
Retail (Pharmacy)	710,385	-	30,150	(16,018)	14,132	-	-	724,517
Hospitals	731,819	(158,004)	(127,607)	(13,015)	(298,626)	-	-	433,193
Water utility	696,960	· -	(9,450)	-	(9,450)	(687,510)	-	-
Insurance (P&C and Medical)	268,100	-	26,729	(15,750)	10,979	=	821	279,900
Of which, P&C Insurance	211,505	-	30,468	(14,749)	15,719	-	821	228,045
Of which, Medical Insurance	56,595	-	(3,739)	(1,001)	(4,740)	-	-	51,855
Investment Stage Portfolio Companies	303,136	158,004	13,266	(8,194)	163,076	34,196	999	501,407
Clinics and diagnostics	-	158,004	(45,826)		112,178	-	-	112,178
Renewable Energy	173,288	-	31,040	(8,194)	22,846	27,854	999	224,987
Education	129,848	-	28,052	-	28,052	6,342	-	164,242
Other Portfolio Companies	224,645	-	(114,248)	-	(114,248)	161,753	1,997	274,147
Equity investments at fair value	3,616,231	-	24,623	(93,875)	(69,252)	(352,169)	3,817	3,198,627

The Group recorded a gain on listed and observable investments of GEL 472,740 in the year ended 31 December 2023. Reflecting a 52.6% increase in BoG's share price to GBP 39.75, which was supported by GEL's 4.8% depreciation against GBP in FY23 and the application of the put option valuation to GCAP's remaining 20% holding in the water utility business. In addition, GEL 80,515 cash dividend and GEL 73,356 buyback dividend income (consideration received as a result of participation in BoG buyback programme) was recorded from BoG in FY23.

The Group recorded a gain on private investments of GEL 45,248 in the year ended 31 December 2023. Valuation assessments of the Group's large and investment stage portfolio companies at year-end were performed by a third-party independent valuation firm. Further detail regarding the gain on private investments is disclosed below:

Short Financial Overview (continued)

- Retail (Pharmacy): The Group recorded a loss on private investments in relation to its retail pharmacy business in the amount of GEL 11,507. Reflecting the continued strong outlook of the businesses driven by a significant expansion and ongoing optimisation of the retail chain, as well as the resilience of the Georgian economy, LTM EBITDA (incl. IFRS 16) was up by 2.0% to GEL 107,629. The business paid GEL 50,904 dividend in FY23.
- Hospitals: The Group recorded a loss on private investments in relation to its hospitals business in the amount of GEL 87,544. The revenue of Large and Specialty Hospitals was up by 2.9% in FY23, reflecting resilient underlying performance at the seven hospitals comprising the business, while Regional and Community Hospitals revenue was down 4.5% in FY23, affected by the new regulations in Georgia. LTM EBITDA (incl. IFRS 16) stood at GEL 44,828 million in FY23. In December 2023, the business signed an agreement to sell one of its regional and community hospitals for a total consideration of GEL 34.6 million. The business paid GEL 6,018 dividend in FY23.
- Insurance (Property & Casualty and Medical Insurance): The Group recorded a gain on private investments in relation to its medical insurance business in the amount of GEL 40,453. Medical Insurance Pre-tax LTM net income was up 2.4 times y-o-y to GEL 8,411 in FY23. The business paid GEL 5,015 dividend in FY23. On private investment in P&C insurance business the group recorded gain of GEL 56,559. Mainly reflecting the growth in the Motor and credit life insurance lines. Pre-tax LTM net income was up by 3.5% to GEL 21,983 in FY23. The business paid GEL 14,888 dividend in FY23. The FY23 valuation assessments take into account the application of the Estonian Taxation Model, which was adopted in the Georgian insurance sector starting from beginning of 2024.
- Clinics and diagnostics: The Group recorded a loss on private investment in relation to clinics and diagnostics
 business in the amount of GEL 3,922. Reflecting the high demand for non-COVID services and the
 expansion of the business, revenue of the combined clinics and diagnostics business was up by 8.9% in
 FY23. The LTM EBITDA (incl. IFRS 16) of the business was GEL 14,738 in FY23.
- Renewable energy: The Group recorded a gain on private investments in relation to its renewable energy business in the amount of GEL 33,497, reflecting the net impact of decrease in electricity generation in FY23 due to the previously planned phased rehabilitation works and increase in the average electricity selling price in FY23. The business paid GEL 5,187 dividend in FY23.
- Education: The Group recorded a gain on private investments in relation to its education business in the amount of GEL 12,282. Reflecting organic growth through strong intakes and a ramp-up of the utilisation and expansion of the business. LTM EBITDA was up by 6.3% to GEL 13,724 in FY23.
- Other portfolio companies: The Group recorded a gain on other private investments in the amount of GEL 5,430. In FY23, the hospitality business successfully completed the sale of two operational hotels, a vacant land plot and two under-construction hotels located in Tbilisi and Kutaisi. The total consideration from these transactions amounts to USD 38.6 million.

The Group recorded interest income of GEL 9,072 in the year ended 31 December 2023 on an average balance of liquid assets and issued loans. Interest income represents the sum of other interest income and interest income using the EIR method.

The Group recorded loss on derecognition of liability in the amount of GEL 3,111.

The Group recorded a net gain from investment securities measured at FVPL in the amount of GEL 1,446 and net realised loss from investments securities measured at FVOCI in the amount of GEL 162 in the year ended 31 December 2023, which related to its marketable securities.

The Group recorded other administrative expenses in the amount of GEL 5,894 in the year ended 31 December 2023, incurred at GCAP level.

The Group recorded expenses for salaries and other employee benefits in the amount of GEL 23,783 in the year ended 31 December 2023, incurred at GCAP level.

The Group recorded interest expense in the amount of GEL 39,660 in the year ended 31 December 2023, which represented interest accrued in respect of the bonds issued by JSC Georgia Capital.

Short Financial Overview (continued)

The Group recorded a net foreign currency gain in the amount of GEL 6,954 in the year ended 31 December 2023, which is related to the impact of currency fluctuations on the foreign currency denominated financial assets and liabilities of GCAP.

There were no R&D activities during 2023.

Future Plans

Georgia Capital's key principle is to buy assets at affordable prices and to remain very disciplined in this regard. To evaluate new acquisition opportunities Georgia Capital has developed a 360-degree analysis framework. The Group performs a 360-degree analysis each time it makes a capital allocation decision and compares: a) the investment opportunity versus buyback opportunity; and b) the sale opportunity versus buyback opportunity. The Group intends to buy assets/companies at a higher discount to their listed peers than GCAP's fair value discount. Another core principle of the Group's investment philosophy is to be mindful about the size of the potential investments in new industries. Georgia Capital typically starts with a small ticket size and tests and develops a management track record before stepping up the investment.

In 2022, the Group introduced an NCC (Net Capital Commitment) Ratio Navigation Tool, which is an integral part of the GCAP's existing 360-degree framework and drives the Group's share buyback and investment decisions. NCC represents an aggregated view of all confirmed, agreed and expected capital outflows at the GCAP holding company level. An NCC ratio (NCC as a percentage of the total portfolio value) between 15%-40% guides GCAP to tactical share buybacks/investments, an NCC ratio below 15% would be expected to lead to more meaningful share buybacks/investments, whilst a ratio above 40% would lead to the implementation of a cash preservation strategy.

Georgia Capital does not have capital commitments or a primary mandate to deploy funds or divest assets within a specific time frame. It focuses on shareholder returns and on opportunities that meet its investment return and growth criteria. In line with its capital allocation strategy, the Group emphasises capital-light, larger-scale investment opportunities in Georgia, which have the potential to reach at least GEL 300 million equity value over 3-5 years and to be monetised through exits as they mature.

The Group aims to have two potential liquidity events for each of its assets: 1st exit - when entering a new industry Georgia Capital intends to develop and grow portfolio companies. The Group's key focus areas at the portfolio company level are the ability to grow operating cash and to make efficient capex investments. Once the business reaches its late stage of development, the Group expects to pursue its first exit route, which envisages dividend flows for GCAP; 2nd exit - as businesses mature, Georgia Capital normally seeks to monetise its investment through appropriate exit options, typically within five to ten years from initial investment.

The Group is also focused on cash generation at both GCAP and portfolio company level as well as management development – adding value for the Company's shareholders by developing top talent within the Group.

As the largest employer in the Georgian private sector, the Group and its portfolio companies have a responsibility to improve the future of its community by building the sustainable businesses of tomorrow. GCAP has a strong track record of investing and managing its portfolio responsibly, facilitated by operating according to its clear and proven governance model and an extensive network of top-quality talent. Georgia Capital's approach to environmental, social and governance (ESG) matters is reflected in the strategy and management principles of the Group's portfolio companies, all of which adhere to sound ESG standards, as well as local policies and regulations. On 3 August 2023, JSC Georgia Capital successfully issued a USD 150 million sustainability-linked bond with a 5-year bullet maturity on the Georgian market. Through the issuance of sustainability linked bonds, GCAP targets to decrease the group's greenhouse gas emissions by 20% by 2027, compared to a 2022 baseline. The SLB target is in line with GCAP's overarching commitment to reaching Net-Zero at the Group level by 2050. GCAP has obtained second party opinion from Sustainalytics on its sustainability-linked bond framework, affirming the alignment with core components of the sustainability-linked bond principles.

Corporate Governance

Georgia Capital recognizes the importance of maintaining sound corporate governance practices and supports high standards of corporate governance in delivering value to the Group's stakeholders.

The Corporate Governance Code for Issuers of Public Securities (№172/04 of December 7, 2021) is mandatory for all the issues of public securities in Georgia, including Georgia Capital. Georgia Capital (as a subsidiary of Public Limited Company) also complies with the standards of reporting and corporate governance under: the UK Corporate Governance Code (except for the combined Chairman & CEO structure); the provisions of the Listing Rules relating to pre-emption rights; and the requirements of Listing Rule 11 relating to related party transactions.

Internal controls and risk management systems related to the financial reporting process

The financial statements are prepared in accordance with International Financial Reporting Standards (IFRS) and with the requirements of the Law of Georgia on Accounting, Reporting and Auditing. Financial reporting procedures of the Group are managed and monitored by the Group's Finance department. A dedicated financial reporting team, comprised of professionals with accounting and reporting backgrounds, prepare financial statements for Georgia Capital on a daily, monthly, quarterly and annual basis. Overall monitoring of the process is performed by the Group's Chief Financial Officer.

The management has established a range of procedures that enable the Directors to discharge their responsibilities with respect to financial reporting process and an appropriate internal control environment has been established to support the integrity and accuracy of financial and management reporting as well as compliance with regulatory matters:

- The Group has established an internal control environment that supports accurate and timely management and financial reporting. Internal controls supporting financial and management reporting include but are not limited to (i) delegations of authority (approvals); (ii) balance sheet reconciliations; (iii) income statement and balance sheet reviews including budget versus actual reviews; (iv) journal reviews and approvals; and (vi) the adoption of segregation of duties with respect to cash inflows/outflows.
- The Internal Audit Department is an assurance function within the Group and is independent from the Group's Management Board and reports directly to the Group's Audit and Valuation Committee at least quarterly. The Internal Audit report covers its activities in accordance with the pre-approved annual Internal Audit plan and any other significant matters that may arise during the reporting period.
- The principal risk management bodies of the Group are: The Supervisory Board, the Management Board, the Audit and Valuation Committee, Internal Audit, the Finance Department, Legal Department, IFRS technical accounting group and Valuation Workgroup.
- The Group's risk management system is implemented primarily by the Finance department, which is supervised by the Chief Financial Officer and is in charge of the Financial Risks Management function.

Authority of shareholders and shareholders' general meeting

Overview

The corporate entities of the Group comprise the General Meeting of Shareholders (GMS), the Supervisory Board, and the Management Board, each possessing distinct responsibilities and powers as per the Georgian legislation and the Group's Charter. The Company adheres to the legal framework of Georgia in its operations.

As of the issue date, the Group's equity share capital is entirely held by Georgia Capital PLC.

The Group's GMS

All shareholders registered on the share register on the record date of the GMS have the right to attend and vote (if applicable) at the meeting. Georgian law provides that holders of preferred shares are not entitled to voting rights at the GMS, unless the Charter or any relevant share issue prospectus allocates voting rights to preferred shareholders. According to the Charter, holders of preferred shares are not entitled to voting rights at the GMS. As of the date of

Corporate Governance (continued)

Authority of shareholders and shareholders' general meeting (continued)

The Group's GMS (continued)

the prospectus, the Group has not issued any preferred shares. Shareholders may be represented at the GMS by a proxy.

Under Georgian law and the Charter, shareholders are authorised to pass resolutions, inter alia, on the following issues at a GMS:

- approval of amendments to the Charter;
- change of the share capital of the Group;
- liquidation of the Group;
- any merger, division or transformation of the Group into another legal entity;
- full or partial cancellation of pre-emptive rights during an increase of share capital;
- distributions of profits;
- appointment and dismissal of the members of the Supervisory Board and determination of their terms of service and remuneration;
- approval of the reports of the Supervisory Board and the Management Board and control of the activities
 of their members;
- selection of auditors;
- approval of participation in litigation against the Supervisory Board and the Management Board members, including the appointment of a representative in such litigation;
- acquisition, sale, transfer, exchange (or such related transactions) or encumbrance of the Group's assets, with the value exceeding 25.0% of the total assets of the Group;
- approval of the annual accounts of the Group;
- approval of related party transactions, with a value exceeding 2% of the Group's assets; and
- other issues provided by Georgian law and the Charter.

According to the Charter, decisions on all other issues are made by the Supervisory Board and the Management Board within their capacities.

The composition and operation of the management and supervision bodies

Supervisory Board

As per the Charter, the Supervisory Board is responsible for overseeing the Management Board's activities. The Supervisory Board comprises a minimum of three and a maximum of 15 members, who are appointed by the GMS. It is mandatory for the Supervisory Board members to act in the best interests of the Group and its business while executing their duties.

The Supervisory Board is responsible for various duties, which include:

- supervising the activities of the Management Board;
- appointing and dismissing the CEO and other directors, concluding and terminating service contracts with them, as well as establishing a code of conduct for the members of the Management Board;
- approving and amending the Group's policy and other regulatory requirements;
- inspecting the Group's accounts and property, including inspection of conditions of cash desk, securities and assets, personally or with the help of invited experts;
- requesting reports of the Group's activities from the Management Board (including information concerning
 associated companies and subsidiaries) and reviewing the information provided by internal audit or external
 inspections;
- convening extraordinary general meetings, if necessary;
- reviewing annual reports and the proposals of the Management Board on profit distribution;
- representing the Group in proceedings against the Group's CEO and other directors;

Corporate Governance (continued)

The composition and operation of the management and supervision bodies (continued)

Supervisory Board (continued)

- approving the annual budget; and
- making decisions in other cases provided by applicable laws.

The Supervisory Board members are: Irakli Gilauri, David Morrison, Massimo Gesua' sive Salvadori, Maria Chatti-Gautier, Neil Janin.

Management Board

The Management Board is an executive body that is responsible for the day-to-day management of the Group (with the exception of those functions reserved to the GMS and the Supervisory Board) and consists of the CEO and not less than two directors. The Management Board is accountable to the shareholders and the Supervisory Board and its members are appointed and dismissed by the Supervisory Board. The Supervisory Board approves the remuneration and other conditions of employment for each member of the Management Board. Certain resolutions of the Management Board are subject to the prior approval of the Supervisory Board.

The Management Board is managed by the CEO, who, together with the Supervisory Board, allocates the responsibilities of the Management Board among its members.

The responsibilities of the Management Board include:

- conducting the Group's day-to-day activities;
- reviewing agenda items for the Group's GMS or Supervisory Board meetings, obtaining all the necessary information, preparing proposals and draft resolutions;
- drafting and presenting to the Supervisory Board for approval the business plan for the following year (such business plan to include the budget, profit and loss forecast and the Group's investments plan);
- ensuring the fulfilment of resolutions passed at the Group's GMS and the Supervisory Board;
- developing policies, by-laws and other regulatory documents which are approved by the Supervisory Board and ensure compliance with such policies, by-laws and regulatory documents;
- deciding on the appointment, dismissal, training and remuneration of staff;
- convening extraordinary general meetings; and
- any other issues which may be assigned to the Management Board by the Supervisory Board and/or the Group's GMS.

The following activities may be carried out by the Management Board only with the approval of the Supervisory Board:

- the acquisition and disposal of shares in other companies (other than in the companies at least 50% of which is directly or indirectly by the Group (the Subsidiary)) if value of the transaction exceeds 2.5% of the Group's equity value as at the end of the previous calendar month;
- except for the transactions with the Subsidiaries, the acquisition, transfer and encumbrance of real estate and related ownership rights, if such transaction falls outside the scope of routine economic activity of the Group and the value of such transaction exceeds 2.5% of the Group's equity value as at the end of the previous calendar month;
- except for the investments in the Subsidiaries, investments, the partial or total amount of which exceeds 2.5% of the Group's equity value as at the end of the previous calendar month;
- securing credits and loans, if they fall outside the scope of routine economic activity and are in excess of 2.5% of the Group's equity value as at the end of the previous calendar month;
- borrowing funds in excess of 2.5% of the Group's equity value as at the end of the previous calendar month;
- the establishment and liquidation of branches;
- launching a new type of activity or terminating or suspending the existing type of activity;

Corporate Governance (continued)

The composition and operation of the management and supervision bodies (continued)

Management Board (continued)

- adopting general principles of business strategy and the business plan of the Group and approving the annual budget and incurrence of long-term liabilities;
- determination of the remuneration and/or additional benefits for the Group's senior management (CEO, other members of the Management Board and any other senior managers so selected by the Supervisory Board);
- the appointment and dismissal of trade representatives;
- except for the contracts and agreements with the Subsidiaries) the approval of an agreement or contract pursuant to which the expenditure of the Group (payable by single or several tranches) exceeds 1.0% of the Group's equity value as at the end of the previous calendar month;
- the determination and approval of internal policies and procedures for lending, investing, foreign exchange, assets and liabilities management, asset valuation, their classification and adequate provisioning; and
- other activities that may be prescribed by applicable laws.

The Management Board currently consists of the members: Irakli Gilauri, Avtandil Namicheishvili, Giorgi Alpaidze.

Shares owned by members of those charged with governance

As of 31 December 2023, no shares of JSC Georgia Capital are owned by the members of those charged with governance.

The diversity policy

JSC Georgia Capital complies and is subject to the diversity policy¹ of Georgia Capital PLC. Georgia Capital, according to the Policy, is fully committed to the elimination of unlawful and unfair discrimination and values the differences that a diverse workforce brings to the organisation. The Company embraces diversity in all its forms. Diversity of skills, social and ethnic background, nationality, experience, cognitive and personal strengths, knowledge, outlook, approach and gender, amongst other factors, will be taken into consideration when seeking to make any new appointment within the business, whether an employee, client, supplier or contractor. Diversity is not always an easily measured characteristic, such as gender. Diversity of outlook and approach is hard to measure but may be equally as important. Employees and job applicants will receive equal treatment regardless of age, disability, gender reassignment, marital or registered civil partner status, pregnancy or maternity, race (including colour, nationality, ethnic or national origin), religion or belief, sex or sexual orientation. All employees are responsible for the promotion and advancement of, and compliance with, the Diversity Policy. Behaviour, actions or words that transgress the Policy will not be tolerated and will be dealt with in line with the disciplinary policy.

Mandatory tender offer

During 2023, there were no mandatory tender offers made defined in Article 532 of the Law of Georgia on Entrepreneurs.

Risk Overview

Risk Factors

Regional Instability

The Georgian economy and the Group's business may be adversely affected by regional tensions. Georgia shares borders with Russia, Azerbaijan, Armenia and the Republic of Türkiye and has two breakaway territories, Abkhazia and the Tskhinvali/South Ossetia regions. In addition to strong political and geographic influences, regional countries are highly linked to the Georgian economy, representing its significant historical trading partners.

Following a significant Russian military build-up near the Russia-Ukraine border and months of rising tensions, on February 24, 2022 Russian troops crossed the border and the situation escalated into a war.

¹ The policy is available at the following link: https://georgiacapital.ge/governance/cgf/policies

Risk Overview (continued)

Risk Factors (continued)

Regional Instability (continued)

During 2022, comprehensive analysis was performed to determine the impact of the Russia-Ukraine war on the private portfolio valuations. During the analysis, the impact of the war on discount rates was estimated and changes in listed peer multiples and overall movement in emerging and regional markets were reviewed. Uncertainties surrounding the geopolitical tensions translated into an increase in discount rates during 2022 and reduced listed peer multiples and were reflected accordingly in the private portfolio companies' valuations, where applicable. As for 2023, no further major movements were observed on the markets in terms of peer multiples or discount rates. Management continues the impact assessment and will update the valuation inputs respectively going forward.

The Group actively monitors significant developments in the region and risks related to political instability and the Georgian Government's response thereto. It also develops responsive strategies and action plans of its own.

Currency Risk and Macroeconomic Environment

Unfavourable dynamics of macroeconomic variables, including depreciation of the Georgian Lari against the US Dollar, may have a material impact on the Group's performance.

The Group continually monitors market conditions, reviews market changes and also performs stress and scenario testing to test its position under adverse economic conditions, including adverse currency movements.

The currency risk management process is an integral part of the Group's activities; currency risk is managed through regular and frequent monitoring of the Group's currency positions and through timely and efficient elaboration of responsive actions and measures. Senior management reviews the overall currency positions of the Group several times during the year and elaborates respective overall currency strategies; the Finance department monitors the daily currency position for stand-alone Georgia Capital, weekly currency positions on a portfolio company level and manages short-term liquidity of the Group across different currencies. Control procedures involve regular monitoring and control of the currency gap and currency positions, running currency sensitivity tests and elaborating response actions/steps based on the results of the tests.

Regulatory Risk

The Group owns businesses operating across a wide range of industries: banking, healthcare, retail (pharmacy) and distribution, property and casualty insurance, medical insurance, real estate, water utility and electric power generation, hydro and wind power, beverages, education and auto service. Many of these industries are highly regulated. The regulatory environment continues to evolve. The Group, however, cannot predict what additional regulatory changes will be introduced in the future or the impact they may have on the Group's operations.

Georgia Capital and its businesses may be adversely affected by risks related to litigations arising from time to time in the ordinary course of business.

Georgia Capitals's continued investment in the people and processes is enabling the Group to meet current regulatory requirements, meaning that the Group is well placed to respond to any future changes in regulation. Further, investment portfolio of Georgia Capital is well diversified, limiting exposure to particular industry-specific regulatory risks

Georgia Capital's integrated control framework also ensures the application and development of mechanisms for identifying legal risks in the Group's activities in a timely manner, the planning and implementation of all necessary actions for the elimination of identified legal risks.

Risk Overview (continued)

Risk Factors (continued)

Investment Risk

The Group may be adversely affected by risks in respect of specific investment decisions.

The Group manages investment risk with established procedures for a thorough evaluation of target acquisitions. Investment opportunities are subject to rigorous appraisal and a multi-stage approval process. Target entry and exit event prices are monitored and updated regularly, in relation to market conditions and strategic aims. The Group performs due diligence on each target acquisition including on financial and legal matters. Subject to an evaluation of the due diligence results an acceptable price and funding structure is determined and, the pricing, funding and future integration plan is presented to the Board for approval. The Board reviews and approves or rejects proposals for development, acquisition and sale of investments and decides on all major new business initiatives, especially those requiring a significant capital allocation. The Board focuses on both investment strategy and exit processes, while also actively managing exit strategies in light of the prevailing market conditions.

Liquidity Risk

Liquidity risk implies that liabilities cannot be met, or new investments made, due to a lack of liquidity. Such risk can arise from not being able to sell an investment due to lack of demand from the market, from suspension of dividends from portfolio companies, from not holding cash or being able to raise debt.

The liquidity management process is a regular process, where the framework is approved by the Board and is monitored by senior management and the Chief Financial Officer. The framework models the ability of the Group to fund under both normal conditions (Base Case) and during stressed situations. This approach is designed to ensure that the funding framework is sufficiently flexible to ensure liquidity under a wide range of market conditions. The finance department monitors certain liquidity measures on a daily basis and actively analyses and manages liquidity weekly. Senior management is involved at least once a month and the Board on a quarterly basis. Such monitoring involves review of the composition of the cash buffer, potential cash outflows and management's readiness to meet such commitments. It also serves as a tool to revisit the portfolio composition and take necessary measures, if required. JSC Georgia Capital successfully issued USD 300 million bonds in March 2018, which was followed by a USD 65 million tap issuance on 16 March 2021. On 3 August 2023, JSC Georgia Capital has successfully issued a USD 150 million sustainability-linked bond with a 5-year bullet maturity. The proceeds from the transaction, together with existing liquid funds of GCAP, were utilised to fully redeem USD 300 million Eurobonds.

Since the adaption of the capital management framework and introduction of the NCC navigation tool in May 2022, the Group's primary emphasis has centred around deleveraging. This strategic approach has resulted in a significant reduction in the Group's liquidity risk. Since the introduction of the NCC concept, the NCC ratio has decreased significantly. Going forward, the Group targets to bring down the NCC ratio below 15% by December 2025. The deleveraging strategy was also implemented across the Group's private portfolio companies, where individual leverage targets have been developed.

As mentioned above, proceeds from USD 150 million bond issuance, together with the existing liquid funds of GCAP will be used to fully redeem the existing Eurobond and decrease gross debt balance from USD 300 million to USD 150 million, which further supports GCAP's deleveraging strategy. On 12 July 2023 JSC Georgia Capital launched an invitation to holders of its outstanding USD 300 million 6.125% Eurobonds ("Notes") due 2024, to tender their Notes for purchase by the Group for cash (the "Tender Offer"). As a result of the Tender Offer, Group purchased in aggregate of USD 176.5 million principal amount of Notes, which together with USD 106.9 million principal amount of Notes owned by the GCAP and held in treasury, were cancelled On 10 August 2023. The remaining USD 16.6 million in Eurobonds, GCAP exercised the right of optional redemption at a "make-whole" price, which was completed in September 2023.

Risk Overview (continued)

Risk Factors (continued)

Portfolio Companies Strategic and Execution Risks

Market conditions may adversely impact the strategy of Georgia Capital and all Group's businesses have their own risks specific to their industry. The businesses have growth and expansion strategies and Georgia Capital faces execution risk in implementing these strategies. The Group will normally seek to monetise its investments, primarily through strategic sale, typically within five to ten years from acquisition and the Group faces market and execution risk in connection with exists at reasonable prices.

For each business, Georgia Capital focuses on building a strong management team and has successfully been able to do so thus far. Management succession planning is regularly on the agenda for the Nomination Committee which reports to the Board on this matter. The Board closely monitors the implementation of strategy, financial and operational performance, risk management and internal control framework and corporate governance of the Group's businesses. Georgia Capital holds management accountable for meeting targets.

For each industry in which the Group operates, industry trends, market conditions and the regulatory environment are closely monitored. Georgia Capital has also sought and continues to seek advice from professionals with global experience in relevant industries. Georgia Capital measures its private portfolio companies at fair value. The valuations are audited, increasing the credibility of fair valuation and limiting the risk of mispricing the asset. In addition, the valuation of private large and investment portfolio companies (54.6% of total portfolio value) is performed by an independent valuation company on a semi-annual basis.

The Group has a strong track record of growth and has accessed the capital markets on multiple occasions as part of the BGEO Group PLC, prior to the demerger in May 2018. The acquisition history of Georgia Capital has also been successful and the Group has been able to integrate businesses due to strong management with integration experience.

In 2022, GCAP successfully completed the water utility business disposal, which represents Georgia Capital's most significant monetization event to date and marks the completion of the full investment cycle for one of the Group's large portfolio businesses.

Emerging Risks

The Group's risks are continually reassessed and reviewed through a horizon scanning process, with escalation and reporting to the Board. The horizon scanning process fully considers all relevant internal and external factors, and is designed to consider and capture the following risks: current risks which have not yet fully crystallised and which the Group does not have previous known experience of against which they can be assessed and risks which are expected to crystallise in future periods, typically beyond one year.

Since 2021, the Group has identified climate change as an emerging risk. Since the Group's businesses are very much dependent on such climate elements as precipitation, wind speed and air temperature, the Group's development will be affected by climate change. This is critical to protecting and enhancing the value of the Group's assets and therefore Georgia Capital monitors its governance and risk management framework to ensure that sustainability-related risks in GCAP's portfolio remain an important part of the Group's agenda and are treated as a priority by GCAP's portfolio company management teams.

Management analyses the impact of climate change on the valuations, such as by incorporation of known effects of climate risks to the future cash flow forecasts or through adjusting peer multiples the known differences in the climate risk exposure as compared to the investment being fair valued. As at 31 December 2023, the management concluded that the effects of the climate risks are reflected in the peer multiples and discount rates used in the valuations and that no specific adjustments are required in relation of the Group's investment portfolio measurement and respective fair value sensitivity disclosures.

The Group has also identified cyber security as an emerging risk. A cyber security incident can result in unauthorised access to, or misuse of, the Group's information systems, technology, or data. This could lead to leakage of sensitive information, disruption of operations and reputational damage.

Employee Matters

Recruiting, developing and retaining talent within the Group is one of the most important priorities. Key factor for working towards that objective is communicating openly with the employees, providing training and opportunities for career advancement, rewarding employees fairly and encouraging them to give direct feedback to senior management. The Group recognises the importance of providing a supportive working environment and a healthy work-life balance for all the employees both in Georgia Capital and in the Group's portfolio companies.

A key factor in the Group's success is a cohesive and professional team, capable of accomplishing the Group's objectives. The Group is committed to attracting and identifying the best professionals, caring and planning for their needs, investing in their development and fostering their commitment.

The Group developed and implemented Human Resource (HR) policies and procedures which promote the key principles, areas, approaches and methods that are crucial for building Human Capital Management systems at each business level and at Georgia Capital level. GCAP maintains a Group-wide Code of Conduct and Ethics for its employees and other effective HR policies and procedures covering matters such as:

- Staff administration, compensation and benefits;
- Recruitment, development and training;
- Diversity and anti-nepotism;
- Succession planning, departure and dismissal;
- Grievances and whistleblowing;

The Group is committed to employee engagement by providing them with a continuous flow of information, which includes information about corporate culture, the Group's strategy and performance, risks relating to its performance, such as financial and economic factors, and the Group's policies and procedures. The Group provides information to its employees in a number of ways, including via managers, presentations, email, intranet and regular off-site meetings. There are feedback systems, such as frequent employee satisfaction surveys, which ensure that the opinions of the Group's employees are taken into account when making decisions which are likely to affect their interests.

Georgia Capital is fully committed to providing equal opportunities as an employer and prohibits unlawful and unfair discrimination. The Group believes that there are great benefits to be gained from having a diverse workforce. At 31 December 2023, Georgia Capital, as an investment holding company, had a total of 47 employees and 19,815 employees at Group level.

Environmental Matters

The operations of Georgia Capital have relatively low energy consumption. However, it recognises the evolving significance of emissions disclosures in the investment community and in line with the commitment to increasing transparency, the Group voluntarily discloses emissions for JSC Georgia Capital and its portfolio investments.

To be more environmentally responsible, the Group's portfolio companies continue to implement energy saving solutions, such as LED lights and other energy-efficient equipment, such as boilers and heating ventilation and air conditioning systems. GCAP's housing development business pioneered the introduction of energy efficient construction materials. In the Group's education business, four of the school campuses successfully introduced solar panels, and gradually other educational infrastructures will follow in due course. GCAP's beverages business reduced its energy consumption and carbon footprint through its CO₂ recovery plant, alongside with the wastewater treatment plant. In addition, the company also introduced the Green Fridge policy which reduces the carbon footprint of cooling bottled and canned products. Additionally, the Group's PTI business adheres to green standards, exemplified by the planting of trees in every Tbilisi branch, contributing to a green space that encompasses 20% of the total territory.

Within the management team, the Chief Financial Officer (CFO), supported by the finance team, is responsible for identifying risks, including climate change risks, in relation to the investment portfolio and including these in the valuation process. The Director of Investments (DoI), supported by the Investment Officers, is responsible for identifying specific risks and opportunities at the initial investment stage.

In support of the evaluation of climate-related risks and opportunities that may be present, a review of GCAP's direct operations and a macro-level review of the portfolio companies' operations were completed. An early-stage scenario analysis was completed as part of the process towards understanding how the climate impacts identified in the qualitative assessment could present as financial risks to GCAP under different plausible future scenarios.

Environmental activities of the Group's portfolio companies

Bank of Georgia 33.4% share of the portfolio at 31 December 2023

Within the medium term, the rapid implementation of climate policy and regulation may result in sharply increasing direct regulatory expenses in relation to fixed assets such as the Bank's retail outlets.

In the short term, and in mitigation, the Bank is already in the advanced stages of implementing energy efficiency programmes within its real estate (retail, office and data centres). By anticipating compliance with regulations relating to fuel efficiency standards, emissions-reducing regulations and building efficiency compliance, the Bank will minimise costs in relation to regulations. In addition, it will lower energy expenditure and generate a financial benefit, especially where renewable energy is utilised. Additionally, the Bank has adopted digital technology to enable all forms of digital banking, potentially further reducing the need for fixed assets.

Retail (pharmacy) 19.4% share of the portfolio at 31 December 2023

The principal risks arise from physical aspects of climate change and may impact the physical assets. Transition risks are considered to mainly relate to carbon pricing and the effect this will have on the supply chain, for example, the purchase of drugs and medicines. As the carbon price rapidly increases post-2030 (medium term) the prices of goods will increase. While this will be felt across the market and will not be unique to the portfolio, given the leading market share, this could result in reputational risk arising from consumer perception.

There is a regulation opportunity for the retail (pharmacy) business. Being an early adopter of fuel efficiency standards, emissions-reducing regulations and building efficiency compliance will reduce overall running costs in the medium term. Good energy management and the use of renewable energy will not only lower the energy expenditure and generate a financial benefit but will also reduce the carbon footprint of the operations.

Healthcare Business - Hospitals and Clinics and Diagnostics 12.4% share of the portfolio at 31 December 2023

Under the delayed transition 1.8°C scenario, it is anticipated that in the medium-term carbon prices will remain low. After 2030, carbon prices may rise quickly year-on-year towards 2050. The implications of this will be financially more severe for carbon-intensive products, services and operations. This will result in increased costs of purchase relating to medical equipment and supplies, particularly those originating out-of-country.

In the short to medium term, commitment to a low-carbon portfolio (for example, low-carbon hospitals) could have certain benefits. A reduction in the portfolio's carbon intensity will mitigate future costs associated with increasing carbon prices.

Medical Insurance 2.5% share of the portfolio at 31 December 2023

An increase in medical insurance claims may arise from both acute short-term weather conditions (flooding and, in some regions landslides, heatwaves) and long-term chronic changes in weather such as increased average temperatures, impacting health. Failure of infrastructure may cause longer-term ill health from waterborne diseases. There is also a risk that the Government introduces a policy for insurers to maintain policy cover for the "uninsurable", the costs of which may not be possible to pass on to the insured.

Encouraging customers to prepare to be resilient with respect to climate risks, for example through premium incentives to have healthy lifestyles, may contribute positively to the business reputation and customer base.

Environmental activities of the Group's portfolio companies (continued)

P&C Insurance 7.8% share of the portfolio at 31 December 2023

Carbon pricing is a fundamental component of the EU's climate change agenda. Under the Delayed Transition 1.8°C scenario, carbon pricing is expected to rise sharply after 2030 (medium term). This will see a progressive rise in the cost of carbon-intensive products and services, logistics, distribution and any other operations within the supply chain associated with high carbon emissions. This will have implications for the cost of insurance, which may be passed on to the customer. Beginning with transition risks, some lines of business may see changes in claims patterns as government policy and regulation relating to carbon emissions evolve. This might result in fluctuating loss ratios and profitability.

Opportunities will likely arise from energy efficiency regulation which will force customers to upgrade their homes and vehicles and may require new product offerings. Commercial opportunities are also likely to arise by creating targeted products that address climate change and energy transition.

Water Utility 4.3% share of the portfolio at 31 December 2023

Acute physical risks may impact utility assets. For example, in the short to medium term, extreme rain events may overwhelm infrastructure, causing damaged water treatment and sewage treatment plants. Pipelines are also at risk from such events, as the overall integrity is placed under pressure. These will require increased maintenance and repair costs. Landslides in more remote locations could cause further damage and may block access in some areas.

In the medium term, decarbonisation of operations will enable the water utility operations to limit the cost consequences of carbon pricing and provide an advantage over more carbon-intensive competition.

Renewable Energy 7.3% share of the portfolio at 31 December 2023

In the short to medium term, the infrastructure and transmission lines are clearly at risk from physical risks such as landslides, or extreme heat impacting the integrity of lines or pipes. However, for each of the HPPs and WPPs, the business has taken steps to improve the resilience of infrastructure to changes in climate.

The renewable energy business generates electricity using renewable sources, and there are a number of policy and Government incentives for solar wind and hydropower generation in Georgia as part of the Georgian 2030 CCSAP. Renewable energy sources are considered to be the future of energy and are valued higher than traditional electricity generation companies.

Education 5.2% share of the portfolio at 31 December 2023

The potential risks relate to transition type risks, in particular energy and air quality regulations, that may be introduced under this scenario at short notice in the medium term. Schools may be expected to retrofit heating and cooling measures/equipment to meet regulations. In addition, energy requirements may arise in response to air conditioner use during prolonged heatwayes for example. These risks are expected for all real estate.

Auto Service

Currently, vehicles on the market and in use in Georgia are mainly diesel and petrol-fuelled. Initially, in the short term, there will be a gradual switch to electric vehicles. After 2030, there will likely be a significant increase in the use of electric vehicles, abruptly reducing the need for emissions checks. Additionally, the anticipated rise of carbon pricing and adoption of border adjustment mechanisms after 2030 will affect Amboli's (the auto service business' car services and parts business) supply chain and trade of car consumables and parts. There will likely be an abrupt rise in distribution and retail costs as a result of increases in carbon pricing.

In the short to medium term, it may be that there will be stricter emissions requirements. This may mean that more vehicles will need to be emissions-checked more regularly or be modified, causing demand at PTI centres.

Environmental activities of the Group's portfolio companies (continued)

Beverages

In addition to physical risks (reduced rain, high intensity events, prolonged heatwaves) affecting hops and grape production, the main identified risk relates to regulatory transition risk. In particular, carbon prices and border taxes such as the EU Carbon Border Adjustment Mechanism will adversely affect the prices of both incoming goods and exported products in medium term (post-2030).

Housing Development and Hospitality

Physical risks to property will occur. These include deterioration of asset integrity due to flooding or extreme heat. In the medium term (post-2030) assets that are not energy efficient will be hit by energy efficiency regulation for retrofitting and increased energy costs due to carbon pricing.

Early adoption of fuel efficiency standards, emissions-reducing regulations and building efficiency compliance will reduce longer-term costs relating to regulations including a reduction in potential declines.

The Group's strategy is to focus predominantly on capital-light, larger-scale investment opportunities in Georgia and it normally seeks to monetise its investment through appropriate exit options, typically within five to ten years from initial investment. Considering this strategic focus, the holding periods of GCAP's investments fall in much shorter time horizons (short to medium term) than the timeframe in which the impacts of climate change, especially of physical risks, may manifest themselves in Georgia. Management takes climate change risk into consideration when determining its investment strategy. Climate change is also reflected in the valuation assessments of the portfolio companies.

Sustainability-linked Bond Framework

In 2023 GCAP has developed a Framework that outlines the key principles to be followed when issuing Sustainability Linked Bonds. This Framework has been established in alignment with the International Capital Market Association's (ICMA) 2020 Sustainability-Linked Bond Principles (SLBP). The SLBPs are a set of voluntary guidelines that establish industry best practices for financial instruments to incorporate sustainability-related outcomes in the future. By defining the approach to issuing SLBs, these principles serve to facilitate the growth and development of the SLB market.

Enhanced integration of ESG issues into the Group's core operations became one of the three strategic priorities of GCAP's overall strategy in 2022. By identifying ESG risks and opportunities and integrating and managing ESG matters into the investment decision-making process, the Group is able to achieve a higher degree of investment optimization, while contributing to Georgia's advances towards sustainable development and improving the future of the community. By issuing Sustainability-Linked Bonds (SLBs) GCAP will deliver on its already established key strategic priority to support the transition towards a more sustainable and low carbon economy.

GCAP's Sustainability-Linked Bond Framework is designed in accordance with the five key components of the Sustainability-Linked Bond Principles (SLBP): 1) Selection of Key Performance Indicators (KPIs); 2) Calibration of Sustainability Performance Targets (SPTs) 3) Bond Characteristics 4) Reporting 5) Verification. GCAP's key performance indicator (KPI) is the total amount of greenhouse gas (GHG) emissions from Scope 1, 2, and 3 sources across its value chain, measured in tons of carbon dioxide equivalent (tCO2e). Scope 1 emissions are from sources owned or controlled by GCAP, Scope 2 emissions are from the consumption of purchased electricity, heat, steam, and cooling, and Scope 3 emissions represent Scope 1 and 2 emissions of GCAP's portfolio companies. This KPI is aligned with GCAP's wider strategy of the Net-Zero initiative. GCAP aims to reduce Absolute Scope 1, 2 and 3 GHG emissions by 20% by 2027 compared to a 2022 baseline. The KPI is material and relevant as it helps measure the company's and portfolio companies' GHG emissions, identify carbon-related risks and support decarbonization targets.

Sustainability-linked Bond Framework (continued)

GCAP has commissioned Sustainalytics, an internationally recognized firm with environmental and social expertise, to conduct a Second Party Opinion (SPO) evaluating the sustainability benefits and alignment of its Sustainability-Linked Bond Framework with the SLBP 2020. Sustainalytics confirmed the framework's compliance with the SLBP 2020 and rated it as ambitious.

For the year ending 31 December 2023, GCAP prepared and published on its website a Sustainability Report.²

Buyback of own shares

There were no share repurchases in 2023. During 2022, the Group repurchased its own shares from the 100% shareholder. The number of shares repurchased was 409,034, with nominal amount of GEL 409 and a total consideration of GEL 87,238. All of the repurchased ordinary shares were cancelled.

Irakli Gilauri

Chief Executive Officer

² The report is available at the following link: https://georgiacapital.ge/ir/sustainability-reports